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Marine Board-ESF
The Marine Board provides a pan-European platform 
for its member organisations to develop common pri-
orities, to advance marine research, and to bridge the 
gap between science and policy in order to meet future 
marine science challenges and opportunities.
The Marine Board was established in 1995 to facilitate 
enhanced cooperation between European marine sci-
ence organisations (both research institutes and research 
funding agencies) towards the development of a common 
vision on the research priorities and strategies for marine 
science in Europe. In 2010, the Marine Board represents 
30 Member Organisations from 19 countries.
The Marine Board provides the essential components for 
transferring knowledge for leadership in marine research 
in Europe. Adopting a strategic role, the Marine Board 
serves its Member Organisations by providing a forum 
within which marine research policy advice to national 
agencies and to the European Commission is developed, 
with the objective of promoting the establishment of the 
European Marine Research Area.
http://www.esf.org/marineboard
European Science Foundation
The European Science Foundation (ESF) is an inde-
pendent, non-governmental organisation, the members 
of which are 79 national funding agencies, research 
performing agencies, academies and learned societies 
from 30 countries.
The strength of ESF lies in the influential membership 
and in its ability to bring together the different domains 
of European science in order to meet the challenges of 
the future.
Since its establishment in 1974, ESF, which has its 
headquarters in Strasbourg with offices in Brussels 
and Ostend, has assembled a host of organisations 
that span all disciplines of science, to create a common 
platform for cross-border cooperation in Europe.
ESF is dedicated to promoting collaboration in scientific 
research, funding of research and science policy across 
Europe. Through its activities and instruments ESF has 
made major contributions to science in a global con-
text. The ESF covers the following scientific domains:
•  Humanities
•  Life, Earth and Environmental Sciences
•  Medical Sciences
•  Physical and Engineering Sciences
•  Social Sciences
•  Marine Sciences 
•  Materials Science and Engineering
•  Nuclear Physics
•  Polar Sciences
•  Radio Astronomy
•  Space Sciences
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Foreword
In 2001, the Marine Board-ESF published its Position 
Paper 4, ‘A European Strategy for Marine Biotech-
nology’, to highlight the many benefits that Marine 
Biotechnology could offer for Europe if its development 
was sufficiently supported. This first Position Paper 
called for a European initiative in Marine Biotechnology 
to mobilise the scattered human capital and strategically 
refocus the extensive but dispersed infrastructure into 
concerted action. Four key objectives were highlighted: 
(i) the development of Marine Biotechnology industries; 
(ii) the identification of R&D requirements to establish 
Europe as a world leader in marine bio-screening and 
derived bio-products; (iii) the promotion of networking 
between European actors in Marine Biotechnology; 
and (iv) recommendations to directly impact on future 
European Union Framework Programmes. In 2002 the 
US National Academy of Sciences published a report 
entitled Marine Biotechnology in the Twenty-first Cen-
tury: Problems, Promise, and Products. This report 
made broadly similar recommendations to the Marine 
Board Position Paper and stressed the need to develop 
new advanced techniques for detection and screening 
of potentially valuable marine natural products and bio-
materials.
Today, European countries are facing complex and 
difficult challenges that will shape our common future. 
Issues that top the agenda include a sustainable supply 
of food and energy, climate change and environmental 
degradation, human health and aging populations. The 
current global economic downturn has made these 
issues even more pressing. Marine Biotechnology can 
and should make an important contribution towards 
meeting these impending challenges and contribute 
to economic recovery and growth in Europe. Not only 
can it create jobs and wealth, but it can contribute 
to the development of greener, smarter economies, 
central components of the new Europe 2020 Strategy 1. 
The potential contribution of Marine Biotechnology 
is, therefore, even more relevant now than it was ten 
years ago and a sound strategy for its development in 
Europe is urgently needed to allow for this potential to 
be realised.
Surrounded by four seas and two oceans, Europe 
benefits from access to an enormous and diverse 
set of marine ecosystems and to the corresponding 
biodiversity. These marine ecosystems are largely 
unexplored, understudied and underexploited in 
comparison with terrestrial ecosystems and organisms. 
They provide a unique environment with an enormous 
potential to contribute to the sustainable supply of food, 
energy, biomaterials and to environmental and human 
health. Marine Biotechnology is, and will become even 
1 http://ec.europa.eu/eu2020/index_en.htm 
more, central to delivering these benefits from the sea. 
Therefore, it is appropriate that this Position Paper 
uses these ‘Grand Challenges’ to structure the logical 
analysis of the current and possible future development 
of Marine Biotechnology set against its capacity to 
deliver products and processes to address these high-
level societal needs and opportunities.
Marine Biotechnology developments in each of these 
areas cannot be seen in isolation from the wider European 
and global scientific and political landscape which has 
changed considerably since 2001. If the most significant 
developments in Marine Biotechnology during the 1990s 
were the result of the molecular biology revolution, it 
is clear that the primary driving force during the last 
decade was the genomic revolution. The overwhelming 
role of marine biodiversity for the future of marine 
resources, ecosystem management, bioprospecting 
and Marine Biotechnology was also recognised. The EU 
research policy was responsive to some extent, notably 
through support for the Marine Genomics and Marine 
Biodiversity (MarBEF) FP6 Networks of Excellence and 
other on-going collaborative projects. Recent efforts to 
support and coordinate European coastal and marine 
research infrastructures to improve, for example, access 
to research vessels, stations and laboratories indicate 
some level of recognition that action is needed to fully 
exploit the vast but fragmented research infrastructure 
available for marine sciences in Europe, including for 
Marine Biotechnology research. However, it is clear that 
objective number 2 of the 2001 Marine Board Position 
Paper on Marine Biotechnology, i.e. establishing Europe 
as a world leader in marine bio-screening and derived 
bio-products, has not been achieved.
The present report was initiated by the Marine Board 
to provide an updated view of Marine Biotechnology to 
policy makers at EU and national levels and to EU and 
national scientific and administrative officers involved in 
research in marine sciences and their interacting fields 
in health, food, environment and energy. The report 
has been produced by the members of the Marine 
Board Working Group on Marine Biotechnology (WG 
BIOTECH), established by the Marine Board in order to:
(i) provide a strategic assessment of the current 
scientific understanding of Marine Biotechnology 
relevant to European Union and Member State 
policies; 
(ii) identify the priorities for further research in this 
field; 
(iii) analyse the socio-economic context in which Marine 
Biotechnology is evolving; and 
(iv) formulate recommendations for future policies and 
critical support mechanisms.
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The resulting product of this joint effort is this new 
Marine Board Position Paper on Marine Biotechnology 
which calls for a collaborative industry-academia 
approach by presenting a common Vision and Strategy 
for European Marine Biotechnology research which 
sketch the contours of the research and policy agenda 
in the coming 10-15 years. 
On behalf of the Marine Board, we would like to sincerely 
thank the Working Group Chair, Dr Joel Querellou, 
and its expert participants, whose efforts resulted in 
a comprehensive overview of Marine Biotechnology 
research achievements and future challenges. Their work 
has been crucial to highlight the diverse and exciting 
opportunities in this field of research and in providing 
a decisive contribution to further develop the Marine 
Biotechnology sector in Europe to its full potential. 
We are also very grateful for the many constructive 
suggestions and critical comments provided by various 
industry representatives and experts. In particular we 
would like to thank Dermot Hurst, Bill Fenical, Yonathan 
Zohar and Meredith Lloyd-Evans for their valuable 
comments and inputs. Finally, we take this opportunity 
to acknowledge the hard work of Jan-Bart Calewaert 
from the Marine Board Secretariat, who provided 
unstinting support to the Working Group.
Lars Horn and Niall McDonough
Chairman and Executive Scientific Secretary,  
Marine Board-ESF
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Executive Summary
Biotechnology, the application of biological knowledge 
and cutting-edge techniques to develop products and 
other benefits for humans, is of growing importance for 
Europe and will increasingly contribute to shape the 
future of our societies. Marine Biotechnology, which 
involves marine bioresources, either as the source or the 
target of biotechnology applications, is fast becoming 
an important component of the global biotechnology 
sector. The global market for Marine Biotechnology 
products and processes is currently estimated at € 2.8 
billion (2010) with a cumulative annual growth rate of 
4-5%. Less conservative estimates predict an annual 
growth in the sector of up to 10-12% in the coming 
years, revealing the huge potential and high expecta-
tions for further development of the Marine Biotechno-
logy sector at a global scale.
This Position Paper, developed by the Marine Board 
Working Group on Marine Biotechnology, presents 
a shared vision for European Marine Biotechnology 
whereby:
By 2020, an organised, integrated and globally com-
petitive European Marine Biotechnology sector will 
apply, in a sustainable and ethical manner, advanced 
tools to provide a significant contribution towards 
addressing key societal challenges in the areas of 
food and energy security, development of novel 
drugs and treatments for human and animal health, 
industrial materials and processes and the sustain-
able use and management of the seas and oceans.
This 2020 Vision for European Marine Biotechnology 
will only be achieved through a coordinated imple-
mentation in a joint effort with active support and 
involvement from all relevant stakeholders, of the 
following high level recommendations:
•	RECOMMENDATION	 1:	 Create	 a	 strong	 identity	
and communication strategy to raise the profile 
and awareness of European Marine Biotechnology 
research.
•	RECOMMENDATION	2:	Stimulate	the	development	
of research strategies and programmes for Marine 
Biotechnology research and align these at the na-
tional, regional and pan-European level.
•	RECOMMENDATION	3:	Significantly	improve	tech-
nology transfer pathways, strengthen the basis 
for proactive, mutually beneficial interaction and 
collaboration between academic research and in-
dustry and secure access and fair and equitable 
benefit sharing of marine genetic resources.
•	RECOMMENDATION	4:	Improve	training	and	edu-
cation to support Marine Biotechnology in Europe.
Marine Biotechnology contribution 
to key societal challenges
In the context of a global economic downturn, European 
countries are now facing complex and difficult challeng-
es such as the sustainable supply of food and energy, 
climate change and environmental degradation, human 
health and aging populations. Marine Biotechnology can 
make an increasingly important contribution towards 
meeting these societal challenges and in supporting 
economic recovery and growth in Europe by delivering 
new knowledge, products and services. 
Sustainable supply of high quality and 
healthy food
Marine Biotechnology is essential to satisfy the grow-
ing demand for healthy products from fisheries and 
aquaculture in a sustainable way. The growing demand 
for marine food will need to be increasingly delivered 
through intensive aquaculture. Since 2001, rapid bio-
logical and biotechnological progress has resulted in a 
more efficient and environmentally responsible aqua-
culture and a greater diversity of marine food products. 
Marine Biotechnology has contributed significantly to 
increasing production efficiency and product quality, to 
the introduction of new species for intensive cultivation 
and the to the development of sustainable practices 
through a better understanding of the molecular and 
physiological basis for reproduction, development and 
growth, and a better control of these processes. How-
ever, commercial aquaculture continues to face chal-
lenges in understanding and controlling reproduction, 
early life-stage development, growth, nutrition, disease 
and animal health management and environmental in-
teractions and sustainability.
Sustainable alternative sources of energy
The ocean is an untapped, sustainable source of bio-
energy. There are many examples of the production of 
bio-energy from marine organisms, but the production 
of biofuel from microalgae presents perhaps the most 
promising option to harvest this huge energy poten-
tial. The theoretical production of oil from microalgae 
is considerably higher than that of terrestrial crops but, 
to achieve viability, the cost of production will need to 
be significantly reduced and the scale of production in-
creased, while maintaining environmental sustainability. 
To cultivate microalgae for the generation of bio-energy 
is an important challenge for Marine Biotechnology in 
the 21st century.
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Securing environmental health
Marine Biotechnology is playing an increasingly impor-
tant role in the protection and management of the ma-
rine environment. Achievements in this field have been 
less substantial than expected during the last decade 
and most of the applications routinely used nowadays 
still rely on traditional methods based on chemistry and 
microbiology. This is mainly the result of the complex-
ity of marine ecosystems on one hand, and the gap 
between results in marine genomic approaches and 
the development of derived commercial assays and 
products on the other hand. However, the potential con-
tribution of Marine Biotechnology for environmental ap-
plications is enormous and requires urgent attention.
Securing human health and well-being
In recent years, the chemistry of natural products de-
rived from marine organisms has become the focus of a 
much greater research effort. Currently there are around 
15 marine natural products in various phases of clinical 
development, mainly in the oncology area, with more 
on the way and several products already on the market. 
Nevertheless, the seas and oceans represent a huge 
potential source of new drugs, innovative treatments 
and diagnostic tools for human health. The main chal-
lenges facing pharmaceutical discovery from marine 
bioresources are linked to: legal aspects (secure access 
to marine resources, property rights and intellectual 
property); quality of marine resources (identification and 
variability); technology (screening of active compounds 
and dereplication, preventing repeated rediscovery); and 
structural costs of drug discovery from natural products 
and especially marine products.
Industrial products and processes
Proteins and enzymes from marine organisms already 
contribute significantly to industrial biotechnology but 
can also support novel process development in the 
food and pharmaceutical industries or in molecular bi-
ology and diagnostic kits. For example, the luminescent 
properties of the jellyfish Aequorea victoria led to the 
characterisation of the green fluorescent protein (GFP). 
GFP and the luciferase enzyme from Vibrio fischeri have 
widespread applications in molecular biology as a re-
porter protein. 
In the past decade, biopolymers of marine origin have 
received increasing attention from the medical, phar-
maceutical and biotechnology industries for numerous 
applications ranging from biodegradable plastics to 
food additives, pharmaceutical and medical polymers, 
wound dressings, bio-adhesives, dental biomaterials, 
tissue regeneration and 3D tissue culture scaffolds. 
However, marine-derived biomaterials science is still 
relatively new and the marine environment is, as yet, a 
relatively untapped resource for the discovery of new 
enzymes, biopolymers and biomaterials for industrial 
applications.
This Position Paper analyses the contributions Marine 
Biotechnology can make to address key societal chal-
lenges and identifies the associated future research 
priorities which are summarised in Executive Summary 
Box A.
Executive Summary
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Executive Summary Box A 
Marine Biotechnology research priorities to address key societal challenges
Target research area 
for development 
Research priorities and objectives
Food: 
Development of food  
products and ingre-
dients of marine origin 
(algae, invertebrates, 
fish) with optimal 
nutritional properties 
for human health
- Develop innovative methods based on -omics and systems biology for selective 
breeding of aquaculture species;
- Develop biotechnological applications and methods to increase sustainability of 
aquaculture production, including alternative preventive and therapeutic measures 
to enhance environmental welfare, sustainable production technologies for feed 
supply, and zero-waste recirculation systems;
- Integration of new, low environmental impact feed ingredients to improve quality of 
products and human health benefits.
Energy: 
Development and  
demonstration of 
viable renewable 
energy products and 
processes, notably 
through the use of 
marine algae 
- Produce an inventory of microalgae resources for biofuel production to support 
optimisation of the most appropriate strains;
- Improve knowledge of basic biological functions, tools for steering the metabolism 
and cultivation methods of marine microalgae to improve the photosynthetic 
efficiency, enhance lipid productivity and obtain microalgae with optimum 
characteristics for mass cultivation (mixed & mono cultures), biofuel production 
and biorefinery;
- Develop efficient harvest, separation and purification processes for micro- and 
macroalgae.
Health: 
Development of novel 
drugs, treatments and 
health and personal 
care products
- Increase the focus on the basic research (taxonomy, systematics, physiology, 
molecular genetics and chemical ecology) of marine species and organisms from 
unusual and extreme environments to increase chances of success in finding novel 
bioactives;
- Improve the technical aspects of the biodiscovery pipeline, including the 
separation of bioactives, bio-assays that can accommodate diverse material from 
marine sources, dereplication strategies and structure determination methods and 
software;
- Overcome the supply problem to provide a sustainable source of novel 
pharmaceutical and healthcare products through scientific advances in the fields 
of aquaculture, microbial and tissue culture, chemical synthesis and biosynthetic 
engineering.
Environment: 
Development of 
biotechnological 
approaches, 
mechanisms and 
applications to  
address key 
environmental issues
- Develop automated high-resolution biosensing technologies allowing in situ marine 
environmental monitoring to address coastal water quality, including prediction 
and detection of Harmful Algal Blooms and human health hazards;
- Develop cost-effective and non-toxic antifouling technologies combining novel 
antifouling compounds and surface engineering;
- Consolidate knowledge on DNA-based technologies for organism and population 
identification and support the development of commercial tools and platforms for 
routine analysis.
Industrial Products 
and Processes: 
Development of 
marine-derived 
molecules exploitable 
by industry including 
enzymes, biopolymers 
and biomaterials
- Develop enabling technologies for high throughput enzyme screening and for the 
expression of marine proteins and enzymes through dedicated hosts;
- Produce marine biopolymers as novel competitive commercial products in food, 
cosmetics and health.
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Drivers, barriers and enablers of 
Marine Biotechnology in Europe 
While it is difficult to predict major innovations in life 
science and their future impact on society, it is clear 
that developments in life science technologies have 
been, and will continue to be in the future, one of 
the key drivers of Marine Biotechnology research. 
In the 1990s Marine Biotechnology developments were 
largely the result of the molecular biology revolution. 
During the last decade, the genomic revolution was 
clearly the primary driving force. Aside from advances 
in -omics, the development and optimisation of appro-
priate bio-engineering tools and the cultivation of mi-
croorganisms and the use of marine model organisms 
need to be stimulated as they are expected to have a 
large impact on future progress in Marine Biotechnol-
ogy. Research and Development priorities associated 
with key marine biotechnological toolkits are presented 
in Executive Summary Box B. 
Since the year 2000, the European Commission has been 
working with Member and Associated States towards 
development of the European Research Area (ERA), one 
of the goals of which is to better integrate scientific 
communities and the research infrastructures they 
need. Through support for marine research Networks of 
Excellence and other collaborative projects, EU research 
policy has been responsive to the growing awareness 
of the important role of marine biodiversity for the 
future of marine resources, ecosystem management, 
bioprospecting and Marine Biotechnology. Recent 
efforts to support and coordinate European coastal and 
marine research infrastructures to improve, amongst 
others, the access to research vessels, stations and 
laboratories also indicate some level of recognition that 
action is needed to fully exploit the vast but fragmented 
research infrastructure available for marine sciences 
and hence Marine Biotechnology in Europe.
Executive Summary Box B 
Marine Biotechnology toolkit research priorities
Target research area 
for development 
Research priorities and objectives
Genomics and  
meta-genomics, 
molecular biology  
in life sciences
- Implement genomic analyses of marine organisms, including the systematic 
sampling of different microorganisms (viruses, bacteria, archaea, pico and micro-
plankton), algae and invertebrate taxa;
- Implement metagenomic studies of aquatic microbiomes and macrobiomes.
Cultivation of marine 
organisms
- Develop enabling technologies for culture and isolation of uncultivated 
microorganisms;
- Develop innovative culture methods adapted to vertebrate or invertebrate cell lines 
for production of active compounds.
Bio-engineering 
of marine  
micro-organims
- Optimise microalgal cultivation systems with respect to energy supply, productivity 
and cost;
- Develop innovative photobioreactors adapted to different species of interest and 
production sites;
- Promote research on the biorefinery approach based on microalgae production to 
develop a long-term alternative to petrochemistry.
Marine Model 
Organisms
- Identify and prioritise new marine model organisms that are still not investigated in 
the tree of life and which are needed to fill critical knowledge gaps;
- Investigate identified marine model organism cultivation and perform genomic and 
chemical analysis.
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We are now in a much better position to collectively 
address key challenges for the successful development 
of Marine Biotechnology. However, a strategic approach 
at EU level is critical to build on the progress that 
has already been made. The EU currently lacks a 
coherent Marine Biotechnology RTD policy and 
needs to prepare one without delay. As it stands, 
individual European countries support, to varying 
degrees, national Marine Biotechnology initiatives, 
programmes, and RTD policies and/or strategies. As 
a result, the European Marine Biotechnology effort is 
fragmented and based on national rather than common 
European needs and priorities. A coordinated effort is 
also needed at pan-European level to mobilise and 
optimise human resources and available infrastructures. 
Such efforts should address both fundamental research 
and advanced application-oriented research and 
take an approach which supports industry-academia 
collaboration.
A multi-disciplinary industry-academia collaborative 
approach will be critical for the success of European 
Marine Biotechnology. With a few notable exceptions, 
most industrial contributions to Marine Biotechnology 
in Europe are generated through specialised Small 
and Medium-sized Enterprises (SMEs). These small 
companies assume most of the risks inherent in RTD 
in a highly unstable economic environment and are 
characterised by a rapid turn-over. There is a danger 
that the current global financial crisis, coupled with 
reductions in available venture capital and public 
research funding, may reduce the capacity of Marine 
Biotechnology SMEs to continue to play a key role in 
developing new technologies products and processes. 
Nevertheless, efforts to involve larger, established 
companies should also be intensified as the technology 
transfer is often incomplete if they are not involved. 
At the same time, specific education and training 
initiatives and pathways are necessary to provide 
both research and industry with skilled graduates. 
The future of life sciences in the 21st century is closely 
linked to the ability of scientists to develop and 
participate in interdisciplinary projects, embracing skills 
and concepts from other disciplines. Hence, training the 
next generation of marine biotechnologists must focus 
on the use of interdisciplinary and holistic approaches 
to solve technological problems specific to dealing with 
marine organisms and the marine environment. 
An important barrier to the further development of 
Marine Biotechnology in Europe is linked to the lack of 
identity and profile of Marine Biotechnology as a 
research field in its own right. This is partly due to the 
broad range of disciplines and activities which contribute 
to Marine Biotechnology. This lack of a coherent 
 
identity in Europe is also a result of inadequate efforts 
to coherently communicate the needs, benefits and 
opportunities to the wider scientific community, to policy 
makers and to the public in general. There is an urgent 
need to communicate how marine biotechnological 
knowledge and applications can provide advances 
in, for example, industrial biotechnology, health and 
agriculture. In particular, there is insufficient awareness 
within the pharmaceutical industry of the potential for 
novel drug discovery based on bioactive molecules and 
compounds derived from marine organisms.
There is also an urgent need to improve information 
exchange among those who are actively involved in 
European Marine Biotechnology. Mechanisms need 
to be developed to mobilise and facilitate the efficient 
pooling of knowledge, data and research capacities 
distributed throughout Europe. Mobility of researchers 
should be encouraged at all levels. The effective 
dissemination of novel Marine Biotechnology research 
discoveries can improve greatly Europe’s capacity to 
generate new commercial opportunities. Creating a 
common identity and information exchange platform 
will also reduce the apparent gap which currently exists 
between researchers and high-tech companies (notably 
companies from the healthcare sector).
Vision, Strategy and recommended 
actions 
This Paper, which is the result of a collaborative effort 
of the members of the Marine Board Working Group on 
Marine Biotechnology, presents a Vision and a Strategy 
with a set of concrete and achievable recommendations 
and actions designed to support and develop European 
Marine Biotechnology research, enhance the European 
biotechnology and bioscience industries and provide a 
considerable contribution to the Knowledge Based Bio-
Economy (KBBE). Central to the Strategy is the shared 
vision for European Marine Biotechnology whereby:
By 2020, an organised, integrated and globally 
competitive European Marine Biotechnology sector will 
apply, in a sustainable and ethical manner, advanced 
tools to provide a significant contribution towards 
addressing key societal challenges in the areas of 
food and energy security, development of novel drugs 
and treatments for human and animal health, and the 
sustainable use and management of the seas and 
oceans.
This 2020 Vision will only be achieved through 
the coordinated implementation of all of the 
recommendations and actions presented in this 
new Strategy for the future development of Marine 
Biotechnology in Europe. The Strategy aims to enable 
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the sector to much better contribute to the resolution 
of some of the most important social, economic, 
environmental and health challenges which we will 
encounter in the coming decade and beyond. In the 
context of a weakened global economy, the strategy 
will focus on optimising the use of marine biological 
resources, better coordination of research programmes 
at EU and national levels, and maximising the benefits 
for European citizens from products and services 
derived from Marine Biotechnology. 
The strategy is designed such that its full implementation 
should contribute to wealth and job creation in EU 
Member and Associated States. It also aims to 
position Europe as a globally competitive leader in 
Marine Biotechnology research, in the advancement 
of associated technologies and in the development 
of marine derived products and services through 
biotechnological applications. At the same time, the 
strategy must provide the means to assist countries with 
limited access to marine resources and/or the means to 
valorise them. An underlying tenet of the strategy is that 
its recommendations must be implemented according 
to the principles of sustainability, ensuring the protection 
and preservation of coastal and marine ecosystems 
and their resources for future generations. In fact, 
Marine Biotechnology can itself better contribute to the 
appropriate protection, remediation and management 
of the marine environment. 
Four recommendations with a set of specific 
implementation actions constitute the core of the strategy 
to achieve the joint vision for Marine Biotechnology in 
Europe. These are presented in Executive Summary 
Box C.
Successful implementation of the strategy will require a 
joint effort with active support and involvement from 
all relevant stakeholders. Europe needs to mobilise 
the necessary support in terms of funding, human 
resources and research infrastructures, and to secure 
the engagement of all of the relevant actors. These 
actors include the science community, the private sector 
(e.g. individual companies, associations and technology 
platforms) policy makers and advisors at national and 
European level, national strategy and programme 
developers and managers, and ultimately the public at 
large. As each actor has an important responsibility to 
bring forward key elements of the strategy, mobilising, 
in a coordinated way, this diverse range of actors will 
be critical.
Executive Summary Box C 
Overview of recommendations and associated actions for implementation as a central component 
of the Strategy for European Marine Biotechnology
RECOMMENDATION 1: Create a strong identity 
and communication strategy to raise the 
profile and awareness of European Marine 
Biotechnology research.
Recommended Actions:
1a) Create a central European information portal which 
provides a one-stop-shop for state-of-the-art re-
ports on novel discoveries and success stories, 
challenges and opportunities.* 
1b) Conduct an audit of Marine Biotechnology effort 
in Europe to allow an economic evaluation of the 
benefits of Marine Biotechnology in Europe and 
facilitate the development of strong support poli-
cies.*
1c) Initiate a series of Marine Biotechnology demon-
stration projects that target the utilisation of marine 
materials in defined sectors.
1d) Develop promotional and education support materi-
als that highlight the potential and the successes of 
European Marine Biotechnology research.
RECOMMENDATION 2: Stimulate 
the development of research strategies and 
programmes for Marine Biotechnology research 
and align these at the national, regional and  
pan-European level.
Recommended Actions:
2a) Create a European Marine Biotechnology Institute 
or Centre, at least virtual, charged with developing 
Europe’s Marine Biotechnology research capa-
bilities through a range of collaborative actions 
including establishing and operating the European 
Marine Biotechnology Portal (see recommendation 
1a).*
2b) Develop a coherent European Marine Biotechnol-
ogy RTD policy to strengthen the integration at EU 
level of Marine Biotechnology research and cor-
responding infrastructures, among others through 
a future Framework Programme support action or 
a dedicated ERA-NET.*
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2c) Strengthen common European platforms in the field  
of omics research which include corresponding 
bioinformatics and e-infrastructures and the devel-
opment of centres for systems biology and synthetic 
genomics, recognising that Marine Biotechnology 
draws from a wide range of multi-disciplinary re-
search outputs and tools.
2d) Develop high level European Marine Biotechnology 
research programmes taking an industry-academia 
collaborative and multidisciplinary scientific ap-
proach in the thematic areas of Food, Energy, 
Health, Environment and Industrial Products and 
Processes.
RECOMMENDATION 3: Significantly improve 
technology transfer pathways, strengthen 
the basis for proactive, mutually beneficial 
interaction and collaboration between academic 
research and industry and secure access and 
fair and equitable benefit sharing of marine 
genetic resources.
Recommended Actions:
3a) Better adapt future FP financial rules and Grant 
Agreements to ensure SMEs are attracted to par-
ticipate in a way that maximises the reward and 
minimises economic risks.
3b) Establish completely new mechanisms and policies 
to circumvent the high risk of investments in critical 
novel drugs developed from marine bioresources, 
in particular for the development of new antibiotics 
of marine origin.
3c) Harmonise the property rights and procedures for 
the protection of intellectual property for marine-
derived products at European level but with a global 
relevance. Develop new European protocols to fa-
cilitate the publication of academic research results 
whilst protecting, through innovative procedures, 
the intellectual property on new discoveries.
3d) Develop a common European position on the sim-
plification and harmonisation of regulations on 
access and fair and equitable benefit sharing from 
the exploitation of marine genetic resources taking 
into account three ‘territories’ : (i) inside Europe; (ii) 
outside Europe; and (iii) international waters. 
3e) Conduct a survey of industry stakeholders to guide 
research towards applications and processes to 
address current industry needs. 
RECOMMENDATION 4: Improve training 
and education to support Marine Biotechnology 
in Europe.
Recommended Actions:
4a) Assure that appropriate biotechnology modules are 
included in all bio-science undergraduate educa-
tional programmes.
4b) Initiate actions that will ensure the participation of 
researchers from non-marine backgrounds in Ma-
rine Biotechnology, thus ensuring that a growing 
pool of exceptional research talent is available to 
the Marine Biotechnology sector. 
4c) Organise regular trainings or summer schools on 
Marine Biotechnology subjects supported, for ex-
ample, by the EU Framework Programme.
4d) Create a European School or Course on Marine 
Biotechnology (virtual and distributed) and a Eu-
ropean PhD programme on Marine Biotechnology 
both of which need to include business and entre-
preneurship training as standard.
*Actions which should be implemented without delay
Executive Summary Box C 
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Executive Summary Box D 
Flow-chart of recommended priority actions for immediate implementation and their expected impact
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Some of the recommended actions provide a structural 
basis for realisation of the strategy and should be 
prioritised for early implementation. These are highlighted 
(with *) in Executive Summary Box C  and presented in 
a flow-chart in Executive Summary Box D. Once up and 
running, these activities will act as a catalyst to drive 
implementation of the other recommended actions that 
make up the strategy. For example, a European Marine 
Biotechnology Institute or Centre could develop a 
roadmap for implementation of the strategy, coordinate 
its implementation and mobilise the relevant actors. A 
Framework Programme support action or ERA-NET, 
bringing together national funding organisations which 
support Marine Biotechnology research, will play a 
key role in aligning existing programmes, coordinating 
investments and informing the development of new 
research programmes and initiatives.
There is now a strong momentum to drive progress in 
European Marine Biotechnology in the coming decade. 
If Europe does not act now through a concerted effort 
by all of the identified actors and stakeholders and 
through increasing its support with targeted funding 
and coordinated research, it will begin to lose ground 
on other global leaders in this field such as the USA, 
Japan and China. The successful implementation of 
the integrated strategy presented in this Marine Board 
Position Paper has the potential, not only to significantly 
advance European research in Marine Biotechnology, 
but, in turn, to contribute significantly towards the 
development of knowledge-based jobs and smart 
economic growth, and to create innovative solutions to 
meet critical societal challenges in the areas of food, 
environment, energy and health in the coming decade 
and beyond.
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1. Introduction
Biotechnology is of growing importance for the 
European Union and will increasingly contribute to 
shape the future of our societies. The rapid rate of 
progress in the life sciences makes it difficult to predict 
our future capabilities and their potential impacts on 
our knowledge and in some cases our economies. 
Nonetheless, it remains crucial to analyse the limits of 
previous RTD policies both at European and national 
level, and to formulate recommendations for future 
research priorities and supporting policies in order to 
enhance the competitiveness of European countries and 
to improve the social benefits of their inhabitants. This 
Position Paper attempts to address these questions 
specifically focusing on Marine Biotechnology (see 
Information Box 1 and Figure 1). 
Information Box 1. 
What is Marine Biotechnology?
Biotechnology, and in turn, ‘Marine Biotechnology’, 
mean different things to different people. A very 
broad and simple definition of biotechnology is ‘the 
application of biological knowledge and techniques 
to develop products and other benefits for humans’. 
As such, the definition covers all modern biotech-
nology but also many more production related and 
traditional borderline activities used in agriculture, 
food and beverage production (e.g. cheese and 
beer). Nowadays, biotechnology is more often 
considered in terms of cutting-edge molecular or 
genomic biological applications where molecular or 
genetic material is manipulated to generate desir-
able products or other benefits. 
What we consider as biotechnology, therefore, large-
ly depends on what techniques we include and this 
is linked, in turn, to what we wish to address. This is 
illustrated by the varying definitions for biotechno-
logy used by different organisations. For example, 
in a single provisional and deliberately broad defi-
nition, the Organisation for Economic Co-operation 
and Development (OECD) defines biotechnology 
as ‘The application of science and technology to 
living organisms, as well as parts, products and 
models thereof, to alter living or non-living materials 
for the production of knowledge, goods and ser-
vi ces’. This broad definition includes both modern 
and more traditional techniques and, for that rea-
son, the definition comes with a non-exhaustive list 
of biotechnology techniques which functions as an 
interpretative guideline to the overarching definition 
and which is considered to evolve over time.
Marine Biotechnology encompasses those efforts 
that involve marine bioresources, either as the 
source or the target of biotechnology applications. 
In many cases this means that the living organisms 
which are used to develop products or services are 
derived from marine sources. At the same time, if 
terrestrial organisms are used to develop a bio-
sensor which is used in the marine environment to 
assess the ecosystem health then it also falls within 
the sphere of Marine Biotechnology. 
A useful website which provides general information 
on Marine Biotechnology and a wide range of exam-
ples is www.marinebiotech.org.
In recent years there has been a rapid increase in 
the inventory of marine natural products and genes 
of commercial interest derived from bioprospecting 
efforts. The rapid growth in the human appropriation 
of marine genetic resources (MGRs) with over 18,000 
natural products and 4,900 patents associated with 
genes of marine organisms, the latter growing at 12% 
per year, illustrates that the use of marine bioresources 
for biotechnological applications is no longer a vision 
but a growing source of business opportunities 2.
While it is difficult to predict major innovations in life 
science and their future impact on society, a crystal 
2. From Arrieta J., Arnaud-Haond S. and Duarte C. Marine Reserves 
Special Feature: What lies underneath: Conserving the oceans’ genetic 
resources. PNAS 2010
Figure 1. Marine Biotechnology Workflow. Marine Biotechnology 
is part of global biotechnology and its specificity lies in the 
uniqueness of marine living resources and their derived products 
and services through the use of a set of tools ranging from 
biodiversity assessment to systems biology, from cultures to 
engineering.
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ball is not required to foresee the importance of the 
ongoing omics revolution for biotechnology, and by 
extension, for Marine Biotechnology. For that reason, 
Chapter 2 of this Position Paper opens with one of 
the key drivers of Marine Biotechnology research: life 
science technologies, including developments in the field 
of omics, cultivation of marine living resources and bio-
engineering. We expect that this chapter will contribute to 
highlight possible developments, evolutions and changes 
for each of the Marine Biotechnology domains.
The seas and oceans represent a unique environment 
with the potential to contribute enormously to the 
sustainable supply of food, energy, biomaterials and to 
environmental and human health. Marine Biotechnology 
is now, and will become even more, central to delivering 
these benefits from the sea. It is appropriate then 
that Chapter 3 provides a logical analysis of the 
achievements and the current and possible future 
development of Marine Biotechnology set against its 
capacity to deliver products and processes to address 
these high-level societal needs and opportunities.
The sustainable supply of high quality and healthy 
food is a fundamental and recurrent issue and was 
considered so strategically important by the EU founders 
that it led to the early introduction of dedicated Common 
Policies in the fields of Agricultural and Fisheries. Marine 
Biotechnology can contribute to the maintenance and 
improvement of food quality, can support sustainable 
production of aquaculture products or other marine 
biomass feedstocks and help to provide viable sources 
of food in developing countries. The role of Marine 
Biotechnology in addressing food safety and supply, 
including its past and potential future applications, is 
considered in Section 3.1 of this Position Paper.
While there might be controversy over the current rates 
and impacts of climate change and the respective 
contributions of greenhouse gases and other factors, 
it is beyond doubt that the use of fossil fuels will have 
to be reconsidered within the next decades owing to 
limited reserves and increasing costs. Already the race 
is on to find viable and sustainable alternative sources 
of energy. It is becoming increasingly recognised that 
Marine Biotechnology could provide a potentially major 
contribution to the production of bioenergy, either by 
providing novel biocatalysts for second generation 
biofuels, or directly by producing algae to build up 
a third generation of biofuels. The development of 
marine bio-energy as a viable and renewable energy 
source is clearly in its infancy, but given the impending 
energy crisis, there is an urgent need to ensure that all 
necessary building blocks and support mechanisms 
are in place to fast-track marine bio-energy research 
(Section 3.2). 
It is hardly surprising that human health has traditionally 
been one of the best supported fields of research. 
With our rapidly changing societies and environments, 
there are always new challenges to add to the list of 
issues which endanger the health and well-being of our 
growing populations. Among many acute problems, 
the increasing development of antibiotic resistance 
combined with a lack of novel antibiotic families raises 
major concerns. Terrestrial ecosystems have long 
provided most of the natural products used to generate 
drugs and to serve as templates for combinatorial 
chemistry to design novel drugs. In the meantime, 
marine environments and marine living resources have 
largely been ignored. With appropriate supporting 
policies and research investment, marine resources 
and Marine Biotechnology can and should contribute 
significantly to address human health concerns in the 
future (See Section 3.3).
One other major trend is the ongoing global migration 
of populations to coastal regions. This is generating 
significant pressures on fragile marine ecosystems 
located close to major coastal population centres which 
receive the by-products of increasing human activities. 
Again, marine biotechnological solutions might help 
to deal with and mitigate against human-induced 
environmental degradation through the development of 
novel products and services. The potential contribution 
of Marine Biotechnology to monitor and protect the 
environmental health of our oceans and seas is 
discussed in Section 3.4 of this paper. 
Finally, marine living resources provide a huge and 
almost untapped reservoir of genes, organisms, and 
various products which may present unique solutions 
for industrial and biotechnological applications. 
Preliminary research has provided evidence that 
products derived from some marine living resources 
can be used to generate innovative biomaterials as 
discussed in Section 3.5 of this report. 
Then, in Chapter 4, we discuss important additional 
support mechanisms and needs for the development 
of Marine Biotechnology and, more specifically, the 
issue of access to marine resources and common 
infrastructures. 
From chapters two to four it will become clear that 
Europe urgently needs to implement a sound strategy 
for development of Marine Biotechnology research in 
Europe to allow for its full potential to be realised. The 
Position Paper therefore concludes in Chapter 5 by 
presenting a common vision for the future development 
and impact of Marine Biotechnology in Europe and a 
strategy, with concrete recommendations, to deliver this 
vision by 2020. To guide further Marine Biotechnology 
research in Europe, the chapter also provides a 
1. Introduction
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summary of research priorities for each of the strategic 
areas discussed in the Position Paper.
This Position Paper is based on the activities of the 
Marine Board Working Group on Marine Biotechnology 
which convened in Brussels on 22 September 2009 and 
on 18-19 March 2010. The preliminary conclusions were 
presented and discussed during the Marine Board-
ESF-COST High Level Research Conference on Marine 
Biotechnology 3 (20-24 June 2010, Acquafredda di 
Maratea, Italy) which provided additional insight on the 
future challenges and research priorities for European 
Marine Biotechnology research which are taken into 
account in this document. 
3. Information and outputs of the Marine Board-ESF-COST High Level 
Research Conference on Marine Biotechnology (20-24 June 2010, 
Acquafredda di Maratea, Italy) are available on the Marine Board 
website http://www.esf.org/marineboard/.
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Figure 2. Sirens Reef Natural Park of Cabo de Gata Nijar in Almería (Spain). The marine environment presents a vast and largely unexplored 
source of bioresources for biotechnology applications. 
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The life sciences, and specifically synthetic biology, 
promise to engineer organisms for the benefit of 
humanity with potential applications in medicine, 
agriculture, industry and environmental management. 
However, these promises cannot obscure the fact that 
synthetic biology may change the human relationship 
with nature. Public debate and dedicated ethics 
committees should establish clear limits to its use, which 
must be anticipated now whilst synthetic biology is still 
in its formative stages. This Chapter provides a brief 
presentation of those technologies which are expected 
to have the largest impact on future progress.
2.1 ‘Omics’ driven technologies
In the mid 1990s, the ‘omics’ revolution started to 
change biology and its application in biotechnology. 
Omics focus on a large-scale, holistic approach to 
understand life in encapsulated omes such as the 
genome, transcriptome, proteome, metabolome, etc. 
(‘ome’ stems from Greek for ‘all’, ‘whole’ or ‘complete’). 
This view, supported by informatics and the internet, 
had a strong influence on all life sciences and provided 
an efficient means to integrate and understand complex 
biological knowledge and systems.
2.1.1 Genomics of marine organisms
Central to the understanding of the biotechnological 
potential of marine organisms is the assessment of their 
genetic capabilities, i.e. sequencing of their genome and 
annotation of the genes. This understanding is the focus 
of genomics. Currently, about 1000 prokaryotic genomes 
have been sequenced and annotated. More than half of 
these genomes are of medical or industrial relevance 
and no phylogenetically systematic genome sequencing 
has been carried out until recently. Sequencing of 
phylogenetically diverse microbial genomes still results 
in the discovery of many novel proteins per genome 
and the trend is linear, demonstrating the existence 
of a huge reservoir of undiscovered proteins. Given 
that about 7500 bacterial species have been validly 
described, it follows that still hundreds of thousands 
of new proteins will be discovered by sequencing, in 
a systematic manner, all cultured bacterial species. 
Another level of diversity has to be expected from the 
uncultured prokaryotes which make up about 70% 
of the more than 100 bacterial phyla. This uncultured 
diversity became apparent when the first whole genome 
analysis of marine microbial communities revealed as 
many new clusters of ortholog groups (COGs) as were 
already known at the time (2004). On the other end of the 
phylogenetic diversity, i.e. comparing different strains 
of a bacterial species, it is becoming clear that each 
new strain can add hundreds of new genes. This means 
that, the pan-genome of a microbial species, comprising 
all genes of all strains of that species, is several times 
larger again than the core genome.
In addition to bacteria, aquatic ecosystems contain 
viruses which are the most common biological entities 
in the marine environment. The abundance of viruses 
exceeds that of prokaryotes at least by factor of ten 
and they have an enormous impact on the other micro-
biota, lysing about 20% of its biomass each day. Recent 
metagenomic surveys of marine viruses demonstrated 
their unique gene pool and molecular architecture. 
Their host range covers all major groups of marine 
organisms from archaea to mammals. Metagenome-
2. Developments and perspectives of key tools and technologies
Figure 3. Marine scientist preparing samples in a molecular 
biology laboratory 
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based estimates of the marine viral diversity indicate 
that hundreds of thousands of different species exist 
with genes completely different from any other form 
of life. Therefore, marine viruses are an untapped 
genetic resource of truly marine character and could 
provide novel proteins, genetic tools and unexpected 
functions. 
In contrast to prokaryotes, the era of the genomics of 
marine eukaryotes, comprising microalgae, macroalgae 
(seaweeds) and protozoa, has just begun. The slower 
progress is a result of their large genome size and 
high cellular complexity. This group of mainly aquatic 
organisms is very old, highly diverse and taxonomically 
still vaguely defined. Currently not much more than 30 
microalgal genomes have been completed, ranging 
from 12 to 165 Mb in size. Algal genome sizes can 
even vary about 20 fold within a genus, as illustrated 
with Thalassiosira species. The overall size range for 
microalgal genomes is 10 Mb to 20 Gb, with an average 
size of around 450 Mb, except for Chlorophyta, that 
are on the average four times larger. Many marine 
microalgae are highly complex single celled organisms 
containing chromosomal DNA as well as mitochondrial 
and chloroplast DNA. They have a complex nucleus that 
has been subjected to extensive exchange of genes 
between the organelles and the nucleus (endosymbiotic 
gene transfer) as well as horizontal gene transfer during 
their hundred millions years of evolution. In addition, the 
first genome of a macroalgae (Ectocarpus) has been 
sequenced and several others are being completed. 
The challenge here will be to analyse this novel ‘terra 
incognita’ through post-genomics, biochemical 
approaches and genetic developments. The reward for 
taking on this challenge is an improved understanding 
of the biochemical functioning of key players in aquatic 
ecosystems with new insights into the regulatory genetic 
network of eukaryotes and their early evolution, and 
moreover, with great potential for the production of a 
huge variety of bioproducts.
For protozoan genomics the situation is even more 
difficult because of their extremely diverse phylogeny, 
their complex life cycles and their even larger range of 
genome sizes than for microalgae. Protozoan genomes 
range from 8 Mb to 1400 Gb for Chaos chaos which is 
a free-living amoeba with the largest genome reported 
to date. The accuracy of the measurements of these 
very large genomes is questionable and complicated by 
the highly polyploid nature of many protozoan genomes 
that can also contain hundreds of small chromosomes. 
Overall, this complexity and diversity illustrate the basic 
research problems of protozoan genomics and explain 
the low number of completed protozoan genomes (25 
genomes, most of them of medical relevance). 
The study of metazoan genomes is highly biased 
towards vertebrates, especially mammals, due to their 
medical and economic relevance. Marine invertebrates, 
ranging from sponges to crustaceans, comprise only 
11% of the currently planned sequence analyses of 
metazoan genomes, despite their substantially larger 
phylogenetic diversity. Only a few commercially relevant 
marine invertebrates such as mussels and oysters have 
 
Figure 4. Epifluorescence micrograph of prokaryotes and viruses 
in a seawater sample stained with a fluorescent dye, SYBR Green I. 
The dye specifically stains doubled-stranded DNA (dsDNA). 
Smallest dots are viruses and larger ones are prokaryotes (bacteria 
or archaea). With about 1 billion bacterial cells and 10 billion viral 
particles per liter of seawater, viruses are by far the most common 
biological entities in the marine environment.
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Figure 5. Amphimedon queenslandica is a demosponge native 
to the Great Barrier Reef which has been the subject of various 
studies on the evolution of metazoan development. In landmark 
effort its genome has recently been sequenced. 
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been sequenced, largely because of their importance as 
aquaculture species. Teleost fishes have, on average, 
a genome size of around 1 Gb. Interestingly, lungfish 
have a much larger genome, ranging from 50 Gb to 130 
Gb with the marbled lungfish (Protopterus aethiopicus) 
having the largest genome of all animals. Only a very 
few teleost fish genomes have been completed, such as 
Takifugu rubripes and the zebrafish (Danio rerio), which 
are of interest to fisheries and developmental biology, 
respectively.
For prokaryotes, the size of the genome is a very 
good indicator of its gene content and thereby its 
biotechnological potential. This correlation vanishes 
for eukaryotes for several reasons: (i) basic molecular 
genetics are very different and substantially more 
complex (exons, introns, splicing), (ii) highly complex 
RNA infrastructure (small and long non-coding RNAs, 
RNA interference, RNA editing, etc.), (iii) large amounts 
of non-coding DNA (can be more than a hundred fold of 
the coding DNA), (iv) polyploidy, and (v) epigenetics. How 
this complexity has evolved and how it is changing for the 
major taxa is far from understood. This knowledge gap 
has major implications for the use of higher organisms 
for biotechnological purposes. Some of these important 
consequences are: (i) eukaryotic genome projects will 
take longer and demand more resources to complete 
annotation, (ii) genetic engineering opportunities 
are very different according to the species, and (iii) 
transcriptomics and proteomics are very complex and 
cannot be used easily to understand the relationship 
between phenotype and genotype. Overall, these major 
differences present a difficult challenge for using ‘omics’ 
approaches on a large scale for higher marine organism 
for the benefit of biotechnology.
2.1.2 Metagenomics of marine communities
Metagenomics, comprising the analysis of all genes 
of a given community of organisms, is even younger 
than the ‘omics’ revolution, with the first successful 
study published in 2001. Metagenomics only became 
technically possible through the availability of Bacterial 
Artificial Chromosomes (BACs) and the possibility to 
clone and sequence long stretches of environmental 
DNA. Metagenomics works like a shotgun by taking 
all the genes of a community apart by complete DNA 
extraction and putting these genes in large clone libraries 
to make them available for later use in biotechnological 
applications. The first metagenomic studies con-
cen trated on bacterioplankton which can easily be 
separated from higher organisms by filtration. Current 
metagenome studies target all domains of life and a 
broad range of environments. Meta-transcriptomics 
and meta-proteomics have been successfully applied 
to bacterioplankton providing exciting insights into the 
functioning of microbial communities. However, these 
approaches lack broader application owing to their 
complexity and are of limited value for biotechnological 
exploitation.
A biological bottleneck for exploitation of newly 
discovered genes from marine genome and 
metagenome projects is the heterologous expression 
of recombinant proteins in well characterised 
biotechnological workhorses like Escherichia coli or 
Bacillus subtilis. Innovative molecular approaches are 
needed whereby enzymes or secondary metabolites, 
useful for biotechnology, can be obtained directly from 
targeted marine systems. In addition, it has become 
apparent that two technical bottlenecks can impede 
metagenomic studies: (i) massive sequencing is needed; 
and (ii) massive computing capacity is essential. The first 
bottleneck has been overcome with the development of 
deep and ultra deep sequencing technology (see below). 
The second bottleneck, however, is becoming even 
more problematic because of the enormous amount 
of sequence data generated and the need for massive 
parallel data processing capability.
2.1.3 Deep sequencing
About five years ago, a set of new sequencing 
technologies reached the market (referred to as second-
generation sequencing) enabling 10 to 100 times faster 
— and thereby substantially cheaper — automated 
sequencing of nucleic acids. These technologies, 
allowing so-called ‘deep’ sequencing, were based on 
sequencing by synthesis, also called pyrosequencing, 
and advanced opto-electronics. Currently, depending 
on the specific technology used, these new sequencing 
2. Developments and perspectives of key tools and technologies
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Figure 6. Schematic overview of the metagenomics process 
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The provision of dedicated web-based resources and 
e-infrastructures is essential for advanced research in 
marine ecology and biotechnology. At the same time, 
there is a growing need to interpret the sequence data 
via laboratory biochemical studies.
Summary Box 1. Recommendations for marine 
genomics research 
The screening of marine genomes with molecular 
tools must be intensified to fully capitalise on the 
novel genes, proteins, enzymes and small mole-
cules found in marine macro and microorganisms. 
This requires:
- Genomic analyses of marine organisms, in-
cluding the systematic sampling of different 
microorganisms (viruses, bacteria, archaea, pico 
and micro-plankton), algae and invertebrate taxa;
- Metagenomic studies of aquatic microbiomes and 
macrobiomes; 
- Establishment of integrated databases for marine 
organisms and communities;
- The development of bioinformatics resources and 
e-infrastructures;
- Relevant annotations for marine specific genes 
through the use of biochemical techniques.
technologies provide read length of 50 to 450 nucleotides 
and generate 20 to 200 Mb of raw sequence data per 
run. They enable de novo sequencing of genomes as 
well as re-sequencing of individual genomes of the same 
species at a price that is about 100 times cheaper than 
the classical Sanger-based, automated sequencer. It is 
expected that the next (third) generation of sequencing 
technology (nanopore) will add, probably during the next 
five years, another order of magnitude in terms of speed 
and reduction of price. It is expected that these ultra-
deep sequencing technologies will enable single DNA 
molecule sequencing with read length in the kilo base 
pair (kbp) range, thereby eliminating gene amplification 
bias and providing improved data for metagenome 
assembly. However, the rate at which new tools and 
instruments become available is not always in line with 
the ability of laboratories and researchers to learn and 
use them and the outputs produced are not always 
comparable. 
The application of more and more genomic and 
metagenomic analyses and deep sequencing will 
generate large datasets from marine environments. 
Bioinformatics resources and tools have been developed 
in an attempt to maximise the capacity to analyse these 
vast datasets. This so-called e-infrastructure (equivalent 
to ‘cyber-infrastructure’ which is the term used in the 
United States) has to support advanced data acquisition, 
data storage, data management, data integration, data 
mining, data visualisation and other computing and 
information processing services over the Internet. 
 
Figure 7. (R)Evolution in 
Sequencing Technology
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2.2 Metabolic engineering and 
systems biology
Knowledge of metabolic pathways and their link with 
genomics and other omics aspects of marine organisms 
are an important basis for the production of unique 
compounds. However, the productivity (the amount 
of product produced per volume of culture over time) 
of the original organisms is often much too low to 
make commercial production possible. In many cases 
it is necessary to increase productivity in the marine 
organism or to introduce the metabolic pathways into 
a new host organism that can be grown much more 
easily.
Metabolic engineering is defined as the optimisation 
of genetic and regulatory pathways to increase the 
production of certain compounds by cells. Many 
techniques for this purpose have been developed for 
prokaryotic systems and need to be developed further 
for eukaryotic systems.
Better processes can be developed if the right targets 
for metabolic engineering are properly chosen. 
The target of metabolic engineering will always be 
determined by the biochemical bottlenecks in the 
process and the economic limitations of the individual 
steps in the production chain. Various modelling 
approaches can be used to identify these bottlenecks, 
including mathematical models, metabolic flux models 
and process design models (see also Section 2.4.3). 
For example, there is currently a strong focus on lipid 
production by microalgae for biofuel applications. It is 
generally assumed that the process will be improved 
if the lipid productivity is increased. However, in most 
microalgae the cell wall is so thick that extraction of 
the lipids is actually the bottleneck in the process. In 
this case, the goal of metabolic engineering should 
be to reduce the thickness of the cell wall instead of 
increasing the productivity of lipids. Thus models 
help identifying interesting targets to be addressed by 
metabolic engineering.
The application of engineered cells produced in 
contained systems could certainly improve the 
prospects for commercial production of certain 
bioactive compounds for medicines, reduce the cost 
price for production of food ingredients or make the 
production of energy ingredients more sustainable. 
Engineered organisms are expected to become more 
commonly used in the future but the biosafety and 
consumer acceptance aspects will need to be taken 
into account.
Systems biology is an emergent field that aims at 
system-level understanding of biological systems. 
In systems biology organisms are studied as an 
integrated and interacting network of genes, where 
these interactions determine the functions of an 
organism. Systems biology studies this network largely 
on mathematical tools to understand gene function 
relationships.
System-level understanding has been a long standing 
goal in the biological sciences. In the early days of 
molecular biology, only phenomenological analysis was 
possible and it is only recently that system-level analysis 
can be grounded on discoveries at molecular-level. 
With the progress of genome sequencing and a range 
of other molecular biology projects that accumulate in-
depth knowledge of the molecular nature of biological 
systems, we are now at the stage where a system-
level understanding based on a sound molecular-level 
understanding, is possible.
2.3 Cultivating the uncultured 
During the last decade it became more and more 
evident that many bioactive molecules are produced 
by unknown and uncultivated microorganisms (the so-
called dark matter), or microorganisms associated with 
invertebrates, often through symbiosis. Metagenomic 
approaches can sometimes give a direct access to the 
gene(s) of interest, but in many cases, it is still necessary 
to culture the organisms to produce enough bioactive 
compounds for further detailed characterisation. In 
some cases, culture techniques for marine organisms 
are similar to the general culture techniques used in 
2. Developments and perspectives of key tools and technologies
Figure 8. Systems biology is the study of an organism, viewed 
as an integrated and interacting network of genes, proteins and 
biochemical reactions which give rise to life. Instead of analysing 
individual components or aspects of the organism, such as sugar 
metabolism or a cell nucleus, systems biologists focus on all  
the components and the interactions among them, all as part of  
one system. 
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biotechnology. However, marine environments induce 
specific culture requirements for most marine organisms. 
This section will address the technical challenges 
associated with cultures: how can we (i) access the 
marine microbial dark matter through cultures; and (ii) 
improve the cultivation of microbial marine invertebrate 
symbionts and cell lines of marine invertebrates?
2.3.1 Access to the uncultured marine 
microbial majority
To date, it has been practically impossible to grow 
on a synthetic medium more than a minute fraction 
of the global diversity present in any crude sample. 
This phenomenon, one of the oldest problems of 
microbiology, is known as ‘the great plate count 
anomaly’ has erroneously been perceived as being of 
minor importance since the emergence of molecular 
environmental microbiology and more recently the 
advent of metagenomics. The result is an exponentially 
growing amount of microbial sequences, most of them 
unrelated to cultivated microorganisms. The gap for 
prokaryotes (bacteria and archaea) is increasing fast. 
While in 1987 much of our knowledge derived from 
pure culture techniques with cultured representatives 
of all the known phyla, twenty years later only 30 of 
the 100 bacterial phyla identified possess a cultivated 
representative. With a doubling of sequencing efficiency 
every 12 months versus a linear trend in isolation of novel 
prokaryotic species there is no sign of improvement. 
Molecular biology and metagenomics opened the lid 
of the microbial diversity box and provided an efficient 
access to the corresponding genetic diversity. They 
contributed to shape our evaluation of the importance 
of the ‘dark matter’ or the uncultivated majority of 
prokaryotes, not just from marine environments but 
from all parts of the biosphere. Access to the gene 
resources is a first step. A second one is to gain access 
to the uncultured majority through innovative culture 
methods.
Why is it so important to improve the number and 
diversity of cultivated microbes?
Firstly, while the output of meta-omics are of high 
interest for data mining, they currently have their own 
limits: sequence errors, length of reads and subsequent 
assembly limitations, gene fragmentation, high frequency 
of hypothetical genes, and the difficulty of relating gene 
resources to complex products other than proteins and 
enzymes. In the case of drug research it is also difficult to 
identify and isolate the ‘host’ organisms to demonstrate 
their absence of pathogenicity. Secondly, metagenomics 
and other meta-omics approaches are as yet of little 
help to unveil and to characterise the interactions 
between organisms and the complex networks that 
control population dynamics, especially when threshold 
phenomena are involved or when viruses play key 
roles in ecosystem regulation. The discovery of novel 
signalling compounds still relies on the ability to control 
cultivation. Finally, prokaryotic and picoeukaryotic strain 
collections either in private collections or in public BRCs 
(Biological Resource Centres) are the cornerstone of 
marine cellular biodiversity research and conservation. 
DNA and genomes cannot replace culturable cells, 
at least not yet. And if synthetic genomics fulfils its 
promise, it will likely remain cheaper for some time to 
isolate, to culture and then to curate a new strain than 
to produce it through synthetic genomics.
 
Figure 9. Micrograph of Lyngbya, a benthic marine filamentous 
cyanobacterium forming microbial mats in coastal areas which is 
known for producing many bioactive compounds
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Figure 10. Analysing cultures of marine microorganisms in the 
laboratory 
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Why does it remain so difficult to improve 
microbial cultivation efficiency?
At present, there seems to be no solution to solve the 
problem of microbial cultivation other than tedious and 
time consuming work at the bench in the microbiology 
laboratory. The slow progress can be mainly attributed 
to the low priority given to research in this supposedly 
old-fashioned field. More specific interdependent 
reasons that could explain the failure to grow many 
prokaryotes by classical approaches include:
•	 Fundamental	lack	of	knowledge.	Most	microbes	are	
not amenable to culture using classical approaches 
probably because of our insufficient knowledge of (i) 
the organisms themselves; (ii) the chemistry of their 
natural habitats; (iii) the natural biotic and abiotic 
interactions; and (iv) the global functioning of their 
ecosystems at microbial level; 
•	 Lack	of	patience	(partly	because	of	the	pressure	
to publish results) and a lack of sensitive detection 
methods for low cell yields; 
•	 Most	in vitro cultivation techniques aim paradoxically 
at isolating strains in pure culture, while most 
organisms in nature live in community and establish 
complex relationships including communication and 
cooperation. Thus the very first stage of isolation 
results in a break in intraspecies communication, and 
the disruption of all interspecific interactions. 
In practice, the social life of microbes has largely 
been underestimated and could be the key to 
developing techniques to cultivate many of them. 
It could also be an invaluable source of novel 
signalling compounds potentially interesting for 
biotechnology; 
•	 During	the	enrichment-isolation	process	the	abiotic	
interactions are most of the time broken off. This 
suggests again that a better understanding of marine 
chemical ecology must be developed. 
The same factors explain the difficulties associated 
with the cultivation of prokaryote and eukaryote 
microorganisms. To improve the cultivation efficiency 
of unknown microbes, the following conditions need to 
be satisfied: 
•	 A	radical	change	in	isolation	rates	and	a	substantial	
increase in the use of medium or high throughput 
based approaches in cultures and isolation pro-
cedures;
•	 An	unprecedented	effort	towards	gaining	a	better	
understanding of the various types of cell-to-cell 
communication in the microbial world and, more 
generally, of the social life of microbes; and
•	 The	 development	 of	 innovations	 enabling	 the	
combination of optimised methods, specific devices 
and robotics.
Summary Box 2. Research priorities to improve 
the cultivation efficiency of unknown microbes
To improve the cultivation efficiency of unknown mi-
crobes, future research priorities should include:
- Extraction of relevant metabolic information from 
genomic data and the use of molecular data to 
trace the cells of interest among community cul-
tures; 
- Improvement in the detection of cultures at low and 
very low densities;
- Refinement of culture media with additional in-
formation from metagenomics and knowledge of 
chemical ecology;
- Mimicking nature through in situ cultivation sys-
tems;
- Design of devices enhancing cell-to-cell commu-
nication;
- Development of automated procedures through ro-
botics in combination with different approaches;
- Development of rapid identification methods for 
efficient dereplication and selection of novel strains 
and species.
2. Developments and perspectives of key tools and technologies
Figure 11. Preparing, maintaining and analysing cultures in the 
marine microbiology laboratory is tedious and time consuming. 
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aquaculture to produce raw material is, in most cases, 
uneconomical. For these reasons synthesis or semi-
synthesis could be a better approach. However, given 
the complexity of the molecules involved, most chemical 
synthesis approaches, if viable, would require a large 
number of synthetic steps. The consequence is that, 
in most cases, chemical synthesis is impractical and 
unviable in terms of chemical yield. Hence, more efforts 
are needed to understand the metabolism that is involved 
in the biosynthesis of the required compound. 
Ideally we would like to produce the bioactive compounds 
in immortalised continuous cell lines. Immortalised 
continuous sponge cell lines are not yet available. 
Animal cell lines from insects and mammals usually 
are transformed cells that have an unlimited capacity 
to proliferate (immortal). For mammals, transformed 
cells can be obtained from tumour tissue or induced 
artificially by, for example, hybridisation of normal 
cells with other transformed cells (e.g. hybridomas), 
by subjecting the cells to mutagenic agents such as 
carcinogenic compounds, viruses or radioactivity, or 
by transfecting the cells with oncogenes. Sometimes, 
immortal cells evolve spontaneously by mutation of 
normal cells growing in rich media. So far, no reports on 
successful immortalisation of sponge cells have been 
published. 
It would appear that sponges are very dynamic 
organisms with a very slow net growth that is the result 
of fast division of cells and a high rate of apoptosis. For 
the development of continuous growing cell lines it will 
be necessary to exploit the strong capability of sponge 
cells to divide and to prevent cells from apoptosis. More 
information is now becoming available on this subject 
from amongst others research on the demosponge 
Amphimedon queenslandica (see Figure 5).
Cultivation of microbial marine invertebrate 
symbionts
Marine invertebrates are the richest source of newly 
discovered bioactive metabolites. In addition, many 
marine invertebrates host a large variety of symbiotic 
bacteria, archaea and other microorganisms. Therefore, 
it was not surprising that many bioactive compounds 
that were previously ascribed to the host are actually 
produced by microbial symbionts. For example, 
halichondrin B and discodermolide are among the 
most promising anti-tumour molecules that have (to 
date) been discovered in sponges. Other potent marine 
invertebrate-derived compounds with anti-tumour or 
potentially anti Alzheimer’s disease activity are the 
tunicate-derived ecteinascidin 743 and bryozoan-
derived bryostatin-1. Halichondrin B, discodermolide 
and bryostatin-1 are type I polyketides, metabolites that 
are mostly associated with bacterial metabolism. For 
bryostatin-1 it has been confirmed that it is produced 
by an uncultured gammaproteobacterial endosymbiont 
of the bryozoan. None of these compounds could 
be obtained by cultivation of marine invertebrate-
associated bacteria.
The unculturability of the producers of bioactive 
compounds confirms the general unculturability of 
marine invertebrate-associated bacteria. New cultivation 
approaches are necessary to overcome this hurdle as 
cultivation will remain an important technique in the 
era of genomic analysis. Cultivation will give access to 
‘clean’ genomes from environmental samples and, in 
addition, allow initial production of complex secondary 
metabolites that are found in marine invertebrates (and 
cannot easily be expressed in a heterologous host). 
New approaches that have to date only scarcely been 
employed are co-cultivation of host and symbionts. They 
could be cultivated for example in ‘together but apart’ 
systems, such as diffusion chambers. Co-cultivations 
can be seen as an intermediate step between the natural 
environment and pure culture. 
 
2.3.2 Cell cultures of sponges and  
sponge cells
Marine sponges are a rich source of bioactive 
compounds. In some cases, sponge symbionts are 
responsible for production of these compounds and in 
other cases it is the sponge itself which produces the 
compound.
A number of avenues for the supply of bioactive 
compounds can be explored. Harvesting the producing 
species and extracting the active compound is seldom 
sustainable owing to variability in yield with location, 
season and biological conditions, and such an approach 
is also deemed ecologically unsound. Moreover, using 
 
Figure 12. Marine sponge Amphilectus fucorum 
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Summary Box 3. Recommendations to address 
microbial cultivation challenges
- Recognise that the microbial cultivation challenge 
is critical for the future of marine microbiology, mi-
crobial ecology and microbial biotechnology and 
actively support the development of innovations in 
this field;
- Promote basic research in the field of marine 
microbial ecology in order to understand and ac-
cess compounds and mechanisms which regulate 
intraspecies and interspecies cellular communica-
tion which might, in turn, lead to new discoveries 
and possibly to novel antibiotics;
- Develop innovative culture methods for symbionts 
producing active compounds and cell line cultures 
of invertebrates of biotechnological interest.
2.4 Technological advances 
in bio-engineering beneficial 
to the development of Marine 
Biotechnology 
2.4.1 Culture of microalgae and use of 
photobioreactors 
A huge variety of cultivation systems have been 
developed for microalgae but the most important 
are based on the use of open raceway ponds and 
photobioreactors. The only one which has been used 
on a large scale and a commercial basis is the shallow 
open raceway pond. These ponds are usually no more 
than 30 cm deep and the water containing nutrients 
and microalgae is circulated by a paddle wheel. CO2 or 
CO2-containing exhaust or flue gases can be sparged 
through the culture. Major drawbacks of these open 
systems are that there is almost no possibility for 
temperature control (unless a source of cheap surplus 
heat is available) and that they are very susceptible to 
invasion of algal predators, parasitic algae or other algal 
strains that grow better at the applied conditions and 
therefore out-compete the desired species. Only a few 
species can be grown in these open systems through 
a selective environment. For example, Dunaliella salina 
requires a high salinity while Spirulina platensis requires 
a highly alkaline environment. Moreover biomass 
concentration and thus volumetric productivity is very 
low due to the long light path and poor mixing. Despite 
these major drawbacks these ponds can allow a simple 
use of largely unexploited shallow coastal regions.
A photobioreactor can be described as an enclosed, 
illuminated culture vessel designed for controlled 
biomass production of phototrophic liquid cell 
suspension cultures. While an open pond could be 
seen as photobioreactor, the term photobioreactor 
mostly refers to closed systems having no direct 
exchange of gases and contaminants with the outside 
environment. Photobioreactors are considered to have 
several major advantages over open ponds. In short 
they can (i) prevent or minimise contamination, allowing 
the cultivation of algal species that can not be grown 
in open ponds; (ii) offer better control over cultivation 
conditions (pH, pCO2, pO2, Temperature, etc.); (iii) 
prevent evaporation and reduce water use; (iv) lower 
CO2 losses due to outgassing; and (v) attain higher 
cell concentrations and, therefore, higher volumetric 
productivity. Certain requirements of photobioreactors 
(e.g. cooling, mixing, control of oxygen accumulation 
and biofouling) make these systems more expensive 
to build and operate than open ponds. In spite of their 
numerous advantages, the viability of photobioreactor 
technology on very large scales remains to be 
demonstrated. Nonetheless, many microalgae which are 
promising for the production of an enormous variety of 
compounds and their products require maintenance of 
monocultures and for that, enclosed photobioreactors 
have to be used. Photobioreactors, as completely 
closed systems, could also be of high interest for 
Genetically Modified Organism (GMO) production of 
targeted compounds for pharmaceutical industry. 
However, certain requirements of photobioreactors 
such as cooling, mixing, control of oxygen accumulation 
and biofouling, make these systems more expensive to 
build and operate than ponds. New cheaper innovative 
photobioreactor systems are being designed and waste 
streams are used to make the production of microalgae 
commercially attractive. 
Information Box 2.  
Photobioreactor optimisation
The fundamental design elements of photobioreac-
tors are targeted at the control of light gradient and 
light/dark cycles, surface to volume ratio, mixing 
and degassing. The Surface-to-Volume (S/V) ratio of 
the bioreactor (i.e. the ratio between the illuminated 
surface of the reactor and its volume) determines 
the amount of light that enters the system per unit 
volume and the light regimen to which the cell popu-
lation is exposed, and is consequently one of the 
most important factors in photobioreactor design. 
The hydrodynamic behaviour of the culture is also 
affected by this as higher S/V ratios can lead to 
shorter light/dark cycles. For these reasons, in re-
cent years a general trend towards the reduction of 
the diameter of tubular reactors and the thickness of 
2. Developments and perspectives of key tools and technologies
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flat panels can be seen. The type of device used to 
mix and circulate the culture suspension is essential 
in the design of a successful photobioreactor. Both 
the productivity of a photobioreactor and the cost 
of its construction and operation are influenced to a 
great extent by the type of mixing mechanism used. 
Mixing is necessary for a number of reasons: to pre-
vent cells from settling, to avoid pH and temperature 
gradients, to distribute nutrients, to supply CO2 and 
remove O2. Yet, excessive mixing can lead to cell 
damage and eventually cell death. For this reason 
the choice of mixing intensity and mixing system 
must be dictated by the characteristics of the or-
ganism to be cultivated. Finally, scaling up from a 
prototype design to full-scale commercial size sys-
tem is still a very challenging issue.
Summary Box 4. Recommendations to improve 
the use of photobioreactors for the culture of 
microalgae
- Optimise microalgal cultivation systems with re-
spect to energy supply, productivity and cost; 
- Develop innovative photobioreactors adapted to 
the different species of interest and define optimal 
scaling-up approaches taking into account local 
space constraints and availability of inputs: CO2, 
light, downstream processing;
- Develop design criteria for culture systems and ad-
vise professionals in the construction of industrial 
scale systems in the near future. Achieve cost re-
duction to be fully compatible with market needs.
2.4.2 Culture of macroalgae
Currently, the European seaweed industry relies on 
macroalgae collected from the wild with the exception of 
some Asian and African seaweeds such as Kappaphycus 
and Eucheuma which are cultivated for carrageenan 
extraction. The growing demand for raw material for 
food, cosmetics and bioactives, raises questions 
surrounding the sustainability of the European industry. 
There is an urgent need to upscale or develop methods 
for mass production of native seaweeds. 
The development of culture methods, particularly for 
rare and slow-growing plants, is expected to have a 
significant environmental benefit in the conservation of 
genetic resources and of algal-associated biodiversity. 
There are several approaches used to cultivate 
seaweeds: fragments of plants, sporelings or spores 
can be seeded onto ropes or other substrates and 
grown to maturity in the wild. An alternative to open 
sea culture is the cultivation of seaweed in artificial 
enclosures, such as tanks or ponds, where seaweeds 
can be grown in high densities on otherwise low value 
land. The nursery phase of open-ocean cultures is 
also operated in controlled conditions with techniques 
for intensive land-based seaweed aquaculture with 
air rotation of the seaweed biomass in tanks (tumble 
culture). Bioreactors designed for tiny species allow even 
higher productivity values. There are clear advantages 
to land-based seaweed aquaculture over cultivation in 
the sea including: better control of both epiphytes and 
photoinhibition by maintaining high algal density within 
the tank and the possibility of high levels of productivity 
all year round. This is made possible through the 
provision of (i) year-round supply of nutrients, and (ii) 
 
Figure 13. Vertical photobioreactor
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artificial light in the winter and the manipulation of day 
length (photoperiod) and thus of plant seasonality to 
control reproductive and nutritional physiology. Heat-
sensitive seaweed species may be cultivated on land 
throughout the summer by use of cold water pumped 
from 20-30m ground depth and cooling the seawater 
tanks by heat exchangers. 
At a first glance, the costs of land-based seaweed 
aquaculture may appear higher than for seaweed 
cultivation performed in the sea, but integration of 
seaweed biomass as a nutrient scrubber into existing 
land-based marine animal farms may reduce the cost 
to such an extent that in future land-based seaweed 
cultivation may compete with seaweed cultivation in 
the sea. 
Both open sea-based aquaculture and alternative 
growing methods are likely to be important for Europe. 
Regardless of the specific technique, these activities 
require detailed information about the biology and life 
cycle of the algal crops and the different production 
options. Marine genomics research is generating 
new tools, such as functional molecular markers and 
bioinformatics, as well as new knowledge about statistics 
and inheritance phenomena that could increase the 
efficiency and precision of algal crop improvement. 
Marker-assisted breeding and selection will be largely 
accelerated by these novel approaches. In addition, it 
is expected that population genomics will help in the 
exploitation of algal genetic resources as well as in the 
development of association genetics.
Among the traits which are of interest for the 
selection of algal crops are their defenses against 
stress and especially biotic stress. Populations of 
algae (Phaeophyceae) can be affected by various 
pathogens, including fungi, oomycetes, bacteria, 
viruses and pathogenic algal endophytes. Intensive 
algal mariculture however, may facilitate disease 
outbreaks. As aquaculture continues to rise worldwide, 
pathogens of algal crops are becoming a significant 
economic burden. Algal chemical defenses which are 
known to exist include secondary metabolites such as 
terpenoids and polyphenolics, as well as fatty acid-
derived compounds, which are either antimicrobial, 
anti-herbivore or act as signalling compounds.
2.4.3 Optimisation of production systems for 
Marine Biotechnology
The production of microbes, microalgae, macroalgae 
or invertebrates for bioactive compounds, biorefinery 
or energy applications is a complex process that 
needs considerable optimisation. Very different but 
complementary approaches can be employed, including 
metabolic flux modelling, biorefinery, bioprocess and 
chain design, and up-scaling.
Metabolic flux modelling
Establishing industrial production and maximising 
productivity requires in-depth knowledge of basic 
biological functions and tools for steering the 
metabolism. This can be achieved through generating 
optimal conditions inside a reactor or through metabolic 
engineering. 
A key technology for optimal metabolic design is the 
metabolic flux model. A metabolic network model can 
be constructed with the known stoichiometry of the 
biochemical reactions. Next, by assuming steady state 
and constructing mass balances over the intracellular 
metabolites, the rates with which these biochemical 
reactions take place (the fluxes) can be connected 
to the consumption of substrates and production of 
biomass and other compounds, including bioactive 
compounds. This is currently difficult to achieve because 
of our fundamental lack of knowledge of biochemical 
processes in marine organisms and notably of the 
equilibrium and rate constants for the reactions. For 
development of metabolic flux models and metabolic 
engineering, the availability of well annotated genomes 
and quantitative tools for genome-scale metabolic 
models that permit understanding and manipulation 
of the genome are important. An integrated approach 
using state-of-the-art omics technologies is therefore 
needed in order to gain the best possible insight into 
metabolic pathways leading to the product of interest.
Biorefinery
Research is often only focused on production of biomass 
or specific biomass ingredients at high efficiencies and 
high volumetric productivities. The biorefinery concept is, 
however, about more than just downstream processing. 
The focus in downstream processing is usually to 
2. Developments and perspectives of key tools and technologies
Figure 14. Marine macroalgae in a tidal pool 
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isolate one specific compound while in a biorefinery 
the biomass is fractionated resulting in several isolated 
products from the biomass. The biorefinery approach 
is, therefore, analogous to today’s petroleum refinery, 
which produces multiple fuels and chemical products 
from petroleum. In order to maintain the functionality of 
the isolated products in a biorefinery, isolation should 
be performed under mild conditions. In this respect, 
production in the biomass should be optimised whilst 
allowing mild extraction and fractionation of the different 
products. For an efficient biorefinery, new extraction and 
fractionation processes will need to be developed. 
Bioprocess and chain design
For the manufacturing of new marine products the 
process design should be done early on. In the early 
stages of development much of the basic information 
for an optimal design is still unknown. Even if many 
aspects are unknown it makes sense (and often 
assumptions need to be made) to make a general design 
of predicted processes. The result of these designs is 
that bottlenecks in the process are identified which will 
determine the agenda of the research programmes. As 
know-how increases, more accurate designs can be 
made and research objectives can be narrowed down 
such that processes are developed more rapidly. 
The whole production process, upstream and 
downstream, should be developed and tested at pilot 
and demonstration scale. Production at large scale 
will be complex with respect to logistics and space 
requirements, especially for bulk applications such as 
food, feed and fuels. Resources for production, such 
as sunlight, land, water, CO2 and nutrients should be 
available. Availability and cost of transport (both in 
terms of economy and energy) will determine the scale 
at which production is efficient. Transport of the different 
feedstocks over long distances is most probably not a 
feasible option. A design of the whole system, including 
the logistics and analysis of the life cycle is a good 
basis to analyse the sustainability and viability of the 
technology.
Scale-up
Developments in technologies aimed at commercial 
production are mainly driven by end users. For new 
processes, the end users usually have a limit in supply of 
biomass to develop further processes. For this reason, 
some production capacity needs to be realised straight 
away. With such a production capacity, end products 
can be manufactured and tested, and research in 
biorefinery can be further developed. In addition, for 
new technology there is little or no experience with 
production at larger scales for longer periods of time. 
It is very important, therefore, not only to do research 
at a laboratory scale but also to develop pilot scale 
production experiments to evaluate and compare their 
performance as a basis for the design of demonstration 
scale facilities.
In order to facilitate rapid development of the 
technology, research at laboratory scale, pilot scale 
and demonstration scale should run parallel with a good 
exchange of information such that technology developed 
in the laboratory can be tested under realistic conditions 
and research at laboratory scale can be targeted at 
addressing the problems encountered at large scale.
Summary Box 5. 
Recommendations for the optimisation of
production systems for Marine Biotechnology
- Develop the use of metabolic flux modelling as 
early as possible in Marine Biotechnology pilot 
scale production projects;
- Promote research on the development of biore-
finery technologies and approaches based on 
microalgae production to develop a long-term 
alternative to petrochemistry (see also Summary 
Box 10 in Section 3.2.2);
- Increase the support to Marine Biotechnology re-
search and development initiatives at European 
levels which integrate bioprocess and chain de-
sign through cooperation between academic 
research teams and industry;
- In parallel to laboratory research, support the de-
velopment of demonstration-scale facilities based 
on projects integrating the knowledge of academ-
ic research groups and the know-how of industry.
2.4.4 Fish culture in recirculating 
aquaculture systems 
In Recirculating Aquaculture Systems (RAS) seafood 
production is combined with water purification to 
maintain a healthy culture environment. RAS refers to 
the process of re-using some (or all) of the water in a fish 
culture facility, for example by circulating it through filters 
to remove fish waste and food and then recirculating it 
back into the tanks. The technology reduces rates of 
water consumption, improves opportunities for waste 
management and nutrient recycling, allows for disease 
and hygiene management, reduces potential wildlife 
interactions (no escapees), and minimises the visual 
impact of farms. In addition, the application of RAS 
technology enables the production of a diverse range 
of (also exotic) seafood products in close proximity 
to (urban) markets, thereby reducing CO2 emissions 
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associated with food transport. Other benefits of the 
RAS approach include:
•	 Being	 generic,	 RAS	 allow	 for	 diversification	 of	
species. As such the selection of species is dictated 
by the economic opportunity, as opposed to the 
geographical location; 
•	 Being	fully	biosecure,	they	are	the	only	aquaculture	
practice that might be considered safe to farm non-
native and transgenic fish;
•	 Being	able	to	fully	tailor	the	environmental	conditions	
in these systems, the fish will perform better and 
grow significantly faster compared to open sea cage 
culture; 
•	 Solid	 waste	 produced	 by	 RAS	 is	 converted	 to	
methane, bioenergy that is captured to offset the 
energy cost of the operation;
•	 RAS	systems	do	not	have	to	be	in	the	proximity	of	a	
source of seawater thus can be developed anywhere, 
close to the markets or to transportation venues, 
reducing the carbon footprint of the operation;
RAS are advanced and complex aquaculture systems 
with technology that relies on both physical and biological 
processes. The biological processes are primarily 
microbial and therefore can benefit from advances 
in marine microbial ecology. There is also potential 
to integrate microalgal systems into recirculating 
aquaculture systems and further downstream in the 
management of fish processing outflows.
Although small, the European RAS industry has a 25 
year commercial history placing it ahead of the US and 
Japan both in terms of size and scope. To maintain this 
competitive advantage, the industry should focus on:
•	 Minimising	the	ecological	impact	of	fish	farming	by	
closing the system, where possible, in terms of water 
and nutrient use;
•	 Maintaining	 top	 quality	 organisms	 in	 quality	
systems;
•	 Producing	healthy	and	safe	seafood	products.
RAS outcompetes any other mode of animal food 
production in terms of consumption of water and 
discharge of nutrients to the environment. Important 
research challenges include fine tuning the quality of 
the wastes produced and maximising waste removal 
efficiency in biofilters while minimising discharge to the 
outside environment. This calls for the development 
of specific RAS feeds and feeding strategies paving 
the way to both reliable and efficient biofiltration and 
profitable production. 
The welfare of culture animals in RAS can be closely 
monitored and controlled. Important welfare related 
research topics in RAS include: (i) fish resilience to 
changes in water quality; (ii) the effect of accumulation of 
substances resistant to microbial breakdown (e.g. humic 
acids) that might bind toxins, metals, steroids, etc.; (iii) 
poor flavour caused by stress; and (iv) welfare impacts 
in relation to the accumulation of bio-active compounds 
in combination with high culture densities. Our 
understanding of the ecology of microbial communities 
in RAS and its interaction with the microbiota in the food 
and gut of culture organisms is still poorly understood. In 
addition, microbiota present during larval development 
are highly variable, and are believed to influence larval 
viability and health.
Summary Box 6. 
Recommendation for the improvement of 
Recirculating Aquaculture Systems (RAS)
Improve the knowledge of microbial communities 
within RAS and consequently optimise its manage-
ment in order to support larval development and the 
establishment of gut microbiota in cultured seafood 
organisms that will contribute to both their health 
and vitality over their entire life cycle. 
2. Developments and perspectives of key tools and technologies
Figure 15. Recirculated fish tank with biofilter (drum on right), 
which uses beneficial microorganisms to remove chemical wastes 
from the water
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2.5 Model species for Marine 
Biotechnology
Conventionally, model organisms are organisms that 
have been selected for in-depth study by scientists 
according to various criteria such as generation time, 
ability to be cultivated in the lab, facility to be genetically 
transformed, genome size, facility to work with, 
evolutionary position, etc. Due to time and human and 
financial capacity limitations it is not possible to perform 
in depth studies of all (marine) organisms of interest. For 
this reason, scientists strive to select a limited number of 
model organisms to focus their attention on, assuming 
that knowledge gained from these model organisms 
could be, to a certain extent, transferred to related 
organisms (e.g. from mouse to human). For reasons of 
space limitations, in this section the discussion focuses 
on marine species only, although it is clear that non-
marine species whether of terrestrial or freshwater (e.g. 
zebrafish) origin are often used as model organisms for 
Marine Biotechnology purposes as well.
Only a few model organisms that are currently 
investigated in biological institutes around the world are 
of marine origin. Among eukaryotes, most of them are 
animals (e.g. sea urchin, sea squirt, lamprey, polychaete, 
platyneris) with a few macro and microalgae and a few 
blue-green algae and archaea. Although they have 
been selected for their interest in fundamental biology, 
model organisms can be very useful for biotechnological 
applications (an overview of marine model organisms 
with their applications can be found in Annex 4).
For example, sea urchin embryos are good models for 
cancer research or neurodegenerative disorders. This 
echinoderm represents a powerful research model 
that has brought almost everything we know about 
the chromosomal basis of development, maternal 
determinants, fertilisation and maternal messenger 
RNA. The genome sequence of the California Purple 
Sea Urchin Strongylocentrotus purpuratus (see Figure 
17), obtained recently, provides a unique opportunity 
to address crucial questions in developmental biology 
and cell cycle regulation. Using sea urchins as a 
model is important since these organisms occupy a 
key evolutionary position with respect to vertebrates. 
Indeed, the echinoderms and their sister group, the 
hemichordates are the only other deuterostome animals 
besides the chordates. The sea urchin is thus more 
closely related to humans than other major invertebrate 
models in use. Therefore, knowledge obtained from sea 
urchin studies gives the opportunity to discover potential 
new targets for therapy in humans.
Extremophiles found in coastal and deep-sea hydro-
thermal vents harbour a huge diversity of micro organims 
 
belonging to Bacteria, Archaea and their related viruses. 
The nucleic acid processing machinery (DNA synthesis, 
replication, repair and recombination) is similar in 
eukaryotes and archaea, with the latter displaying a 
simplified version. The DNA replication machinery -or 
replisome- of Pyrococcus (hyperthermophilic archaea) 
does not only offer thermostable DNA polymerases 
commonly used in high fidelity PCR, but also provides 
a set of proteins and enzymes that might contribute 
to solving unanswered questions about the human 
replisome like the resolution of its 3D structure which 
is of much interest in the design of new anti-cancer 
therapies.
It is difficult to estimate the importance of models 
for Marine Biotechnology innovations and there is 
no ideal model that should be developed specifically 
for biotechnological purposes, but there is a wealth 
of information and data that could be of interest for 
developing new products and services, that are either 
not produced, made available or that are underutilised 
by the wider scientific community. Moreover, marine 
models could lead to entirely new insights, particularly at 
the larval stages where different kinds of host-defence 
mechanisms are operating. 
Figure 17. California Purple Sea Urchin Strongylocentrotus 
purpuratus. Sea urchins are important as research models in 
developmental biology, cell biology, gene regulation molecular 
biology, evolutionary biology, metabolic biochemistry and marine 
biology. The genome of Strongylocentrotus purpuratus was 
sequenced and published in 2006 providing a unique opportunity 
to address crucial questions in developmental biology and cell 
cycle regulation. 
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2. Developments and perspectives of key tools and technologies
The oceans are the cradle of life and the three do-
mains of the tree of life, namely Bacteria, Archaea, 
and Eukaryotes have evolved in the marine envi-
ronment from a common ancestor. Prokaryotic life 
originated in the oceans about 3.6 billion years (Gyr) 
ago. Eukaryotic life originated between 0.6 and 1 Gyr 
later and the most ancient fossils currently known of 
multicellular organisms dates back to 2.1 Gyr. Land 
became colonised by fungi about 1 Gyr ago and by 
green plants only 0.7 Gyr ago. Thus the very long ev-
olution period of marine life compared to terrestrial 
life has generated a massive biodiversity at the gene, 
the genome, the species, the lineage and the ecosys-
tem level. For example, the animal eukaryotic lineage 
that includes sponges, molluscs, invertebrates and 
mammals, is simply one single independent lineage 
in the tree of life that contains tens of lineages, all 
of which comprise marine organisms. This diversity 
includes lineages that have evolved multi-cellularity 
such as animals, green plants, red and brown algae 
and fungi but most of them are unicellular (microbial) 
eukaryotes. The same evolutionary diversity can be 
found in the two other prokaryotic domains, Archaea 
and Bacteria. Even more importantly, bacterial and 
archaeal diversity is surpassed ten-fold by the diver-
sity of viruses. 
This evolutionary richness combined with an adap-
tation to a wide range of environmental conditions 
(temperature, salinity, tides, pressure, radiation, light, 
etc.) and to a specific aquatic habitat, makes marine 
organisms a huge reservoir for new developments in 
both basic knowledge and biotechnological innova-
tions and both aspects are related. At present only 
a few marine lineages have been investigated with 
modern biological approaches, and many remain as 
yet totally unexplored or even undiscovered.
Figure 16. Eukaryotic tree of life  (modified from Baldauf S., 2008)
Information Box 3. Exploration of marine life
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about these signal molecules which most of the time, 
are produced at very low concentrations and that could 
offer novel options for biotechnological applications. 
Marine chemical ecology, the discipline that addresses 
these questions, is still in its infancy worldwide with a 
very restricted scientific community in Europe.
Once a molecule/compound/enzyme from a marine 
organism has been identified as being valuable for 
biotechnological application, the immediate subsequent 
question is one of access to the biomass. When the 
molecule is an enzyme, then expression in heterologous 
systems is often possible provided that the gene is 
identified and available. If the molecule is not easily 
synthesised and belongs to an organism that is rare 
and not amenable to cultivation then biotechnological 
development may take different routes according to the 
cost/benefit outcome. Access to the natural resources 
is also an important issue and exploitation or sampling 
should be performed according to the international 
policy on biodiversity protection and using sustainable 
management practices.
Summary Box 7
Recommendations to improve the use of marine 
model organisms for Marine Biotechnology
- Identify and encourage the development of new 
priority marine models that have not yet been in-
vestigated in the tree of life, to fill critical gaps;
- Improve access to the knowledge generated from 
model organisms for biotechnological purposes. 
Identify the mechanisms that should be imple-
mented for facilitating the transfer of knowledge 
from scientists studying marine models for bio-
logical reasons to more applied research;
- Foster and support the development of the newly 
emerging field of marine chemical ecology;
- Ensure that marine organisms of biotechnological 
interest are exploited in a sustainable way. Always 
consider cultivation issues and access to the  
biomass in parallel to the screening and research 
activities for biotechnological development.
There are many different marine models being 
investigated in European laboratories that may be 
of interest for biotechnological purposes for various 
applications or molecules such as:
•	 New	enzymes	(bio-catalysts);
•	 Proteins	and	peptides;
•	 Secondary	metabolites;	
•	 Polysaccharides	(bacteria,	archaea,	algae,	marine	
plants);
•	 Fatty	acids	and	lipids	(microalgae).
Nevertheless from a phylogenetic and evolutionary 
point of view, only a limited number of marine models 
even within the animal lineage, are established as 
biological models and this deficit is detrimental to 
the advancement of Marine Biotechnology. While the 
recent revolution in sequencing techniques now makes 
it possible to sequence many more genomes at much 
lower cost, the establishment of a model organism is 
much more than genome sequencing. The knowledge 
gained from the development of new marine models 
could provide the basis for more targeted studies in 
closely related marine organisms with specific interests 
for biotechnological applications. We can now access 
whole genomes of marine organisms and metagenomes 
more easily. The major challenge facing us is to mine 
the genes of interest, to identify novel functions and 
to store and utilise all these metadata. This requires 
novel bioinformatics developments as well as the 
establishment of collective e-infrastructures. 
Besides the typical biological models concept, one 
needs to emphasise the value of defining ecological 
models that are not relevant biological models because 
they do not satisfy the criteria detailed before, but which 
play a significant role in the marine ecosystem. This 
is the case for instance for the diatom Thalassiosira 
pseudonana, or the haptophyte Emiliania huxleyi. This is 
the case also with seagrass populations in coastal areas 
where they play a critical role in marine ecosystems and 
have a huge impact on aquaculture grounds and fisheries 
as well as a significant role in carbon sequestration. 
In a similar manner, fish such as seabream, seabass 
and salmon or shellfish such as oysters, mussels, 
clams that are supplied through fisheries and 
aquaculture can be considered as economic models.
Interaction between marine organisms is critical in our 
choice of model organisms. Communication in the 
marine environment is different than in the terrestrial 
environment and marine organisms have developed 
a whole set of molecules (aldehydes, halogenated 
compounds…) that are used for communicating among 
communities of the same species, in defence responses 
against pathogens, as signals for larval development 
or in host-symbiont interactions. Very little is known 
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2.6 High throughput tools for 
proteins, enzymes and biopolymers
Enzymes have for many years been the driving force of 
biotechnology. There is an ever increasing demand for 
novel enzymes for a variety of applications ranging from 
the degradation of natural polymers such as cellulose, 
starch and proteins, or for use in the pharmaceutical and 
chemical industries, involving numerous chemically and 
structurally diverse molecules. It is clear that Moore’s 
Law 4 that applies to sequencing technology does not fit 
to enzyme screening, expression of novel recombinant 
proteins and structural genomics despite all the 
recent innovations in proteomics. Filling these gaps 
is a challenge that is not specifically limited to Marine 
Biotechnology. However, it is even more important in this 
case due to the size of the untapped protein reservoir 
provided by marine life.
Every genome or metagenome project increases the 
number of putative genes whose functions are often 
unknown and at best deduced from sequence analysis. 
But even the best annotation provides little information 
about detailed substrate specificity and functionality.
Sensitive high throughput screening methods to identify 
genes encoding novel enzymes for specific applications 
need to be established. These methods need to be based 
on easily identifiable phenotypes such as colourimetric 
assays, that can ideally be automated, combine many 
substrates in one assay system and be compatible 
with liquid high-throughput screening facilities. The 
challenge is to use existing enzymatic activity detection 
methods based on changes in spectroscopic properties 
for the design of high throughput chips that can identify 
the product formed. Thus, the development of high 
throughput technologies based on robotic systems 
to directly screen samples or colonies for specific 
substrates should be a priority. 
Future advances should focus on designing cell-
free systems with the aim of increasing substrate 
bioavailability and reducing the inhibitory and cross 
reactivity of cellular components. Small molecule 
microarrays (SMMs), involving the use of synthetic 
molecules as capture agents, will contribute to an 
expansion in the capabilities in high-throughput 
screening for novel enzymes. Interesting contributions 
to direct mapping of metabolic pathways have 
recently been made with the design of tools capable 
4. Moore’s law describes a long-term trend in the history of computing 
hardware where the number of transistors that can be placed 
inexpensively on an integrated circuit has doubled approximately every 
two years. The trend has continued for more than half a century and is 
not expected to stop until 2015 or later and will continue to profoundly 
impact all applications and technologies that rely on transistor power for 
their processing. 
of generating non-destructive, real time functional and 
dynamic knowledge with microbial reactomes.
While a number of expression systems are already 
available for expressing genes encoding enzymes, 
additional expression systems are urgently required for 
marine invertebrates and plants. The situation is even 
worse for exopolysaccharides where the production of 
the targeted products is often strictly dependent upon 
the ability to induce production, e.g. through stress, and 
to recover end-products which implies time consuming 
and labour intensive control of cultures of the strain or 
species of interest. This illustrates the urgent need for 
basic and applied research to develop and improve high 
throughput tools for proteins, enzymes and biopolymers 
from marine bioresources which will be beneficial for a 
wide range of biotechnological applications.
2. Developments and perspectives of key tools and technologies
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3.1 Marine Food: Marine 
Biotechnology for sustainable 
production of healthy products 
through fisheries and aquaculture
3.1.1 Science driving aquaculture 
development
The world’s oceans harbour a wide range of 
environmental niches, host an as yet largely untapped 
and underutilised source of biodiversity, and remain a 
significant source of food. Marine fisheries have leveled 
off and an increasing number of fish stocks are now 
overexploited or even in danger of extinction. There is 
a general consensus, therefore, that the oceans have 
reached their maximal sustainable yield. Most fisheries 
scientists agree that, if current trends continue, many 
fisheries could collapse by 2050. 
In securing healthy food from the seas and oceans, 
Marine Biotechnology can contribute by selection and 
captive breeding of stock for return to their natural 
environment, in order to replenish wild stocks and 
mitigate the effects of overfishing to some extent. 
However, to satisfy the growing demand for seafood, 
marine food will need to be increasingly delivered 
through intensive aquaculture. In fact, according to 
FAO statistics, close to 50% of the seafood produced 
globally today originates from farming operations. 
While salmonids are probably the most well known 
farmed finfish species in the western world, other 
species like seabass, seabream, catfish, tilapia, 
turbot and pangasius, are among a growing number 
of species being farmed today, demonstrating that 
aquaculture is only at the early stage of conquering the 
marketplace. Aside from fish and shellfish aquaculture, 
macroalgae are also harvested and cultivated for a 
range of components, including food additives. The 
cultivation issues related to macroalgae are discussed in 
Section 2.4.2. 
To meet the challenge of supplying growing seafood 
markets, aquaculture will need to become more efficient 
and cost-effective, whilst simultaneously reducing its 
environmental impact. Thus both the aquaculture 
research community and the industry itself have 
focused on increasing production efficiency, increasing 
product quality, introducing new species for intensive 
cultivation and on developing sustainable practices. In 
order to achieve these goals, there was a need to better 
understand the molecular and physiological aspects of 
reproduction, development and growth, and to better 
control these processes. Science has contributed 
significantly to achieving these goals. 
Some examples of progress include:
•	 Molecular	 diagnostics	 and	 novel	 immunisation	
strategies which have decreased the impact of 
diseases and their transmission;
•	 Traditional	selection	has	led	to	growth	improvements	
of up to 25% per generation in some aquaculture 
species, a value in which has never been achieved in 
farm animals;
•	 Marine	genomics	projects	at	EU	and	national	levels	
have also had a significant impact on selective 
breeding, particularly through the integration of 
quantitative genetics and molecular screening, 
whole genome wide association studies and marker 
assisted selection;
•	 Ecological	and	genetic	approaches	have	 largely	
contributed to a better assessment of chemical and 
biological interactions between aquaculture and the 
environment and to develop strategies to reduce 
the harmful environmental impacts from intensive 
production systems;
•	 Microbial	 bioremediation,	 particularly	 in	 land-
based mariculture, and improved microbial control 
of intensive production systems have improved 
containment and environmental compatibility;
•	 A	better	understanding	of	the	life	cycle	of	cultured	
organisms has improved the ability to support 
sustainable aquaculture through improved nutrition, 
intensified selection and disease management, 
resulting in improved food quality.
As such, through rapid biological and biotechnological 
progress, a more efficient and environmentally 
3. Marine Biotechnology: achievements, challenges  
and opportunities for the future
Figure 18. Evolution of world capture fisheries and aquaculture 
production from 1950 to 2005. Current FAO Statistics indicate that 
in 2010 about 50% of the aquatic food produced globally originates 
from aquaculture activities. (Source: FAO. 2009, FishSTAT Fishery 
Statistical Collections Global Aquaculture Production. Produced by 
Hugo Ahlenius, Nordpil)
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responsible aquaculture has been achieved and food 
products from the marine sector are diversifying. 
Moreover, the feed which we use in the culture of fish is 
fast becoming the key to deliver a healthier fish and, in 
turn, a healthier consumer and environment.
Fish oil and fish meal, derived from the wild catch 
sector, are critical components of the artificial diets 
used in carnivorous finfish aquaculture. Aquaculture 
enterprises represent the major consumer of fish meal 
and oil using almost half of the global production. 
Pessimistic forecasts concerning fisheries catches 
have prompted a major research focus on delivering 
alternative oil and meal sources in the diets used for 
these aquaculture species. In this respect, molecular 
approaches are of use to investigate the effectiveness 
of marine product substitution by e.g. plant-derived 
materials and more recently algal products. There 
has been a particular surge in research investigating 
the effects of dietary oils on the fatty acid profile of 
fish and it has been demonstrated that the fatty acid 
profile in the end product can be specifically modified 
by the design of the feed used and thus be adjusted 
based on consumer preferences. Dietary shifts may also 
induce an impact on other aspects of fish physiology 
including, for instance, metabolism, health and immunity 
which can be monitored by molecular tools studying 
metabolic profiling, liver enzymes-biomarkers and 
immune parameters. 
In another example, carotenoid substances are 
commonly included in the diets of farmed species such 
as salmon and trout to produce a natural colouration 
in the final product. Research also indicates additional 
benefits from dietary carotenoids other than colouration 
of the flesh. Other biological functions of these 
substances related to growth, reproduction and tissue 
health have been evident in salmonids and shrimp. 
However, the full function of such compounds is not 
yet completely understood, and considerable research 
is still required to ‘tailor’ artificial aquaculture diets with 
ingredients designed to increase the functional and 
health properties of the end-product. It follows that a 
healthier diet which benefits the farmed species, will 
also ultimately benefit the consumer. This is a valid 
reason for delivering improvements in aquaculture 
diets, as many new options open up for using aquatic 
animals as carriers of essential nutrients in human 
nutrition.
3.1.2 Development of new methods for the 
optimisation of marine aquaculture
There is a strong rationale for the move towards 
using the aquatic environment to grow food. It opens 
a production volume representing more than 90 % of 
the culturable biosphere of the planet and two-thirds 
of the surface, and in contrast to terrestrial farming, 
production can be achieved utilising a three dimensional 
space. However, commercial aquaculture is currently 
faced with several important bottlenecks at the level of 
overall performance, reproduction (no or unpredictable 
spawning), early (larval) development (low survival, cost), 
growth, nutrition, disease/health management and 
interactions with the environment.
The significant challenges to farming the oceans need 
to be addressed in a wider context. Challenges include 
the physical constraints of temperature and weather 
conditions at the surface, and light and pressure 
deeper in the water. There are also many factors to 
consider when choosing organisms to target, including 
adaptation or efficiency at prevailing environmental 
conditions and nutrient availability, the capacity of the 
organism to deliver food of optimal quality and health for 
the consumer and securing a sustainable environment. 
While our understanding of the nutritional loops in the 
oceans is good, the technological potential of typical 
complex marine biological systems is still widely under-
investigated. Intensifying production of a target organism 
by supplying feed presents challenges of balancing the 
local biosphere. 
It is thus necessary to select physical conditions 
optimal for sustainable production and minimal risk. 
Development of key technologies for overcoming the 
natural constraints is necessary to release the vast 
potential of aquaculture. The application of molecular 
and biotechnological tools will be particularly important 
to support the development of sustainable aquaculture. 
Better understanding of reproduction, development and 
growth will result in better control of those processes, 
and continually improving methods for diagnostics 
and immunisation will decrease the impact of diseases 
and their transmission. Novel ecological and genetic Figure 19. Finfish aquaculture 
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approaches are required to assess chemical and 
biological interactions between aquaculture and the 
environment, and improved understanding of microbial 
control and bioremediation in mariculture will improve 
environmental compatibility.
Which organisms to culture, and how?
The common perception of aquaculture today is the 
farming of finfish, crustaceans or molluscs in sea cages or 
other confined structures suitable for supporting growth. 
Some attempts have been made at ‘ocean ranching’, 
but with limited success. In some areas macroalgae are 
successfully grown (see also Section 4.2.4).
The number of aquaculture species has been increasing 
over the years, but is still limited relative to the number 
of species with potential for farming. Further, most 
aquaculture is intensive monoculture. This concept 
has several disadvantages both from an environmental 
point of view, and from the perspective of disease 
development. 
Polyculture production systems could represent ways 
of increasing production volume and utilising the 
biodiversity of marine ecosystems. The most advanced 
systems are termed Integrated Multi-Trophic Aquaculture 
(IMTA) and combine the cultivation of fed species (e.g. 
finfish fed with sustainable commercial diets) with 
extractive species, which utilise the inorganic (e.g. 
seaweeds) and organic (e.g. suspension and deposit 
feeders) excess nutrients from the fed aquaculture. 
Seaweeds and invertebrates produced in IMTA systems 
could be considered as candidates for nutrient/carbon 
trading credits within the broader context of the 
ecosystem, and IMTA could become an integral part of 
coastal regulatory and management frameworks. The 
challenge is to establish safe and stable systems with 
an economically feasible output. Hosts (particularly 
invertebrates) may harbour bacteria that may be 
detrimental or pathogenic to other organisms within the 
same culture or ecosystem. This is a particular challenge 
in the marine environment, where the principles of 
host-microbe interactions, symbiosis, commensalism 
and epidemiology are not yet well understood, while 
the medium is open to pathogen transmission. 
Consequently, a fundamental understanding of 
aquatic ecology, including competition and symbiotic 
principles, is necessary for the sustainable farming of 
marine organisms in complex systems such as IMTA. 
Indeed, a better mastery of host-microbe interactions 
within such confined marine ecosystems may provide 
us with completely new tools to understand disease 
development in general and how to fight new diseases 
in a more ecological way.
The concept of a disease-free animal production 
system is unrealistic and may lead to strive towards the 
development of systems that are ecologically unstable 
and unreliable. The challenge will be to understand 
complex ecosystem processes in order to further 
develop production of existing species and to introduce 
new species, while maintaining the basic biological 
foundations of health, competition and interactions in 
such systems. 
 
Figure 20. Scallop larvae (approximate size about 1/10 mm) grown 
in Argenton, France. Global scallop production amounted up to 
1,265,000 tonnes in 2005 with aquaculture producing more than 
fisheries as early as 1992. 
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Figure 21. Conceptual diagram of an Integrated Multi-Trophic 
Aquaculture (IMTA) operation including the combination of fed 
aquaculture (e.g. finfish) with suspension organic extractive 
aquaculture (e.g. shellfish), taking advantage of the enrichment 
in small particulate organic matter (POM), inorganic extractive 
aquaculture (e.g. seaweeds) taking advantage of the enrichment in 
dissolved inorganic nutrients (DIN), and deposit organic extractive 
aquaculture (e.g. echinoids, holothuroids and polychaetes), taking 
advantage of the enrichment in large particulate organic matter 
(POM) and faeces and pseudo-faeces (F&PF) from suspension-
feeding organisms. The bioturbation on the bottom also 
regenerates some DIN, which becomes available to the seaweeds. 
(Source: Thierry Chopin)
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Marine Biotechnology contribution to aquaculture
Intensive production of genome and transcriptome 
sequence information from a variety of organisms, 
including some farmed fish species, has been made 
possible by major technological developments in the 
21st century. There is a growing interest in applying 
genomics approaches to aquaculture, creating the 
opportunity of making new aquatic products through 
altering their genetic make up. Moreover, progress in 
transgenic technologies has provided considerable 
opportunities, including improved growth rates and 
improved health and quality of broodstocks.
However, there is increasing consumer concern 
regarding genetically modified organisms (GMOs) 
and transgenic products. Manipulation of the genes 
controlling growth hormone production has resulted in a 
30-fold increase in growth rate in some fish species (e.g. 
in salmonids). Interestingly, both the enhanced growth 
phenotype and the genotype can be inherited to the 
progeny thus producing second and third generation 
transgenic offspring. Therefore, the introduction of 
transgenic technology necessitates the need for 
production of sterile progeny and the development of 
better engineered aquaculture systems such as RAS 
(see Section 2.4.4) in order to minimise the risk of 
released transgenic stocks mixing with wild populations, 
and this may, in turn, question the long-term benefits of 
such manipulations. For these reasons biotechnological 
applications should focus on disease control and 
production of healthy fish instead of boosting growth 
rates.
To develop a new species for aquaculture requires the 
ability to control its reproduction. Common methods 
of spawning induction have largely relied upon 
external stimulation of reproduction through control 
of environmental parameters or direct administration 
of gonadotropin releasing hormones. For example, 
spawning can be induced in tuna with the help of 
hormones (see Figure 22) administered through implants. 
Sex manipulation can be optional for particular species 
displaying sex-specific growth differences where 
monosex culture is preferred. This can be accomplished 
through a number of methods with the most common 
being the treatment of fish with methyl testosterone to 
produce the male phenotype, although other methods 
such as specific crossing of closely related species with 
varying genetic make-up can also result in single sex 
hybrids. For the production of sterile fish, with a high 
market value, triploidy can be induced through heat or 
pressure-shock to inactivate the sperm. Sex inversion 
using steroids can also be used to produce fertile males 
with the female genotype, allowing the production of 
single-sex offspring. However, the question is whether 
such methods would be acceptable to the consumer in 
the near future.
Combating disease in cultured fish and shellfish stocks 
is a critical issue for the commercial aquaculture sector 
and has thus been a key area for applied research. 
Firstly, bacterial pathogens are usually treated with 
antibacterial agents (some of the most commonly 
used globally include oxytetracycline, oxolinic acid, 
potentiated sulfa), a practice which can eventually lead 
to antibacterial resistance with a subsequent and direct 
impact on human health. The control of ectoparasites, 
notably Atlantic salmon lice, has commonly been 
achieved with emamectin benzoate (SLICE®) and 
teflubenzuron (Ektobann). As with antibacterials, the 
repeated use of the same products to fight parasites 
over a number of years increases the probability of 
acquired resistance by the parasite as demonstrated 
with emamectin on lice. As a consequence, there is 
clearly the need for alternative strategies.
Secondly, marine organisms with increased resistance 
to pathogens can be produced with the use of transgenic 
technology, incorporating genes encoding antimicrobial 
activity. Derived from specific organisms, these genes 
can deliver increased resistance to pathogenic infection 
when incorporated in the genotype of other fish species. 
Even though some improved resistance from genetic 
manipulation has been claimed for Vibrio anguillarum 
in salmon, there are reasons to question the long-term 
efficiency of transgenic technology for disease control 
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Figure 22. Spear guns are used to implant Tuna with hormone 
releasing implants to induce spawning in attempts to domesticate 
this fish with a high market value which is under growing pressure 
from over-consumption. 
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of intensively cultured species. This is particularly true 
in the marine environment, where many organisms may 
harbour commensal microorganisms that do not cause 
disease, but are potentially pathogenic. Moreover, there 
are occasions where gene alteration may compromise 
fish immunity. A much more promising approach that 
has been neglected in the past is the development of 
advanced vaccines. DNA vaccines are now ready to 
be recruited to the battle against fish diseases. This 
novel method is based on the administration of the gene 
encoding the vaccine antigen, rather than the antigen 
itself, providing a valuable tool for more sustainable 
aquaculture production.
A third approach is based on the preventive use of 
probiotics and immunostimulants such as yeasts. In the 
marine environment a remarkably high percentage of the 
potentially pathogenic microflora may be resident in a 
host without causing disease, or could be harmless to 
one host and cause disease in others. Aquatic systems 
lend themselves perhaps better than any other, to disease 
management through the use of probiotics, which has 
mainly concentrated on pathogen exclusion, competition 
or microflora manipulation. Improved microbial control 
could result in improved disease management, as well 
as having positive effects on the environment. Up to 
now, such studies have been largely empirical, but some 
promising results are beginning to emerge, particularly 
at critical stages such as larval production, or stress 
situations. During recent years, data has emerged on 
the genetic basis of host colonisation in the zebrafish, 
and such studies could provide a better basis for 
microflora manipulation or pathogen exclusion, either by 
competition, exclusion or interference with the microflora 
signalling or sensing systems.
Seafood and health – Opportunities in aquaculture
Scientific and technological developments in food 
science have led to a marked shift in how consumers 
deal with food and health. The beneficial health effects 
of seafood consumption have primarily been attributed 
to the ω-3 fatty acids EPA and DHA. Emerging research 
suggests that other components in seafood are also 
beneficial as they may have synergistic or additive 
effects with ω-3 fatty acids. Taurine is a component 
that is relatively abundant in seafood, and synergistic 
effects with ω-3 polyunsaturated fatty acids (PUFAs) 
have been found on markers for cardiovascular disease. 
There is also evidence to support the contention that 
eating seafood is more beneficial than taking ω-3 fatty 
acid supplements, suggesting that the isolation of single 
components is too simplistic.
Much of the research on the beneficial health effects 
of fish has been focused on ω-3 fatty acids. However, 
recent and emerging research on seafood proteins 
suggests that the contributing health effects from the 
proteinaceous part of fish have to date been largely 
ignored. Eating fish proteins has, in some dietary studies, 
been found to protect against the development of type II 
diabetes and obesity. Also, it is worth noting that a meal 
of seafood generally replaces another protein source, 
for instance red meat, and thus the health effects of 
seafood consumption may arise from the low content 
of saturated fat.
Aquaculture offers opportunities to modify the nutritional 
contents of farmed species. Dietary modulation enables 
sea farmers to produce seafood with added health 
benefits by incorporating functional components into the 
feed, and thus increasing the beneficial components in 
the fish. However, the optimal method to manipulate and 
optimise the content and profile of fatty acids in cultured 
fish is still a matter of research and debate. It is a matter 
of research since innovative methods based on genomics 
and molecular biology could be established in the future 
to directly allow for the production of genetically modified 
fish with enhanced fatty acid synthesis capabilities. It 
is a matter for debate since another route to a similar 
end would be to rely on the production of genetically 
modified plants with the capability of synthesising the 
right fatty acids to be used as food for fish. Obviously 
it is also a matter of debate since the culture of those 
GMOs would be controversial. While not cost effective 
yet, a viable and promising approach might therefore be 
to use cultured algae in the fish feed for obtaining the 
desired fatty acid profile in the fish for consumers.
Summary Box 8. Research priorities for Marine 
Biotechnology applications in aquaculture
- Ensure a better control of reproductive processes 
in aquaculture species to improve the quality of 
juveniles;
- Develop innovative methods, based on omics and 
systems biology, for selective breeding and inte-
gration of feed ingredients to improve the quality 
and health benefits of the end products;
- Develop new methods for environmental quality 
preservation, animal disease and welfare control 
(including vaccines and probiotics) and for feed 
ingredient optimisation to ensure the economics 
and sustainability of aquaculture production; 
- Develop and employ alternative therapeutic measures 
including plant extracts to limit the use of antibiot-
ics and chemicals in intensive aquaculture systems.  
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3.2 Marine Energy: Marine 
Biotechnology for energy supply
3.2.1 New opportunities and challenges
There is a growing need for supply of energy on a 
global scale and Marine Biotechnology can provide an 
important contribution to satisfy these energy needs in 
very different ways. For example, Microbial Enhanced Oil 
Recovery (MEOR), a bio-based approach to improve the 
efficiency of recovery of fossil oil reserves, could help 
to increase the life of mature oil reservoirs. At the same 
time, the ocean itself is an untapped, sustainable source 
of bio-energy. The production of biofuel with microalgae 
poses one option to harvest this huge potential but there 
are many more examples related to the production of 
bio-energy from marine organisms. 
The efficiency of oil recovery from petroleum reservoirs 
is about 50%. The efficiency of collection can be 
enhanced by decreasing the viscosity of oil and/or 
the permeability of rock material in oil reservoirs. Two 
main strategies are employed in MEOR: (i) injection of 
nutrients to stimulate growth and/or metabolic activity 
of indigenous bacteria already thriving in the oil field; 
or (ii) injection into the reservoir of specific bacteria 
and a nutrient solution. The results of MEOR trials are 
controversial and their conclusions and benefits are still 
a matter of debate. The future challenges for MEOR will 
be to make it technically and economically feasible and 
environmentally friendly.
A lot of research has already been done demonstrating 
that both microalgae and seaweeds are possible 
resources for the production of renewable fuels. In some 
European regions, like Brittany (France), indigenous 
seaweeds constitute a valuable resource for food 
and cosmetics industries but thousands of tonnes of 
undesirable seaweeds are polluting the coasts and 
regularly need to be collected. Despite various trials, 
it appears that bioconversion of this huge quantity of 
seaweeds is technically feasible but not yet profitable. 
Producing seaweeds specifically for biofuel production 
has also been suggested but its viability remains 
questionable. 
Microalgae can accumulate large quantities of 
hydrophobic compounds which can be converted 
into biodiesel and the production of biodiesel from 
microalgal tri-acylglycerides is the focus of much 
interest. The concentration of lipids in microalgae 
varies between 10 and 60%. Accumulation to these 
high concentrations in lipid globules generally takes 
place as a result of stress such as that induced by 
Nitrogen limitation. However, any benefit gained through 
an increase in oil content is usually offset by lower 
production rate induced by the same stress. Therefore, 
using the whole algal biomass is essential for achieving 
a good energy balance. 
Based on previous work on a limited scale it is estimated 
that a theoretical production of 20,000-80,000 litres 
of oil per hectare, per year can be achieved from 
microalgal culture although on the basis of the present 
technology the maximum productivity will not be 
higher than 20,000 litres per hectare per year. This is 
considerably higher than production from terrestrial 
crops; for example, palm and rapeseed oils are 
produced at 6,000 and 1,500 litres per hectare, per year, 
respectively. In contrast to terrestrial crops, there is no 
debate about algae as an energy crop competing with 
food crops. This is because the productivity of algal 
biomass is higher than for terrestrial crops and, even 
more importantly, because microalgae can be grown 
in closed systems with close to complete recycling of 
nutrients and water. Also, for cultivation of microalgae, 
areas can be used that are not suitable for agriculture. 
To cultivate microalgae for the generation of bio-energy 
is a great challenge and one of the key objectives for 
Marine Biotechnology in the 21st century. The detailed 
challenges are manifold because of the enormous up-
scaling which will be needed for commercial production 
(from a few hectares to thousands of square kilometres). 
Therefore, a highly multidisciplinary approach is needed 
and success will depend upon the overall energy 
efficiency and environmental sustainability at all levels 
of the production chain. The following main challenges 
are foreseen: 
•	 Exploration	and	understanding	of	the	biodiversity	
of microalgae at the molecular level and on a global 
scale;
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Figure 23. The ideal photosynthetic cell factory for production of 
biofuels (from Wijffels and Barbosa, 2010)
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•	 Exploitation	of	the	physiological	potential	of	microalgae	
to produce biofuels with the bioengineering tools of 
the 21st century;
•	 Harvesting	 and	processing	 of	 large	 amounts	 of	
microalgae for the production of the optimal mix of 
bio-energy and bioproducts;
•	 Achievement	of	a	net	energy	gain	along	the	whole	
production chain necessary to convert microalgal 
biomass into biofuels;
•	 Achievement	 of	 full	 sustainability	 of	 the	 whole	
production chain in terms of regional and global 
impact.
3.2.2 Perspectives for the future  
of microbial enhanced oil recovery
The principles of Microbial Enhanced Oil Recovery 
(MEOR) have long been established. The basic 
mechanisms behind the technique are, however, poorly 
understood. The technique has enormous prospects 
if it can be applied in a controlled way with little or no 
negative impact on the environment. 
Summary Box 9. Research priorities to improve 
Microbial Enhanced Oil Recovery (MEOR)
- Identification and isolation of new strains or com-
munities of marine bacteria suitable for MEOR;
- Monitoring of bacterial populations using in vitro 
and in situ tests (with molecular and genomic 
tools) and tracing of metabolic activities in experi-
mental models and in pilot experiments;
- Understanding and optimisation of the MEOR 
process on a pilot and field scale;
- Reservoir engineering for in situ trials of MEOR 
and assessment of its environmental impact and 
sustainability.
Biofuels from microalgae
Worldwide research programmes have been initiated 
to develop technologies for the production of biodiesel 
from microalgae giving rise to the generation of many 
new companies in this field with a major emphasis in 
the USA. In contrast to terrestrial crops, only a very 
low production capacity for microalgae exists at this 
stage. Production is done in niche markets for high-
value products such as carotenoids and ω-3-fatty 
acids. The world production of microalgae is about 5 
million kg of dry biomass with a total market volume 
of € 1.25 billion. Today, the market price of microalgae 
is on average 250 €/kg dry biomass. For microalgae 
to be used for the production of bio-energy, the cost 
of production will need to be significantly reduced and 
the scale of production significantly increased. There 
are many challenges to be faced in reaching this goal 
but with a major multi-disciplinary effort it should be 
possible within ten to fifteen years.
Economic and environmental sustainability are the major 
issues for the production of biofuels from microalgae. 
The overall process will need to be optimised in 
terms of the input or use of energy, water, land and 
materials, relative to energy output and a close to 
complete recycling will be needed. Indeed, achieving 
environmental sustainability will complement the 
achievement of economic sustainability. Microalgal 
production will help bio-remediate our environment, 
through the use of nutrients in waste-water and CO2 
in flue gases in large scale algal production. As less 
production resources are needed, and more are 
recycled, energy output per volumetric production unit 
will be improved. For example, the use of industrial 
waste products for an efficient and low cost supply of 
water, nutrients and CO2, will be crucial for achieving a 
good energy budget. Based on these ‘waste’ resources, 
the right algal cultures (mixed cultures, mono cultures) 
will need to be adapted to the prevailing climate and 
seasonal conditions (though there are limitations for 
higher latitudes and cold climate regions), and an 
optimal cultivation strategy determined based on an 
increased knowledge of their physiology. Therefore, the 
major goals for biofuel production from microalgae are: 
(i) a high rate of algal production per volume/area; (ii) a 
high oil content of the biomass; (iii) an efficient low-cost 
and low-energy harvest procedure; (iv) a highly positive 
energy balance; and (v) an overall high sustainability.
 
Figure 24. Conservation room for microalgal strains. Laboratory of 
algal physiology and biotechnology, Nantes, France (2008). 
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Microalgae for biorefineries
Microalgae produced for energy could reach profitability 
more rapidly if the uses of their organic compounds 
were optimised. The high number and the diversity of 
organic compounds are a strong incentive not to limit 
the use of microalgae to energy production alone but 
to develop a new algal-chemistry that would, on long-
term basis, deliver multiple and profitable uses of all 
components of the algal biomass. This is a key step 
towards viability of microalgae for biofuels.
Summary Box 10. Recommendations for 
the development of sustainable production 
systems for biofuel from microalgae 
- Initiate a major programme of bio-prospecting 
of aquatic environments and strain collections to 
provide a global inventory of algal species and 
their habitats to understand their natural growth 
conditions and requirements;
- Develop an in-depth knowledge of basic biologi-
cal functions and tools for steering the metabolism 
of microalgae, with the objective of improving 
photosynthetic efficiency and enhancing lipid pro-
ductivity; develop metabolic flux modelling as a 
tool to steer the cellular metabolism;
- Develop cultivation methods with the objective to 
obtain microalgae with excellent characteristics 
for mass cultivation (mixed and mono cultures), 
for biofuel production and biorefinery;
- Design pond systems/photobioreactors in which 
high volumetric productivities can be obtained 
and which can be scaled up for large-scale bio-
fuel production;
- Develop efficient harvest, separation and purifi-
cation processes to biorefine crude biomass not 
used for biofuel production into different com-
pounds such as ω-3-fatty acids, carbohydrates, 
vitamins and proteins (e.g. study of autofloccula-
tion processes of algae and enzymatic driven use 
of algal biomass);
- Develop a complete production chain from al-
gal cultivation to biofuel and by-products with 
detailed life cycle analysis, optimising both the 
individual stage processes and the process chain 
as a whole;
- Assess the sustainability and socio-economy of 
the biofuel production from microalgae at all lev-
els of the production chain.
3.3 Human Health: biodiscovery of 
novel marine-derived biomolecules 
and methodologies 
Because of the physical and chemical conditions in 
the marine environment, almost every class of marine 
organism possesses the capacity to produce a variety 
of molecules with unique structural features. These 
molecules offer an unmatched chemical diversity and 
structural complexity, together with a biological potency 
and selectivity. In recent years, the chemistry of natural 
products derived from marine organisms has become 
the focus of a much greater research effort. This is due 
in large part to the increased recognition of marine 
organisms as a source for bioactive compounds with 
pharmaceutical applications or other economically 
useful properties. The fact that marine resources are 
still largely unexplored has inspired many scientists 
to intensify their efforts by using novel technologies 
to overcome the inherent problems in discovering 
compounds which may have potential for further 
development as pharmaceuticals or as functional 
products such as cosmetics, nutritional supplements 
and functional foods.
3.3.1 Achievements: marine natural products 
in various phases of clinical development
Currently there are around 15 marine natural products 
in various phases of clinical development, mainly in the 
oncology area, with more on the way. It is now almost 
five decades since spongothymidine and spongouridine 
were isolated from the marine sponge Tethya crypta 
which eventually led to the development of Ara-C used 
against leukemia and Ara-A for treating viral infections 
(FDA approval 1969/1976). However, it was not until 2004 
that the next marine natural product ziconotide (Prialt®) 
was approved followed by trabectedin (Yondelis®) in 
2007, both of which were commercialised by European 
companies (Prialt by Elan, Ireland and Yondelis by 
Pharmamar, Spain).
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Figure 25. Left: Schematic representation of the three-dimensional structure of ziconotide (C102H172N36O32S7; coloured from N-terminal 
end (red) to C-terminal end (blue) with disulfide bonds shown in gold), a synthetic version of a peptide first isolated from the venom of the 
cone snail Conus magus. Right: Cone shell (Conus sp.) ingesting a small fish after incapacitating its prey by injecting a neurotoxin which can 
be dangerous to humans. Ziconotide was developed into a synthetic drug for the treatment of patients suffering from neuropathic pain. It was 
approved for sale under the name Prialt® by the FDA in December 2004 and by the EU in February 2005.
clinical trial name source target developed by
In Clinical Use ectenaiscidin 743 (Yondelis) tunicate tubulin PharmaMar, Rinehart
phase III E7389 (halichondrin B inspired)* synthetic tubulin Eisai
phase II dehydrodidemnin B (Aplidine) tunicate ornithine decarboxylase PharmaMar, Rinehart
phase II soblidotin (aka TZT1027, dola-10 insp.) synthetic tubulin Teikoku, Pettit
phase II synthadotin (aka ILX651, dola-15 insp.) synthetic tubulin ILEX 
phase II bryostatin 1 bryozoan PKC GPC Biotech, Pettit
phase II squalamine shark angiogenesis Zasloff
phase II kahalalide F mollusk multiple PharmaMar, Scheuer
phase I PM02734 (kahalalide insp.) synthetic solid tumor PharmaMar
phase I Zalypsis (jorumycin insp.)* synthetic DNA PharmaMar
phase I E7974 (hemiasterlin insp.)* synthetic tubulin Eisai
phase I taltobulin (aka HTI286, hemiasterlin insp.)* synthetic tubulin Wyeth, Andersen 
phase I salinosporamide A (aka NPI0052) bacteria proteasome Nereus, Fenical 
phase I spisulosine (aka ES285) clam Rho PharmaMar
phase I KRN-7000 (agelasphin insp.)* synthetic NKT Koezuka-Kirin
phase I NPI 2358 (halimide insp.) synthetic tubulin Nereus, Fenical
phase I LBH 589 (psammaplin insp.)* synthetic HDAC Novartis
Discontinued
phase II (<2004) dolastatin 10 sea hare tubulin Pettit
phase II (<1999 didemnin B tunicate antineoplastic Rinehart
phase II (<2004) cemadotin (dola-15 insp.) synthetic tubulin BASF, Pettit
phase II (<2002) cryptophycin 52 (≈ arenastatin)* synthetic tubulin Lilly, Valeriote
phase I (2004) discodermolide* sponge tubulin Novartis, HBOI
phase I (2002) LAF 389 (bengamide insp.)* synthetic MetAP Novartis, Crews
phase I (<2006) LAQ 824 (psammaplin insp.)* synthetic HDAC Novartis, Crews 
phase I (<2000) girolline (aka girodazole)* sponge protein synthesis Potier 
 * Substances from marine sponges
Table 1. Selected marine natural products in development as anticancer drugs (based on Sashidhara K et al., 2009)
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Information Box 4. The case of Trabectedin, a unique marine compound with anti-cancer properties 
3. Marine Biotechnology: achievements, challenges  
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Yondelis® (Trabectedin, ET-743), is a unique anti-
cancer agent that binds the minor groove of DNA. 
Extracts of E. turbinata were shown to have anti-
tumour effects in 1969, but isolation of the active 
compound was not achieved until 1990. Phase I 
and II clinical trials were carried out using material 
derived from aquaculture, but this was not deemed 
feasible for the larger phase III trials. For this reason, 
an economically viable semisynthetic process was 
developed starting with the natural product safracin 
B isolated from the microorganism Pseudomonas 
fluorescens. Pharmamar received approval to mar-
ket Yondelis® in Europe in September 2007 for the 
treatment of soft tissue sarcoma and this was the first 
drug to be approved for this condition for more than 
25 years. Centocor Ortho Biotech Products, L.P. has 
obtained worldwide marketing rights for Yondelis® 
except in Europe. In September 2009, they received a 
Complete Response letter from the FDA regarding the 
NDA for Yondelis® when administered in combination 
with DOXIL® for the treatment of women with relapsed 
ovarian cancer. In November 2009, Pharmamar won 
final European approval for the use of Yondelis® in 
the treatment of ovarian cancer. This drug has now 
been approved for use in 57 countries worldwide, of 
which 26 are outside Europe. Subsequent to approval 
for ovarian cancer, sales have increased to € 17 mil-
lion in the first quarter of 2010, delivering a net profit 
for Pharmamar.
Figure 26. A colony of the marine tunicate Ecteinascidia 
turbinata which is at the basis of a commercially available anti-
cancer agent (Yondelis®) with sales at € 30 million in 2008, 
rising to € 45 million in 2009 
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3.3.2 Development of novel products 
and methodologies for Human Health 
and well-being 
While a number of marine-derived products have found, 
and continue to find, industrial applications in areas such 
as functional foods, nutraceuticals and cosmeceuticals, 
the recent approvals of two important marine-derived 
drugs has renewed interest in compounds produced 
by marine macro and microorganisms, not only from 
within the scientific community but also from large 
pharmaceutical companies and SMEs. However, in the 
quest to discover structurally interesting new products, 
it is clear that it will be necessary to go beyond the 
current frontiers in terms of both the source of the 
materials that can be potentially exploited and the 
technologies currently being employed. In order to fully 
exploit the enormous opportunities and potential from 
Marine Biotechnology, the challenges will keep getting 
bigger.
Challenges in pharmaceutical discovery
The lack of interest by industry in natural products 
from all sources can be attributed to a number of 
common problems, some of which are perceived 
to present insurmountable obstacles. Some of 
these problems (taxonomy, variability, supply) are 
particularly acute for marine-derived compounds. 
These reasons, coupled with an industry-wide 
preference for technology-intensive discovery methods 
has led to the pharmaceutical industry largely turning 
away from natural products as a source of chemical 
diversity. Industry also has a lack of familiarity with 
the marine environment and prefers the traditional 
source of terrestrial resources for biodiscovery. The 
increasing awareness that nature covers a greater 
chemical diversity than synthetic chemicals and that 
many of these perceived obstacles can be addressed 
using modern technologies has resulted in a renewed 
interest from industry in natural products as part of 
their portfolio of approaches to find new chemical 
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entities. However, without adequate and relevant high-
content and high-throughput screens and associated 
data capture and analysis systems, all the novelty in the 
marine environment will simply overwhelm any potential 
end-user. Where to place the screening power in the 
chain from biodiversity explorer to end-user is also 
challenging, as industry is often reluctant to take on 
novel molecules without adequate evidence of likely 
efficacy and safety, but it is unlikely that researchers 
discovering novel molecules have the capacity or 
resources to carry out such high-content broad-target 
screening.
The main challenges facing pharmaceutical discovery 
from marine bioresources are:
•	 Legal	aspects:	secure	access	to	marine	resources,	
property rights and intellectual property 5;
•	 Quality	 of	 marine	 resources:	 identification	 and	
variability;
•	 Technology:	screening	of	active	compounds	and	
dereplication (preventing repeated rediscovery);
•	 Structural	 costs	 of	 drug	 discovery	 from	natural	
products and especially marine products.
Addressing the challenges
(i) Biodiversity issues 
The lack of taxonomic expertise for marine species 
can lead to either the unnecessary recollection of a 
particular species or, conversely, difficulty in targeting 
the recollection of a species when this is required 
for further study. A similar situation exists for marine 
microorganisms where there are very few experts 
in taxonomy and systematics. An increase in marine 
invertebrate and microorganism taxonomy expertise 
and effort, employing both classical and DNA methods, 
is required to increase the speed and efficiency of 
marine biodiscovery. Another problem for biodiscovery 
to address is that the same marine invertebrate from 
separate locations often produces different metabolites, 
making it difficult to recollect specimens to isolate 
material for follow-up studies. This may result from the 
fact that symbiotic microorganisms are often believed 
to be the true source of the metabolites, causing this 
observed variability with different microorganisms 
present in the same invertebrate species collected in 
different locations.
(ii) Supply issue
The lack of a sustainable supply has completely 
stopped further development of several promising 
marine-derived compounds. In some case, to overcome 
this synthesis or semi-synthesis has yielded kilogram 
5 This challenge is not limited to the pharmaceutical industry but applies 
to discoveries from marine bioresources for all other industries as well
quantities of compounds or their analogues for clinical 
trials and applications. In other cases material for clinical 
evaluation has been supplied through aquaculture 
using adaptations of existing methods for the seafood 
industry. The increased focus on culturable marine 
microorganisms is in part due to the need to overcome 
this supply problem and has led to the discovery of 
a number of highly active compounds, one of which, 
Salinosporamide (NPI0052), is in phase II clinical trials 
sponsored by Nereus Pharmaceuticals of San Diego, 
USA. The search for methods to cultivate microorganism 
symbionts from marine invertebrates to produce 
the bioactives found in the invertebrate needs to be 
intensified. Finally, methods to find, identify, clone and 
genetically manipulate complex biosynthetic pathways 
will need to be greatly improved to have an impact in 
resolving the supply issue.
(iii) Technical issues
A recent statistical survey analysing chemical space 
indicated that marine-derived compounds showed the 
broadest coverage of this space, including many drug-
relevant areas. In addition, fungal and actinobacterial 
products populate the boundaries between natural 
product and drug-like space, making them worthy 
of investigation. This study (Grabowski,  Baringhaus 
and Schneider, 2008) also highlighted that few plant-
derived natural products populated drug-like space. 
Therefore marine natural products, particularly those 
from actinobacteria and fungi should be regarded 
as favoured sources of chemical diversity for drug 
discovery, and must be made compatible with current 
industrial paradigms.
New chromatographic instruments and media together 
with simple protocols are available to prepare extract 
libraries with drug-like properties. In addition, these 
methods prepare extracts much more suited to modern 
high-throughput or high-content screening platforms. 
The use of such methods would also increase the speed 
of follow-up isolation and structure determination once 
an active compound has been identified. Bioactive 
compounds found at this stage have to be screened 
for their novelty. This is done through the use of 
dereplication (‘de-discovery’) at multiple levels. The 
use of organisms from unexplored and extreme 
environments is an excellent starting point together 
with the use of reliable taxonomy to source genetically 
distinct organisms will increase the chances of finding 
novel chemistry. Extracts and fractions can be screened 
using biological methods to pinpoint compounds with 
known activity profiles. Coupled liquid chromatographic 
methods can identify known compounds, and more 
recently, statistical methods have been applied to 
spectroscopic data of extracts as a dereplication tool. 
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At the stage of pure compound, dereplication can 
easily be achieved through interfacing spectroscopic 
information with databases. Further development of 
novel rapid dereplication tools is required.
The use of modern spectroscopic methods utilising very 
sensitive high field NMR spectrometers and extremely 
accurate MS systems has reduced the difficulty in 
determining complex structures from limited amounts 
of material. The advent of computer aided structure 
elucidation packages using a combination of expert 
systems and constraint satisfaction paradigms offers the 
possibility of reducing the time taken to deliver accurate 
and reliable solutions. These tools need to become 
more widely available, faster and easier to use as well 
as being able to deal adequately with the relative and 
absolute stereochemistry of complex compounds.
(iv) Lack of a coherent rationale
It is now becoming clear that there are evolutionary 
reasons, elucidated at the genetic and protein fold 
level, why natural products fit so well into target active 
sites. More studies to understand and validate the 
coupling between genetics, protein folding, targets 
and natural products are necessary. The rational use 
of such information will lead to a greater acceptance 
of natural products in the drug discovery pipeline. In 
addition, the use of chemical ecology in the selection 
of organisms will improve the ‘hit rate’ in assays where 
the target and ecology of the organism are carefully 
matched. For instance, proven antifeedants have been 
used to derive anti-cancer, anti-viral and anti-aging 
products; toxins have been used to develop pain-killers; 
and functional products have been obtained from the 
materials used by sessile organisms to colonise free 
surfaces. Knowledge of eco-physiological interactions 
may serve as a platform to facilitate the search for new 
biotechnological candidates, as well as to optimise 
culture conditions and achieve production of biomass 
for industrial applications.
Information Box 5. The search for novel 
antibiotics: an urgent challenge
Hundreds of publications and public reports have 
drawn attention to the problem of antimicrobial 
resistance resulting from the intensive use of anti-
biotics worldwide for human health and veterinary 
purposes. Multi-resistance dramatically reduces 
the possibility of treating infections effectively and 
increases the risk of a fatal outcome. A better use 
of existing antibiotics is certainly needed but new 
antibiotics to tackle resistant bacteria are also  
urgently needed. However, the antibiotic develop-
ment pipeline is dry and for several reasons the 
industry has been, and is still, reluctant to invest in 
research and development of antibiotics. The lack 
of investment, despite various incentives to encour-
age drug companies to invest in this field, is mainly 
due to the fact that a novel antibiotic may be less 
profitable than drugs in other therapeutic areas (low 
frequency prescriptions for severe infections, lim-
ited duration of use compared to drugs for chronic 
diseases, possible rapid growth of resistance short-
ening clinical lifespan, etc.). There may need to be a 
policy shift to support increased research and focus 
from the industry in this area.
The World Health Organisation has identified anti-
microbial resistance as one of the three greatest 
threats to human health. The European Centre 
for Disease Prevention (ECDP) and the Infectious 
Diseases Society of America (IDSA) have both, in re-
cent reports, highlighted that there are few candidate 
drugs in the pipeline offering benefits over existing 
drugs (for more information see: http://www.ecdc.
europa.eu/en/healthtopics/Pages/Antimicrobial_
Resistance.aspx). The ECDP and IDSA analysed 
changes in policy needed to tackle this problem. 
Meanwhile the European Union has committed to 
the development of innovative solutions to make 
sure that the boon of antibiotics is never lost and 
that we do not have to face a post-antibiotic era 
(http://www.consilium.europa.eu/uedocs/cms_data/
docs/pressdata/en/lsa/111608.pdf ).
Figure 27. Life near an active smoker at the Rainbow hydrothermal 
vent field located southwest of the Azores on the Mid-Atlantic 
Ridge (MAR) at 2270- 2320 m depth in international waters. 
The rainbow hydrothermal system is associated with vent fluids 
at temperatures as high as 364°C. The use of organisms from 
unexplored and extreme environments is an excellent starting 
point to source genetically distinct organisms which increases 
the chances of finding novel chemistry. (Picture taken by the ROV 
Victor 6000) 
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For the same reasons the IDSA has committed to 
the 10x‘20 initiative which entails the development 
of ten new antibiotics by 2020. 
In 2009, the EU and USA agreed, through the 
Washington Declaration,
“To establish a transatlantic task force on urgent 
antimicrobial resistance issues focused on appro-
priate therapeutic use of antimicrobial drugs in the 
medical and veterinary communities, prevention of 
both healthcare- and community-associated drug-
resistant infections, and strategies for improving the 
pipeline of new antimicrobial drugs, which could 
be better addressed by intensified cooperation be-
tween us.”
The fact that most antibiotics in current use are from 
terrestrial origin, and that screening projects mainly 
focus on samples from terrestrial environments, 
suggests that the probability of finding novel anti-
biotic families from the same type of environments 
is rather low. In order to increase the probability 
of finding novel bioactives, it seems reasonable to 
target untapped reservoirs of genes. Obviously the 
greatest such reservoir on the planet is the marine 
environment with its enormous range of ecological 
niches.
For the above reasons, we recommend that 
special attention is given to the search for novel 
antibiotics from marine environments. Referring 
to the IDSA 10x‘20 initiative, appropriate meas-
ures should be taken to strengthen the focus on 
marine environments, e.g. developing a 5m x‘20 
initiative (5 new antibiotics of marine origin by 
2020). 
Summary Box 11. Recommendations to 
improve biodiscovery of novel marine-derived 
biomolecules and the development of new tools 
and approaches for human health
- Simplification of access and benefit sharing 
agreements throughout Europe and its territories 
through the development of a common template 
agreement. However, simplification and harmo-
nisation of regulations on access and ‘fair and 
equitable’ benefit sharing (commonly called ABS) 
from the exploitation of genetic resources should 
not be limited to the European level but also needs 
to be addressed at the international level; 
- Resolution of the clash between the UN 
Convention on Laws of the Sea and intellectual 
property rights with the assistance of legal ex-
perts and practitioners/industry;
- A workable legal environment must be developed 
to bring functional products to the market safely, 
quickly and at low cost;
- Increased focus on the taxonomy, systematics, 
physiology, molecular genetics and (chemical) 
ecology of marine species via additional targeted 
basic research funding, including training pro-
grammes in taxonomy of marine species. Greater 
emphasis is needed on organisms from unusual 
and extreme environments to increase the chanc-
es of success in finding novel bioactives;
- Improvements in technical aspects of the biodis-
covery pipeline are necessary to make marine 
derived compounds acceptable to the pharma-
ceutical industry. This includes separation of 
bioactives, dereplication strategies and structure 
determination methods and software;
- For sustainable modes of supply there will need 
to be a focus on integrated development of aqua-
culture, tissue culture, microbial isolation/culture, 
chemical synthesis/semi-synthesis, molecular ge-
netics and the availability of appropriate central 
resources for scale-up by these methods;
- Develop appropriate measures to strengthen the 
focus on marine environments to secure a 5m 
x‘20 initiative (5 new antibiotics of marine origin by 
2020). These measures should be included in the 
comprehensive action plan on ‘innovative incen-
tives for effective antibiotics’ that the European 
Commission has to publish by December 2011. 
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3.3.3 Nutraceuticals and cosmetics
Currently there is also great interest in marine derived 
products as nutraceuticals and cosmeceuticals because 
of their beneficial effects on human health. These often 
have drug-like properties (hence the term –ceutical) 
and contain active ingredients such as vitamins, 
phytochemicals, enzymes, antioxidants and essential 
oils which are finding uses as natural additives in foods, 
as nutritional supplements including colour additives 
and antioxidants, and as vitamins, oils, and cofactors 
which enhance general well-being. These products 
form the middle ground between bulk products such 
as biofuels and the high value pharmaceuticals in that 
they are medium-volume/medium-value products which 
have a rapid route to market. In fact many companies 
have chosen to go along the functional product 
route as it offers lower risk and a quicker potential 
return on investment than the high-risk high-reward 
pharmaceutical market.
Information Box 6. Astaxanthin as an example 
of a multi-functional high value compound 
derived from marine biotic resources
The carotenoid astaxanthin is a pigmented anti-
oxidant produced by many microalgae which is 
responsible for the red colour often associated with 
crustaceans such as shrimps, crabs, and lobsters. 
Astaxanthin has been used extensively in the feed 
of farmed fish as a nutritional supplement and is 
partly responsible for the strong colouration often 
observed in farmed salmon, a fish which naturally 
accumulates astaxanthin in the wild resulting in the 
pink hue of its flesh. Recent studies have shown that 
the carotenoid astaxanthin is effective in reducing 
inflammation and in stimulating the immune system 
in humans. In vitro and in vivo studies have also 
shown anti-tumour effects, as well as effectiveness 
in preventing and treating retinal oxidative damage 
and macular degeneration. A demand for natural 
astaxanthin is now emerging in the fast-growing, 
multi-billion dollar nutraceutical market. In fact, in-
creasing evidence suggests that astaxanthin is a 
stronger antioxidant than vitamins C and E, or than 
other carotenoids such as β-carotene, lycopene, 
lutein and zeaxanthin. Algatech based in the Arava 
desert in Israel is a worldwide leader in the produc-
tion and supply of natural astaxanthin for human 
applications but there are many other examples of 
biotechnology companies which produce astaxan-
thin as dietary supplements.
Current high value chemical markets from marine 
organisms are mostly focused on a limited number of 
high value chemicals such as carotenoids due to their 
high market value, projected to reach € 77 billion per 
year by 2010. Carotenoids have much potential as food 
colourants, feed supplements, nutraceuticals, and for 
cosmetic and pharmaceutical purposes. 
More revealing is the discovery of the role that another 
carotenoid, fucoxanthin, may play in reducing obesity. 
So far, only animal studies have been conducted but 
these show that fucoxanthin, found in edible brown 
seaweed and other marine sources, promotes the 
loss of abdominal fat in obese mice and rats. Although 
it is not fully understood how fucoxanthin works, 
it appears to target protein UCP1 that increases the 
rate at which abdominal fat is burned. Fucoxanthin 
has also been found in animal studies to decrease 
insulin and blood glucose levels. Researchers 
hypothesise that fucoxanthin may have anti-diabetes 
effects because it stimulates the formation of ω-3 
fatty acids which are thought to increase insulin 
sensitivity, improve triglycerides and reduce LDL (‘bad’) 
cholesterol.
The other major market is for polyunsaturated ω-3 
fatty acids such as EPA, DHA and ARA which are 
purported to have a range of beneficial effects including 
improved heart health and reduced inflammation. 
Several population studies report that dietary ω-3 
fatty acids or fish oil may also reduce the risk of 
developing breast, colon, or prostate cancer. A recent 
report from the Global Organisation for EPA and DHA 
(GOED) indicates that the ω-3 market had reached 
US$ 13 billion in 2008. In addition to the traditional sources 
of the ω-3-desirable fish oils, there are other sources 
either just entering the marketplace or in the pipeline. 
These other sources are much more expensive than 
fish oil but are now of interest as the price of fish oil 
has increased hugely since 2006. One of the new 
products on the market is krill oil. This oil is different 
from the traditional fish oils because it contains three 
active components: ω-3 fatty acids, phospholipids, and 
astaxanthin. For example, Norway’s Aker BioMarine 
markets a range of vitamins and nutraceuticals 
derived from krill and krill by-products which are very 
rich in ω-3 fatty acids. There are also many companies 
and institutions evaluating different marine algae 
for ω-3 oils. The effort in this case is directed toward 
finding organisms that will produce high levels 
of oil, which will increase yields and improve the 
economics. A potential spin-off might come from 
the biofuels development work going on around 
the world with the production of algal oils in addition 
to biofuels.
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The European market for cosmetics is booming and is the 
biggest in the world, at over € 27.6 billion per year. The 
results published by COLIPA (The European Cosmetics 
Association), related to cosmetic market in the year 2006, 
revealed that Germany had the highest consumption 
rate of cosmetic products (€ 11.7 billion), which covered 
18.7% of the whole European market. France was in 
second position (€ 11.4 billion), followed by Great Britain 
(€ 10 billion). The first five countries, including Italy at 
forth position, covered more than 77% of the total world 
market of cosmetics. The most consumed articles were 
skin care products with 25.7% of the cosmetic market, 
followed by hair products (23.7%) and ‘toiletries’ (23.4%). 
In 2008 the innovative products (and those with high 
technological index) registered the most significant 
growth in production and sale: facial serviettes (+4.9%), 
whitening agents (+6.0%), and anti-age/anti-wrinkle 
creams (+0.5%) produced a modest but very significant 
income of € 447 million. Undoubtedly, the most sold 
products were the anti-ageing creams, covering 38% 
of skin care cosmetic market. In this context, safety, 
innovation and efficacy are always the most requested 
parameters by consumers, and therefore represent an 
important priority for cosmetics industries. Consumers 
are always more concerned about the mechanisms 
of action of the products they use, and are therefore 
generally interested in understanding the scientific base 
of the product efficacy. The trend is moving forward 
cosmetic natural products, in particular those derived 
from plant and marine organisms, as long as they are 
certified as free of any biological or chemical pollutant.
Various metabolites such as terpenoids, nitrogenous 
compounds, tocopherol, polysaccharides, carotenes, 
phenolic compounds, mycosporine-like amino acids, 
parabens, chitin, chitosan and unsaturated fatty acids 
from different types of marine organisms such as 
bacteria, micro and macroalgae, crustaceans and fish 
have been investigated for their potential applications 
as cosmeceuticals. Some specific examples include 
the cosmetics giant Estée Lauder which uses 
pseudopterosin, an anti-inflammatory extracted from 
a sea fan in skin lotions (ResilienceTM), and the French 
company Phytomer, a specialist in marine cosmetics 
which uses a blue-green algal extract in some of its 
products. The French cosmetics company, Clarins, uses 
the algae Durvillea antarctica in its Extra Firming Day 
Cream, which it markets for the treatment of mature skin. 
Sederma (France) sells VenuceaneTM, a skin protection 
product that includes a radical-scavenging enzyme 
originally discovered in the extremophile bacterium 
Thermus thermophilus.
One of the main concern for any functional products 
is safety and efficacy, and it is likely that legislation 
covering pharmaceuticals will change to include 
nutraceuticals and cosmeceuticals if they wish to make 
efficacy claims. This legislation needs to be adapted 
so that it does not damage a nascent industry creating 
unique and highly marketable functional products.
Summary Box 12. Recommendations for the 
development of functional products with health 
benefits from marine living resources
- Develop a workable legislation to bring functional 
products to the market safely, quickly and at low 
cost;
- Implement further investigations to verify the actu-
al health benefits of functional products of marine 
origin;
- Develop sustainable and economically viable 
production methods for functional product ingre-
dients;
- Increase industry awareness of opportunities for 
drug discovery based on marine resources.
Towards a common platform for biobanks
Many of the concerns outlined above, particularly those 
expressed by industry, can be addressed by coordinated 
activity between academic scientists and industry. 
To streamline the biodiscovery pipeline, a number of 
overarching changes must be made so that the content, 
format, and speed of academic research outputs match 
that required by the pharmaceutical and functional 
product industry. Together with these changes, a re-
education is necessary to convince industry that marine 
bioresources are an important source of chemical 
diversity for drug discovery. A major focus of this 
campaign must be on the unique characteristics and 
high activity found in chemical diversity from marine 
species which makes the perceived risk and cost 
acceptable for the development of new pharmaceuticals 
and functional products.
Throughout Europe, researchers in the field of 
biodiscovery utilise a vast array of methods and protocols 
to obtain, extract and fractionate bioresources and 
interact in a variety of ways with screening facilities. If 
this resource could be harnessed and utilised efficiently 
through the use of common protocols and procedures, it 
would be a powerful adjunct to Europe’s pharmaceutical 
and functional product industry. A common online 
‘portal’ could give access to all the biobanks, compound 
and extract libraries and bioscreening facilities. Such a 
portal, which could for example be maintained by the 
proposed European Marine Biotechnology Institute or 
Centre (see Section 5.2), will only work if ownership of 
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resources and libraries is maintained by the institutions 
and the portal works only as a zero cost ‘dating 
agency’ between academic partners, institutes and 
industry. Once a contact has been formalised, the legal 
aspects can be addressed. The portal should contain 
different types of information for different facilities, for 
example:
•	 Biobanks:	 type,	 organism	 focus,	 taxonomy	 of	
organisms, amount available, format (preserved, 
freeze dried, chemical extract, DNA, strain) and any 
residual ownership/IP rights associated;
•	 Extract	 libraries:	origin	of	 extracts,	preparation,	
format, complexity, known activities and any residual 
ownership/IP rights associated;
•	 Compound	libraries:	origin	of	compound,	structure,	
format, known activities and any residual ownership/
IP rights associated;
•	 Screening	facilities:	targets	&	validation,	types	of	
screen, format, presentation of extract/compound 
libraries required, volume of testing possible at 
facility, how results should be interpreted and facility 
for validation and follow-up testing of actives.
Greater simplification could be attained if these facilities 
could agree on a common set of standards for the 
preparation of extracts and libraries that can be used in 
the majority of screening formats, as well as a common 
format for data exchange. This could include: the use of 
common extraction procedures giving drug-like purified 
extracts; accepted concentrations of pure compounds 
and assay-plate format; common presentation of data 
for the screening facility; common reporting format of 
screening data; and procedures for prioritising hits. 
Capability to carry out validation of hits and conduct 
follow-up studies to translate a hit into a lead or products 
is also a necessity.
In effect this would generate a number of European 
academic Small to Medium-sized Enterprises (SMEs) 
in a number of different disease areas, coordinated 
via a central portal. These could provide compound 
and extract libraries and screening services to larger 
pharmaceutical companies, as well as executing drug 
discovery projects on neglected diseases. The model 
of accessing a natural compound library in a non-
exclusive fashion is becoming a more common mode of 
operation, with SMEs providing extract and compound 
libraries and with the large pharmaceutical companies 
providing expertise to effectively manage and complete 
the expensive large scale clinical trials.
Many of these goals are compatible with, and 
complementary to, the aims of the EU-OPENSCREEN 
project (http://www.eu-openscreen.eu/) promoted 
by ESFRI (European Strategy Forum on Research 
Infrastructures). The recommendations above will 
require the broadening of the OPENSCREEN project to 
include biobanks and extract libraries rather than just 
pure compound collections. On the screening side the 
inclusion of applications outside of chemical biology 
and pharmaceuticals will be necessary to evaluate 
potential use of materials in the personal care and 
nutrition market. There is also a need to integrate this 
activity with other elements of the biotechnology chain, 
including Marine Biotechnology SMEs with dedicated 
screens in-house, SMEs set up to provide innovative 
screening activities, and end-user companies, some of 
which may be large multinationals, since there is still a 
question of the minimum data-sets required to support 
further industrial development of novel molecules from 
marine sources. Industry associations should therefore 
be part of strategic thinking on how best to make use 
of marine biodiversity. 
Care also needs to be taken that setting up a system 
of standard procedures does not lead to a limitation 
or restriction on innovative thinking, and an over-
codification of the types of screens that might be 
used, which could artificially limit the scope for 
commercialisation of novel marine-derived molecules 
into truly innovative therapeutic areas and uses. 
Innovative predictive screens are an essential element 
of progress in marine bioactives, in addition to better 
and faster characterisation of molecules.
Summary Box 13. Recommendations to 
improve the use of biobanks, compound and 
extract libraries and bioscreening facilities for 
Marine Biotechnology applications
- Develop a common online ‘portal’, operated as 
a zero cost ‘dating agency’ between academic 
partners, institutes and industry, giving access 
to all relevant biobanks, compound and extract 
libraries and bioscreening facilities, where owner-
ship of resources and libraries is maintained by 
the institutions;
- Collaborate with the OPENSCREEN project to in-
corporate biobanks and extract collections and 
include screens for functional products;
- Create new opportunities for interactions between 
marine-derived molecules and innovative high-
content screens;
- Increase industry awareness of opportunities for 
drug discovery based on marine resources.
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3.4 Marine Environmental Health: 
Marine Biotechnology for protection 
and management of marine 
ecosystems 
Marine Biotechnology is playing an increasingly 
important role in optimising the sustainable use of 
marine environments by the wide range of human 
activities which require marine space and resources. 
Environmental applications of Marine Biotechnology 
are numerous and diverse, ranging from biofouling 
control, environmental monitoring for ecosystem 
and human health to marine habitat restoration, 
bioremediation and more generally natural resource 
and environment management. At the same time, it is 
becoming increasingly clear that the oceans represent 
a huge reservoir of biomolecules, genetic resources 
and organisms of which we still know very little. A 
rational exploitation of these resources for economical 
purposes, together with adequate preservation and 
management of marine environments, will be beneficial 
for the future use of these resources through existing 
Marine Biotechnology knowledge and methods or from 
further developments in this field.
3.4.1 Promises and achievements
Achievements in this field have been less substantial 
than expected during the last decade and most of the 
methods and techniques routinely used nowadays 
still rely on the use of traditional methods based on 
chemistry and microbiology. This is mainly the result of 
the complexity of marine ecosystems on one hand, and 
the gap between results in marine genomic approaches 
and the development of derived commercial assays and 
products on the other hand.
Biofouling can be defined as the settlement and 
accumulation of organisms on surfaces immersed 
in an aquatic environment. It is a worldwide problem 
with significant economical and safety implications for 
sectors such as shipping and aquaculture, and for the 
maintenance of any man-made structures deployed in 
the marine environment including platforms, pipes and 
coastal defence and monitoring equipment (see Figure 
29) as a result of (amongst other): 
•	 Increased	frictional	resistance	(drag)	of	fouled	ship	
hulls; 
•	 Structural	deterioration	(corrosion)	of	engineered	
materials; 
•	 Restricted	flow	through	fouled	aquaculture	cage	
netting;
•	 Mechanical	blockage	of	intake	and	outfall	pipes;
•	 Losses	in	heat-transfer	efficiency	of	marine	cooling	
systems; and
•	 Increased	costs	for	maintaining/replacing	all	of	the	
above. 
Marine biofouling is the result of a succession of events 
occurring over time on immersed materials. Initial steps 
involve adsorption of dissolved organic and inorganic 
molecules and early microbial colonisers followed by 
macroorganisms like barnacles and mussels. Traditional 
antifouling strategies involved the use of biocidal tin-
oxide marine paints (e.g. on the hulls of vessels). These 
paints successfully inhibited fouling for several years 
but resulted in contamination of surrounding waters with 
tributyltin (TBT) which has been shown to have a high 
toxicity for many invertebrates and coastal ecosystems. 
Following the worldwide ban on use of TBT in anti-fouling 
paints, there is an urgent need to develop effective and 
more environmentally acceptable alternatives. However, 
up to now it has been impossible to substitute the use 
of chemical paints with an efficient and lasting biobased 
process. While a better understanding of the biofouling 
process will be critical, Marine Biotechnology has 
already delivered some interesting results in the search 
for anti-fouling strategies. They notably include:
(i) The investigation of methods for immobilising bacteria 
including the marine bacterium Pseudoalteromonas 
tunicata which produces antifouling compounds 
in gels, and the use of enzymes to inhibit bio-
fouling;
(ii) The evaluation of novel classes of chemical 
compounds isolated from marine organisms such 
as bacteria, microalgae, cnidaria, bryozoa, chordata 
other sessile benthic invertebrates and chordata 
with more than 160 compounds displaying biofouling 
inhibition properties. However, in most cases the 
issue of supply is a major obstacle; 
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Figure 28. North Sea sunset at Ostend (Belgium) 
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(iii) The evaluation of antimicrobial peptides from 
crustaceans to prevent biofilm formation;
(iv) The discovery of compounds like furanone, 
synthesised by macroalgae that impair bacterial 
cell-to-cell communication systems and prevent 
microbial biofilm formation on engineered surfaces, 
of a preliminary stage of substrate exploration by 
barnacle larvae characterised by a weak adhesive 
bond that might be targeted by enzymes in order to 
disrupt the microbial community; and
(v) The development of biomimetic analogues of mussel 
adhesive proteins (MAPs) which could ultimately 
lead to MAP-inspired antifouling coatings which 
inhibit biofouling.
In spite of these and other promising research results, 
we are still a long way off the development of cost-
effective commercial paint products containing 
functional biological ingredients which efficiently 
inhibit biofouling. The main problem is that many of 
these actives (e.g. antifoulants) have ‘fine chemical’ 
structures and cannot be produced in bulk, as required 
for commercial production. The agrochemical industry 
experience could serve as a model of how this can be 
achieved.
Ex situ detection of marine pathogenic bacteria, 
viruses and toxic compounds produced by harmful 
algal blooms (HABs) is still the rule and despite significant 
advances in research, commercial applications of Marine 
Biotechnology for in situ monitoring of marine ecosystems 
are not yet available. The current situation is that for 
most groups of toxins, even if biosensor technologies 
are sufficiently sensitive to comply with the regulatory 
limits, few of these methods have been validated and/
or accepted as an alternative to the mouse bioassay 6. In 
most cases, these techniques would be good tools to be 
used at least as screening methods in order to reduce 
the number of animal bioassays. Biosensor technologies 
offer several advantages over analytical methods and 
animal bioassays including low cost, speed and ease-of-
use, and avoidance of legal and/or ethical issues related 
to the use of laboratory animals. The gene probe-based 
monitoring technologies currently under development for 
detection and quantification of bacterial and viral disease 
agents are still expensive. Some molecular probes able 
to detect the presence of toxic species have already 
been developed but they do not provide information 
on the level of expression of genes controlling toxin 
production. 
The monitoring of man-made chemicals in the 
marine environment is still mainly based on chemical 
analytical techniques (chemical concentrations in water, 
6 While still ex situ, the Jellet tests for a range of biotoxins are accepted 
in the USA in place of the mouse bioassay.
sediment and biota). However, to evaluate the true impact 
of these substances on the different compartments of 
coastal and open sea ecosystems, there is a clear need 
to fully implement state-of-the-art environmental risk 
assessment procedures which combine both exposure 
and effect assessments. Future European monitoring 
programmes should, therefore, include both chemical 
analyses and biological effects measurements. Marine 
Biotechnology can play an important role in the further 
development, evaluation and validation of efficient 
biological effects assessment tools operating at 
different levels of biological organisation. To achieve 
this, more research is needed on both conventional and 
new techniques such as genomics and proteomics. The 
latter are, due to the current lack of knowledge on the 
ecological relevance of associated endpoints, not yet 
ready for inclusion in long-term monitoring efforts.
Bioremediation of marine ecosystems has a long 
history and progress is often determined by our 
reaction to cleaning up major oil spills. In many cases 
contaminants have been removed over time from the 
marine ecosystems by natural processes based on 
the activity of endogenous hydrocarbon compound 
degrading microbes. In case of major oil spills, residual 
oil can be further broken down through a process of 
‘biostimulation’, whereby fertilisers (Nitrogen and 
Phosphorous) are added to enhance the activity of 
microbial communities. Protocols employed during 
the cleanup of the 1989 Exxon Valdez oil spill in 
Prince William Sound, Alaska, demonstrated that the 
application of fertilisers led to a significant increase 
in the rate of biodegradation, with oil-contaminated 
shorelines appearing significantly cleaner after a few 
3. Marine Biotechnology: achievements, challenges  
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Figure 29. A tripod used for the deployment of oceanographic 
measuring instruments heavily fouled by hydroids (genus Tubularia) 
after two months in the sea off the harbour at Zeebrugge (Belgium) 
in spring 2010 
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weeks of application. The time it takes for an oil spill to 
breakdown and dissipate naturally depends on several 
factors including the volume of the spill, the physical 
characteristics of the crude oil, the weather and sea 
state conditions, and whether the spill remains at sea 
or is carried onshore. The key benefit of biostimulation 
in the case of the Valdez oil spill was that it sped up the 
natural recovery process and reduced the possibility 
of exposure of wildlife to dangerous oil contamination. 
The current view is that biostimulation can shorten the 
recovery time for severely oil-impacted shorelines to as 
little as 2-5 years, compared with 5-10 years if sites are 
left untreated. With the ability to cut the site recovery 
time by half, there is a strong argument in favour of 
biostimulated remediation as a cost effective component 
of a marine oil spill response strategy.
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Figure 30. Red Tide 
Microalgae (A: Useful, mostly 
harmless; B: Potentially 
harmful by oxygen depletion; 
C: Harmful, responsible for 
fish mass mortality)
56 | Marine Biotechnology: A New Vision and Strategy for Europe
Biostimulation is based on the fact that rare taxa 
displaying oil degrading properties are present in most 
marine ecosystems. Less used and more controversial 
is the process called bioaugmentation: the introduction 
of additional oil-degrading microbial populations to the 
marine environment. Despite very active research in 
this field, the evidence remains mostly empirical and 
this is again demonstrated by the BP oil spill in the 
Gulf Mexico (April-July 2010). This is not surprising 
given the complexity of microbial communities and, 
more generally, food chains in marine environments. 
Detailed knowledge about the physiological aspects 
and bioremediation capacity of specific microbial strains 
may begin to emerge as whole-genome sequencing 
studies are initiated for key biodegrading taxa. Once 
entire genomes are elucidated, whole-genome DNA 
microarray analyses would allow detailed examination 
of the expression of all the genes in the genome under 
a variety of environmental conditions. 
3. Marine Biotechnology: achievements, challenges  
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Figure 31. National guard dressed in protective gear during the 
cleanup after one of the worst oil spills in Norwegian history 
(August 2009) 
Figure 32. Posidonia oceanica (commonly known as Neptune 
Grass or Mediterranean tapeweed) surrounded by Caulerpa 
taxifolia (Théoule-sur-Mer, France). Posidonia oceanica is a 
seagrass species that is endemic to the Mediterranean Sea where  
it forms large underwater meadows that are an important part of the 
ecosystem. Caulerpa taxifolia is a species of seaweed native to the 
Indian Ocean which produces a large amount of a single chemical 
that is toxic to fish and other would-be predators. Caulerpa taxifolia 
is one of two algae on the list of the world’s 100 worst invasive 
species compiled by the IUCN Invasive Species Specialist Group.
Marine Biotechnology could efficiently contribute to the restoration 
of specific marine habitats such as seagrass beds. 
Obviously,  to minimise the impacts of future oil spills 
in Europe on both marine environments and on human 
activities which rely on their use, a specific action plan 
should be developed and corresponding conclusions 
enforced. The isolation and maintenance of stocks 
of microbial strains suitable for biostimulation and 
bioaugmentation should be evaluated. 
Marine Biotechnology can also contribute to better 
management of marine resources as illustrated by several 
examples where DNA-based methods were used for this 
purpose. This is the case, for example, for whales and more 
generally for marine mammals and sharks. The technology 
used is rather simple and requires characterisation of 
appropriate and specific molecular markers and routine 
PCR or multiplex PCR. DNA-based methods have been 
developed to identify species or populations within species 
for salmon, rockfish, abalone, seals, tuna, halibut, crab, 
and many other marine fish, shellfish and macroalgae. 
Highly variable DNA markers can be used to determine 
if a sample comes, for example, from a threatened or 
a stable population. In addition, preliminary work has 
demonstrated that Marine Biotechnology could efficiently 
contribute to the restoration of specific marine habitats 
such as coral reefs, coastal wetlands and seagrass beds. 
However, much more basic research on the functioning 
of these complex ecosystems is still required in order to 
understand the mechanisms controlling processes such 
as reproduction, inter-organism communication and 
stress responses and interactions. 
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Another management issue relates to the reduction 
of aquaculture impact on the environment and the 
containment of aquaculture risks for human health. One 
of the increasingly acute problems for marine aquaculture 
management is the control of fish diseases in more or 
less open environments where the use of antibiotics 
contributes to the increase in antibioresistance of 
bacterial pathogens, generating multidrug resistant 
bacteria that might ultimately impair both fish and human 
health. Depending on the diseases, diverse strategies 
have been developed in the past to meet profitability 
criteria but with little consideration of environmental 
issues and impacts such as the effects of high nutrient 
loads on aquatic primary producers and effects on 
altered foodweb dynamics in general. Reconsidering 
these strategies and, more specifically, the development 
of alternative approaches based on environmentally-
friendly techniques is urgently required.
3.4.2 Fast forward: Marine Biotechnology 
innovations for environmental applications
Antifouling
To control fouling on immersed structures and notably 
ship hulls, requires a coating or system that will provide 
a clean smooth hull, resistance to slime, resistance to 
roughness, resistance to fouling, be long lasting and 
have a negligible impact on the marine environment. 
Despite much research and some progress in this field, 
there is still no viable non-toxic antifouling agent (green 
AF) which can meet these requirements. Up to now, the 
promises of laboratory assays are rarely if ever con-
firmed by field trials and considerable improvements 
should be made to stabilise green AF in commercial 
paints. In addition, the supply of the most promising 
green AF molecules is often limiting and efforts are 
needed to solve this problem. The development of 
more efficient nanostructured coating mimicking (or 
not) physical defences of marine macroorganisms is 
also needed (see AMBIO project 7). Therefore, estab-
lishing cost-effective optimal combinations of non-toxic 
AF compounds for paints and designing novel sur-
faces remain very important objectives for the future. 
Multidisciplinary approaches including materials sci-
ence and engineering, chemistry, toxicology, biology, 
omics, ecology, and modelling will be critical in solving 
this problem, not only for limiting the dramatic impacts 
of current antifouling measures on the environment, but 
to limit energy consumption in maritime transport and 
to provide a competitive advantage to Europe in this 
potentially lucrative field. 
7. http://www.ambio.bham.ac.uk/ 
Tools to monitor environmental or microbial-
related variables
The development of tools based on automated sensing 
technologies to monitor environmental or microbial-re-
lated variables is of great interest for adaptive sampling 
and management. Several approaches should be in-
vestigated in parallel. The first one does not belong to 
Marine Biotechnology sensu stricto but is an adaptation 
of innovations from medical, food control and terrestrial 
environmental sectors such as gene probe-based tools 
and Surface Plasmon Resonance (SPR)-based tech-
nology which uses chips with probes targeting toxic 
compounds. Specific equipment for in situ analyses, 
with technical specifications adapted to the various 
types of environments (e.g. coastal waters, seabed and 
deep-sea) monitoring stations should be developed. 
Some other approaches belonging strictly to Marine 
Biotechnology should also be further investigated, 
including bioluminescence-based microbial biosen-
sors, whole-cell biosensors and the development of 
bio markers. Until recently, it seemed impossible to pre-
dict the interactions of thousands of toxic compounds 
released in the oceans with thousands of marine or-
ganisms. Marine Biotechnology might well contribute 
to address this in the future using relevant biomarkers 
such as enzymes and hormones produced by living 
organisms in response to toxic compounds. The main 
advantage of this strategy is that it is integrative. The 
use of marine models coupled with omics technologies 
opens new perspectives in this field and deserves an 
increased research effort. These tools should be cost-
effective, reliable (notwithstanding biofouling), and as 
efficient as traditional laboratory methods. Despite re-
cent advances in gene probe-based technology, the use 
of derived assays on a routine basis is still not practical. 
In short, there is an urgent need for simple, cheap and 
reliable methods and techniques to circumvent these 
problems.
The field of marine bioremediation and habitat restoration 
is characterised by the fact that the intervention takes 
place in the open environment, resulting in interactions 
between physico-chemical parameters, dissolved or 
particulate matter and marine biota. Therefore, Marine 
Biotechnology will have intrinsic limits owing to our lack 
of knowledge and to the limits in our ability to reliably 
predict the effects on the environment of chemicals 
(fertilisers, dispersants) or microbial inoculates. Despite 
these limits, enzymes from marine microbes may also 
have a role in increasing the efficiency of oil recovery 
and in the bioremediation of Arctic soils resulting from 
increased oil operations and in human activity in the 
Arctic. For example hydrocarbon cold seeps and oil 
spills have led to the adaptation of certain marine 
microbiota which utilise alkanes as carbon sources. 
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Such bacteria and their enzymes have a potential role 
in bioremediation and oil processing. Indeed alkane 
hydroxylase genes, encoding enzymes with specificity 
for alkanes of varying lengths, have been isolated 
from deep sea and cold seep metagenomic libraries 
(See Annex 3). Environmental bioremediation using 
microorganisms is characterised by relatively low-
tech empirical practices and the limited ability to use 
advances in microbial ecology for management. A long 
term approach should be followed, combining microbial 
ecology, including the development of mathematical 
models, whole genome studies for key biodegrading 
taxa, and field assays in mesocosms in order to improve 
our future capability to predict how diverse assemblages 
will respond in defined conditions.
Marine resource management
How to best manage marine resources on a global 
basis is critically important for the current and future 
sustainability of those resources and the environments 
they occupy. Marine resource management and 
sustainable development require an holistic approach, 
integrating biological, environmental, economic and 
social components. In many cases, the status of marine 
resources, notably fish and shellfish resources, is 
determined by the will to enforce optimal management 
options based on already available management 
tools. Paper-based traceability can be enforced by 
developments in molecular barcoding. DNA probe 
technology has reached the maturity to identify taxa 
routinely and will soon do so at the origin level. DNA-
based analysis of marine shellfish, fish and mammals 
is one of the most promising approaches for detailed 
assessment and control of fisheries and the traceability 
of fresh and processed fish products. Similar tools will 
also be needed:
(i) To improve the monitoring and the management of 
the most dangerous invasive species, especially 
during the very first stages of colonisation;
(ii) For the control of fish and shellfish populations 
escaping from farms or culture grounds; and
(iii) For the control of aquacultured GMOs in case of 
introduction in Europe.
These capabilities should be fully developed in order to 
evaluate the efficacy of trade agreements and treaties on 
specific resources either threatened or endangered. In 
addition, the restoration of marine ecosystems through 
either habitat restoration or protection measures 
could benefit from molecular evaluation tools besides 
traditional population dynamic approaches. 
A common feature of all these aspects of environmental 
monitoring, including bioremediation, restoration and 
management, is that they will benefit very much from 
advances in Marine Biotechnology. The most obvious 
step changes will be realised through DNA-based 
technologies and improvements in omics approaches. 
Developing Marine Biotechnology tools to that end could 
contribute to improve marine ecosystem management 
and reconcile the biotech development and the 
sustainable management of the marine ecosystems. 
This is both a challenge and an opportunity. 
A more basic aspect impacting environmental issues 
is linked to the knowledge of the interactions among 
the various components of marine ecosystems. To 
a large extent these interactions are linked to issues 
such as the control of biofilm formation and maturation, 
the regulation of the microbial world and changes in 
ecosystems and their resilience. In order to understand, 
to describe and to predict these interactions, it will be 
very important to enhance the understanding of the 
social life of microbes and to obtain a more complete 
picture of the factors which control interactions between 
microbes and invertebrates.
Summary Box 14. Recommendations for the 
development of marine biotechnological 
applications for the protection and 
management of marine ecosystems
- Develop cost-effective and non-toxic antifouling 
technologies combining novel antifouling com-
pounds and surface engineering;
- Develop automated high-resolution biosensing 
technologies allowing in situ marine environmen-
tal monitoring of coastal water quality, including 
prediction and detection of HABs and human and 
environmental health risks;
- Consolidate knowledge on DNA-based technolo-
gies for organism and population identification 
and support the development of commercial tools 
and platforms for routine analysis;
- Support basic research in all aspects of marine 
sciences contributing to a better knowledge 
of biotic interactions, including the social life of 
microbes, microbe/invertebrate interactions, 
chemical ecology, and connectivity;
- Incorporate novel Marine Biotechnology ap-
proaches in existing and new action plans for 
combating marine oil spills based on marine bio-
technological products or processes.
3. Marine Biotechnology: achievements, challenges  
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polymerases, DNA ligases from marine Thermococcales 
(Thermococcus and Pyrococcus) that are the enzymes 
of choice for high-fidelity in vitro gene amplification.
In addition, Shrimp Alkaline Phosphatase (SAP) 
from Marine Biochemicals has become a popular 
DNA-modifying enzyme due to its heat inactivation 
properties. The luminescent properties of the jellyfish 
3.5 Enzymes, biopolymers, 
biomaterials for industry and the 
development of other life science 
products
Many Marine Biotechnology advances including the 
isolation, synthesis or use of enzymes, biopolymers 
and biomaterials can have applications in several 
domains. Proteins and enzymes from marine organisms 
contribute significantly to industrial biotechnology but 
can also support novel process development in the 
food industry or in molecular biology and diagnostic 
kits. In the past decade, the medical, pharmaceutical 
and biotechnology industries have directed increasing 
attention towards biopolymers of marine origin for 
numerous applications ranging from biodegradable 
plastics, food additives to pharmaceutical and medical 
polymers, wound dressings, bio-adhesives, dental 
biomaterials, tissue regeneration and 3D tissue culture 
scaffolds. However, marine-derived biomaterials science 
is still relatively new and the marine environment is, as 
yet, a relatively untapped resource for the discovery of 
new biopolymers and biomaterials. All of these products 
with very diverse applications are of high interest for the 
future and will, in many cases, contribute to answer to 
the grand challenges discussed in Chapter 1.
3.5.1 Proteins and enzymes
To date, over 3,500 microbial enzymes have been isolated, 
with the majority being derived from either mesophilic 
bacteria or fungi, predominantly sourced from terrestrial 
environments. In contrast, marine environments have 
received little attention, with the possible exception of 
extreme environments. Because they live in a unique 
environment, marine organisms can provide some 
potentially useful characteristics such as an increased 
salt tolerance, hyperthermostability, cold adaptivity and/
or barophilicity, together with other potentially novel 
chemical and stereochemical properties. While some 
enzymes derived from marine organisms have been 
isolated (See Annex 3), the potential of isolating enzymes 
from the diversity of available unique marine ecosystems 
has until now been largely underexploited.
Enzymes have, however, been isolated from marine 
extremophiles such as psychrophiles, acidophiles, 
thermophiles and hyperthermophiles. A limited number 
of biocatalysts such as amidases, lipases, proteases 
and carbohydrases, have been isolated, biochemically 
characterised, and in some cases, optimised through 
protein engineering. For example, enzymes from marine 
hyperthermophilic archaea are used in molecular biology 
research, diagnostics, food safety and environmental 
monitoring. They include DNA-dependent DNA 
 
Figure 33. Pandalus borealis is a species of shrimp found in cold 
parts of the Atlantic and Pacific Oceans. P. borealis is an important 
food resource, and has been widely fished since the early 1900s 
in Norway followed by other countries. At the same time this 
shrimp species is also the source of Shrimp Alkaline Phosphatase 
(SAP), a hydrolase enzyme used in molecular biology for removing 
phosphate groups from many types of molecules, including 
nucleotides, proteins, and alkaloids. Shrimp Alkaline Phosphatase 
(SAP) has become one of today’s highest-selling DNA modifying 
enzymes beacause in contrast with other alkaline phosphatases 
(from E. coli or Calf intestine) SAP can be completely inactivated by 
heating it for 15 minutes at 65 °C. 
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Aequorea victoria led to the characterisation of the green 
fluorescent protein (GFP). The GFP and the luciferase 
enzyme from Vibrio fischeri have widespread uses in 
molecular biology as a reporter protein. By using DNA 
technology, researchers can now connect GFP to 
other interesting, but otherwise invisible, proteins. This 
glowing marker allows them to watch the movements, 
positions and interactions of the tagged proteins. The 
aequorin protein from the Aequoria jellyfish has also 
found use as a biosensor for Ca2+ signalling in the 
research laboratory.
Enzymes such as silicateins involved in biosilicia 
production in marine sponges and enzymes involved 
in dissolving or etching silica such as silicases, 
have enormous potential in nanobiotechnology and 
biomedicine. For example, biosilica can be used as 
a coating for metal implants used in surgery, for drug 
delivery via encapsulation of bioactive compounds, and 
in microelectronic fabrication. In addition, silicateins and 
silicases may also find uses in organosilicon chemistry, 
specifically in drug design through the synthesis of novel 
drug analogues by the replacement of specific carbon 
atoms with silicon, or the regeneration of tooth and 
bone defects. Future applications may be in structuring 
nanoengineered fibre-optics and etching nanoscale 
silica structures.
The Arctic Ocean, where sea ice temperatures range 
from -1.9°C to 3°C, provides one of the coldest habitats 
on earth for marine life, and has been targeted by a 
number of biotechnology companies for novel enzymes. 
Focusing in particular on highly cold-adapted and salt-
tolerant enzymes, these companies now have a number 
of products either in development or already on the 
market.
3.5.2 Marine-derived biopolymers and 
biomaterials
Biopolymers of marine origin are currently being 
examined for a wide variety of applications. There is 
a particularly strong interest in the biomedical sphere, 
with developments such as pharmaceutical and medical 
polymers, bio-adhesives, wound dressings, dental 
biomaterials, tissue regeneration and 3D tissue culture 
scaffolds. 
Polysaccharides (also called glycans) are an emerging 
class of marine-derived biopolymer with numerous 
applications. In addition to their potential direct use as 
biomaterials, marine derived polysaccharides are readily 
amenable to chemical modification, permitting a greater 
flexibility in the design of, for example, novel alginate 
co-polymers which have significant promise as drug 
delivery systems. Marine macroalgae synthesise a great 
diversity of polysaccharides, which constitute their cell 
wall and energy storage. They are characterised by their 
high levels of sulphated polysaccharides which have no 
equivalent in land plants and which are currently being 
investigated as potential immune boosters in cattle. 
The ban on using antibiotics in cattle feed adds extra 
3. Marine Biotechnology: achievements, challenges  
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Figure 34. Jellyfish Aequorea victoria (left – picture taken at the Monterey Bay Aquarium, USA) and Green Fluorescent Protein (right 
– Courtesy Roger Tsien, UCSD). The luminescent properties of the jellyfish Aequorea victoria led to the characterisation of the green 
fluorescent protein (GFP) which has widespread uses in molecular biology as a reporter protein. Martin Chalfie, Osamu Shimomura, and 
Roger Y. Tsien were awarded the 2008 Nobel Prize in chemistry on 10 October 2008 for their discovery and development of the green 
fluorescent protein. 
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impetus to the development of these novel approaches 
using compounds derived from marine organisms.
Red algae produce agars and carrageenans and brown 
algae produce alginates, fucans and laminarins. These 
hydrocollids are well-known for their gelling properties 
and are used in a variety of laboratory and industrial 
applications. Laminarin for example is used for the 
stimulation of natural defences in terrestrial crop cultures 
(Iodus 2®), thus allowing the partial replacement of 
pesticides used in conventional agriculture. In this 
application, the priority is given to the crop protection 
rather than to the pathogen destruction.
Chitin (and its derivative chitosan), derived principally 
from shellfish waste (prawn, crab, crayfish), can be 
used in combination with natural or synthetic polymers 
and is widely used in biomedical applications due to 
its lack of toxicity, biodegradability, anti-bacterial and 
gel-forming properties. Chemical deacetylation of chitin 
improves the reactivity and solubility of the resulting 
product, chitosan. Chitosan is also widely employed in 
biomedicine. In addition to the characteristics detailed 
above, chitin and chitosan are capable of forming films 
and chelating metal ions.
Collagen-based marine sponges have been utilised as 
a potential collagen biomaterial for bone repair. Once 
again, native sponge materials and chemically modified 
derivatives have been investigated.
Hydrothermal conversion of calcium carbonate to 
hydroxyapatite, a calcium phosphate compound found 
at high levels in mineralised tissue/bone of vertebrates, 
has received much attention in the past 10-15 years. 
Hydroxyapatite formed in this manner permits synthesis 
of a compound with a similar microstructure to that of 
bone. In recent years, bioceramics based on calcium 
phosphates, have been examined extensively as bone 
substitutes, since these materials may be bioactive 
(hydroxyapatite, bioactive glasses), resorbable 
(tricalcium phosphate), porous for tissue in-growth 
(hydroxyapaptite coated metals) or composites. 
Recently, the hydrothermal conversion of coralline algae 
to hydroxyapatite has also been investigated. 
Bioplastics such as polyhydroxyalkanoate (PHA) have 
also received considerable attention owing to their high 
molecular weight, thermoplastic/elastomeric properties, 
biodegradability, biocompatibility, non-toxicity and 
potential for production from renewable carbon sources. 
PHAs are synthesised by a wide variety of Gram-positive 
and Gram-negative bacteria, by members of the family 
Halobacteriaceae of the archaea and recently by marine 
bacteria including Paracoccus seriniphilus strain E71, 
Bacillus sp. NQ-11/A2, Pseudomonas sp. CMG607w, 
a Pseudomonas guezennei sp, Halomonas profundus 
sp, Pseudomonas raguenesii and the cyanobacterium 
Spirulina subsalsa.
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Figure 35. Experimental bioreactor for marine bacterial 
exopolysaccharide production 
Figure 36. Young Chondrus Crispus, a species of red algae which 
grows abundantly along the rocky parts of the Atlantic coast of 
Europe and North America. Chondrus crispus is an industrial 
source of the polysaccharide carrageenan, which is commonly 
used as a thickener and stabiliser in milk products such as ice 
cream and processed foods including meat. 
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Finally, spicules in marine sponges, which contain 
silicia are excellent light transmitters and exhibit some 
advantages over technical optical fibres such as 
enhanced fracture toughness and fibres with higher 
refractive indexes.
3.5.3 Future perspectives and avenues 
There is currently an upsurge in interest by biotechnology 
companies in isolating and characterising novel 
enzymes, biopolymers and biomaterials with properties 
which meet identified needs and circumvent existing 
barriers. Biomolecules and biomaterials from marine 
sources are of particular interest as they likely to have 
novel characteristics such as increased salt tolerance, 
pressure tolerance, cold adaptivity, heat tolerance and 
may have novel physical, chemical/stereochemical as 
well as original biochemical properties.
Mining for enzymes
If we consider (i) the vast reservoir of enzymes identified 
through large-scale sequencing projects of genomes 
and metagenomes (mostly marine for the latter); and (ii) 
the current and near-future advances in screening and 
expression technologies (see Section 2.6), the potential 
to unveil novel interesting enzymes from marine sources 
is very high. But this does not automatically guarantee 
novel commercial products. Of course, the issues of 
supply of raw material, property rights and intellectual 
property, combined with the current limitations in 
screening and expression technologies are important (as 
stated in Section 2) and deserve attention. However, the 
main obstacle to progress in this case is the inability of 
academic and industry partners at EU level to work in a 
coordinated fashion in order to develop common projects. 
This cooperation is, to some extent, a prerequisite for 
enzyme development and commercialisation. Indeed, 
hundreds of novel enzymes without industrial applications 
have been identified through past projects and a better 
focus on detailed specifications of enzymes required 
for new processes or for the improvement of existing 
ones is required. Since the detailed specifications of a 
product, notably the precise substrate specificity and 
conversion efficiency can be of high value, they are not 
easily shared. This implies that huge screening projects 
of enzymes should preferentially be operated by the 
industry possessing the precise technical specifications 
of the enzymes of interest. 
Marine Biomaterials
Chemical and enzymatic modification of marine-
derived polymers can improve their mechanical and 
functional properties, biocompatibility, solubility and 
biodegradability. In addition, chemical modifications 
permit a wider application of such biopolymers 
and can result in significant improvements to their 
reactivity and the ease with which they are processed. 
Chemically modified, marine-derived biopolymers are 
3. Marine Biotechnology: achievements, challenges  
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Figure 37. Research to underpin the technology and environmental management of marine sponge aquaculture to obtain high value collagen
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now being used in the areas of wound healing, drug 
delivery systems and tissue engineering. Alginates 
have also been investigated for their ability to act as 
gel entrapment systems and for their potential use in 
bone repair.
In recent years, there has been increasing industry 
interest in the isolation of novel marine microorganisms 
which produce extensive exopolysaccharides (EPS). 
Many such microorganisms produce EPS of novel 
chemical composition which may have applications in 
adhesives, textiles, pharmaceuticals and food additives. 
Strong sampling infrastructure/capabilities will be 
required for this type of approach, since most gains 
are likely to be made from microorganisms derived from 
extreme marine environmental niches. 
Perhaps the area of greatest potential importance will 
be the development of marine-derived biomaterials 
which are suitable for tissue repair and regeneration. 
This will require a multidisciplinary approach to 
translate advances in the characterisation and chemical 
modification of lead materials and culture scaffolds to 
clinical applications. Identification of scaffolds onto 
which regenerative cells (stem cells, neuronal cells, 
osteoblasts or chondrocytes) can be seeded and 
retained to generate functional three dimensional 
tissue scaffolds represents a major future direction of 
biomaterial-based regenerative medicine.
Summary Box 15. Recommendations for the 
discovery and application of novel enzymes, 
biopolymers and biomaterials from marine 
bioresources 
- Actively support the development of enabling 
technologies for high-throughput enzyme screen-
ing and for the expression of marine proteins and 
enzymes through dedicated hosts;
- Actively support projects aiming at the emergence 
of marine biopolymers as novel competitive com-
mercial products in food, cosmetics and health.
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4.1 Facilitating access to marine 
resources, biodiscovery and marine 
bioresource information
The coasts, seas and oceans around Europe host 
an incredibly diverse set of ecosystems and habitats 
ranging from coastal marshes to lagoons, bays, deep-
sea, polar and tropical marine environments, tropical 
and cold coral reefs, deep-sea anoxic sediments and 
brine lakes, continental margin cold seeps and mud-
volcanoes, and coastal and deep-sea hydrothermal 
vents. These ecosystems, in turn, host an extraordinary 
biodiversity. 
The European Union has a complex mode of regulation 
and exploitation of the marine resources in its EEZ 
(Exclusive Economic Zone), ranging from common 
policies (for aquaculture and fisheries) to national and 
in some cases regional policies for other types of living 
resources, including resources for biotechnology. 
Sampling of marine resources for biodiscovery 
(‘bioprospecting’) is controlled by each Member State 
and special permits are normally required to sample 
habitats of interest. In many cases, this means that 
bioprospecting in the waters of a third country is allowed 
only for the purposes of academic research, even if the 
material taken is of negligible intrinsic value. In fact, 
the ‘gold mine’ syndrome (according to which each 
crude sample contains a hidden treasure) hampers the 
ability of partners to agree on an a priori chain value. An 
alternative approach would be to uncouple access from 
benefit sharing as in the case of biodiversity legislation 
used in Queensland, Australia 8.
Another obstacle has regularly been identified in EU 
research projects which involve collaboration between 
academia and industry. Often academic scientists and 
commercial enterprises will differ on how to utilise 
and/or protect promising research results. Complex 
intellectual property (IP) and consortium agreements 
can act as a disincentive for SMEs to participate in 
research partnerships with academic institutions. 
Where appropriate, SMEs should own the IP derived 
from SME/academic collaborations since SMEs need 
it to raise investment. On the other hand, the interests 
of universities and public research organisations must 
also be preserved in the frame of partnership with the 
industry to avoid negative effects.
Beyond the EU-EEZ, European countries have access 
to the ‘zone’ under international jurisdiction thanks to 
research fleets, deep-sea submarines and ROVs from 
several countries. The United Nations Convention 
8 See Queensland Nature Conservation Act 1992 and Biodiscovery Act 
2004 available at http://www.environment.gov.au/biodiversity/science/
access/contacts/qld/index.html 
on the Law of the Sea (UNCLOS) governs access to 
the seabed, and rights to conduct scientific research 
in international waters (see also Section 4.2 below). 
The sea and seabed are regarded as common human 
heritage, and the convention states that research in 
these waters must address ‘peaceful uses of the seas 
and oceans, the equitable and efficient utilisation of their 
resources, the conservation of their living resources, 
and the study, protection and preservation of the marine 
environment’. The convention was developed before 
the biotechnological potential of the oceans had been 
anticipated, and many of its statements refer to large 
scale mining of the seabed for resources, and not for 
the small-scale sampling necessary for biotechnological 
applications. The main issue to be resolved is the clash 
between the need for ownership to claim intellectual 
property protection over an invention derived from 
marine genetic resources, and the convention’s 
statement that ‘no state shall claim sovereignty over 
any part of the area or its resources’ (although there 
is no specific reference to marine genetic resources). 
Additionally, the freedom to conduct scientific research 
in the oceans requires the sharing of results, again 
incompatible with the need to keep inventions secret 
until a patent application has been filed. UNCLOS states 
that the International Seabed Authority ‘shall provide for 
the equitable sharing of financial and other economic 
benefits derived from activities in the area’, although 
it provides no clear mechanism for doing so. It is also 
worth noting that a number of countries bordering the 
Arctic (Denmark, Norway, Canada, Russia and the US) 
are currently claiming territorial rights to Arctic water, 
with a view to future exploitation. All of these issues 
need to be resolved before we can develop a genuinely 
equitable and transparent process to open access for 
the sampling of marine resources for biotechnological 
applications.
4. Supporting the development of Marine Biotechnology 
Figure 38. Remotely Operated Vehicle (ROV) Victor (Ifremer, 
France). ROVs are indispensible tools to explore the deep-sea. 
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The absence of a common policy to provide equitable 
access to marine resources for biodiscovey is further 
compounded by a complete lack of coordination 
between Member States on this issue and concrete 
coordination bodies such as a ‘Marine Biotechnology 
Centre or Institute’ operated at the European level or 
within the frame of an intergovernmental agreement. 
It is, therefore, difficult to get an accurate up-to-date 
figure on the status of biodiscovery based on marine 
resources in Europe, at least for the primary steps in the 
process which include sampling, and possibly culture, 
fractionation, and screening for active compounds. 
An analysis of the scientific literature will shed light on 
some of the marine biodiscovey effort that is ongoing 
but will provide little if any information on screening 
activities being undertaken by the private sector which 
is missing.
For marine drug discovery, the last decade was 
characterised by a very low level of investment from 
major pharmaceutical companies. Moreover, the 
pharmaceutical industry has tended to privilege R&D 
on chronic diseases with less attention paid to infectious 
ones, driven by the need to minimise risk and maximise 
profitability. In fact, marine drug biodiscovery has 
been mainly conducted by academic teams funded 
by governments and a few small and medium sized 
pharmaceutical companies willing to assume the risks 
of this preliminary step in drug R&D.
However, EU policy during the last decade has already 
paved the way for further coordination in marine 
biodiscovery at European level. Multiple initiatives 
have been developed and there is already a very active 
network of marine biological stations with a specific 
policy dedicated to the management and conservation 
of various marine resources (see Section 4.2 below). 
4.2 Marine bioresource and 
biotechnology research 
infrastructures
Since the year 2000, the European Commission has 
been working with Member and Associated States 
towards the development of the European Research Area 
(ERA), one of the goals of which is to better integrate 
the scientific communities and the infrastructures they 
need to conduct interdisciplinary and collaborative 
research. The Networks of excellence (NoEs) funded 
under FP6 have contributed to this integration, including 
some marine-focused projects. The overall objective of 
the MarBEF NoE, was to investigate the relationships 
between marine biodiversity and ecosystem functioning 
and to understand the economic, social and cultural 
value of marine biodiversity. The major goal of the 
Marine Genomics Europe NoE was to integrate 
genomics with marine biology in order to implement 
high-throughput approaches in genomics and post-
genomics in the biology and ecology of marine organisms 
and ecosystems. EUR-OCEANS NoE focused on the 
development of models for assessing and forecasting 
the impacts of climate and anthropogenic forcing on 
food web dynamics of pelagic ecosystems. Even though 
the communities covered by these three large projects 
were only partially overlapping, their members came 
from the main marine research institutes in Europe as 
well as a number of other partners from transdisciplinary 
fields of expertise (e.g. genomics, data bases, outreach). 
In total, over one hundred marine institutes and close to 
two thousand scientists have contributed to the activities 
of the three marine Networks of Excellence and this large 
community represents an impressive potential both in 
academic and applied research (see Annex 2 for some 
of the major achievements of these marine Networks 
of Excellence). While the project funding has ended, 
all of the marine NoEs are pursuing, through different 
mechanisms, lasting integration of their networks. 
This momentum has deeply shaped the area of marine 
biology and although there is still progress to be made, 
we are now in a much better position to collectively 
address key challenges for the successful development 
of Marine Biotechnology. The community is much less 
fragmented than before and several infrastructures such 
as Marine Institutes and Marine Biological Resource 
Centres (MBRC) have gained visibility and are more 
accessible to scientists from throughout Europe. MBRC, 
however, do not cover all academic groups in Europe 
involved in Marine Biotechnology and further interaction 
with, and involvement of, other relevant research groups 
and infrastructures is needed.
Other activities and networks supported by the EU, 
which can contribute to the integrated view of Marine 
Biotechnology, include ASSEMBLE, TARA Oceans, 
EUROFLEETS, MARS and, above all, projects under 
ESFRI, the European Strategy Forum on Research 
Infrastructures.
ASSEMBLE is an EU FP7 research infrastructure initiative 
comprising a network of marine research stations which 
provide transnational access to a comprehensive set of 
coastal marine ecosystems, research vessels, state-
of-the-art experimental facilities and to a wide variety 
of marine organisms. A major objective of ASSEMBLE 
is to enhance complementarity and interoperability 
of the various Marine Biological Resource Centres 
and to collectively provide a representative set of 
experimental ecological and biological systems to 
feed, for example, developments in genomics and post 
genomics. The TARA Oceans project is a three-year 
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international scientific expedition aiming to study the 
composition and dynamics of planktonic ecosystems 
and certain unexplored coral reefs around the globe. 
TARA Oceans is developing a new integrated marine 
biobank to integrate all the data acquired in the course 
of the expedition. The goal is to provide a tool to extract 
functional correlations between genes, the diversity of 
organisms present in a given region and its physical 
environment. While the main objective of TARA Oceans 
expedition is to study the effects of climate change on 
marine biodiversity, the integrated biobank could be 
screened for biotechnological applications.
There are also a number of initiatives for improving 
the coordination of European Marine Research fleets. 
EUROFLEETS is another EU FP research infrastructures 
project which aims to bring together the European 
marine research fleets to enhance their coordination 
and promote a more efficient, collaborative and cost-
effective use of the vessels and their associated heavy 
equipment. OFEG, the ‘Ocean Facilities Exchange 
Group’ represents Europe’s leading oceanographic 
research organisations and provides a forum to consider 
exchange and co-operation opportunities for the Global 
and Ocean Class research fleet. OFEG aims to maximise 
the overall scientific output of its partners, using its 
state-of-the-art facilities in support of the worldwide 
oceanographic community. Finally, ERVO, a network of 
European Research Vessel Operators, aims to promote 
the co-ordination of small to medium sized research 
vessel operators in Europe. The harmonisation of the 
European fleet is essential for facilitating international 
access to marine biodiversity and to remote/extreme 
ecosystems such as deep sea habitats, polar 
environments or the open ocean. These areas will surely 
provide numerous new species, novel molecules and 
biocatalysts for biotechnological applications.
Another level of integration is realised with the MARS 
foundation, a network of European marine research 
institutes and stations which pursue common goals such 
as generating a critical mass and focus for European and 
global marine research activities, engaging stakeholders 
and facilitating ‘durable integration’ of marine research 
stations in the long-term.
ESFRI, the European Strategy Forum on Research 
Infrastructures will also have a major impact on 
marine research infrastructures and will play a role 
in Marine Biotechnology development in Europe 
since the forum aims to identify the scientific needs 
for research infrastructures for the next 10-20 years 
in the context of the Lisbon agenda. ESFRI projects 
are generally characterised by large investments and 
long project lead-times, with associated needs for 
long-term commitment. In the ESFRI policy, research 
infrastructures are at the core of the knowledge triangle 
comprising Research, Education and Innovation. So far, 
four marine projects have been adopted by ESFRI, some 
of which are in the negotiation phase while others are 
still in the preparatory phase:
•	 EMSO ‘European Multidisciplinary Seafloor 
Observatory’ is a distributed infrastructure for long 
term monitoring of environmental processes;
•	 EURO-ARGO is a global ocean observing infra-
structure delivered through an array of Argo autono-
mous monitoring floats throughout the ice-free areas 
of the deep ocean;
•	 EMBRC ‘European Marine Biological Resource 
Centre’ is a distributed pan-European infrastructure 
including the main existing coastal marine laboratories 
for providing access to model marine organisms and 
related genomic resources;
•	 LIFE WATCH ‘Science and Technology infrastructure 
for Biodiversity data and observatories’ is not 
strictly marine but is a distributed e-infrastructure 
for providing access to interoperable biodiversity 
databases and biological collections. 
These diverse initiatives truly reflect an unprecedented 
momentum that is fundamentally changing the 
European landscape for marine sciences and marine 
research infrastructures. This momentum can be 
characterised by the following keywords: critical mass, 
interoperability, integration, complementarity, and the 
sharing of access to resources, infrastructures and data. 
At the European level, the challenges are now to build 
on the achievements of the projects mentioned above, 
keep the momentum to improve collaboration and to 
streamline the access to ‘marine knowledge’ through the 
shared access to marine research infrastructures and 
4. Supporting the development of Marine Biotechnology 
Figure 39. ROV deployment from RRS James Clark Ross operated 
by the National Oceanography Centre, Southampton, UK, on behalf 
of NERC.
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to samples that are deposited in marine biobanks. The 
new context described here could provide a beneficial 
background and novel opportunities for fostering 
Marine Biotechnology provided that the topic is clearly 
acknowledged as a priority.
Summary Box 16. Recommendations to 
improve access to marine bioresource and 
biotechnology research infrastructures
- Identify recognised Marine Research Centres, 
promote synergies and facilitate interactions be-
tween these centres where the scientific expertise, 
the resources and the technological platforms are 
established, and where there are new emerging 
Marine Biotechnology start-ups or companies.  
One model could be to develop ‘incubators’ or 
marine biotechnological institutes co-located 
with marine laboratories as demonstrated at the 
European Centre of Marine Biotechnology, based 
at the Scottish Association for Marine Sciences 
(SAMS) in Oban, Scotland;
- Biobanks and Biological Resource Centres (BRCs) 
must meet their obligations with respect to the 
convention on biodiversity. If the bioresources 
held at these biobanks are to be shared through-
out Europe, then very clear access and benefit 
sharing agreements must be put in place;
- Encourage and establish linkages between current 
and planned European scientific research infra-
structures networks and Marine Biotechnology. 
This could be part of the activities of the pro-
posed European Marine Biotechnology Institute 
or Centre (see below);
- Establish a European Marine Biotechnology 
Institute or Centre, at least virtual, through a per-
manent Secretariat and network with key nodes, 
to capitalise the knowledge and experience 
gained in different Member States for further opti-
misation of nationally based projects, cooperative 
initiatives and funding. 
 The proposed European Marine Biotechnology 
Institute or Centre should be set up at the EU level 
or as a major inter-governmental research organi-
sation, with equivalent standing to the European 
Molecular Biology Laboratory (EMBL). It should 
be charged with developing Europe’s Marine 
Biotechnology research capabilities through a  
range of collaborative actions including: the 
provision of research leadership in Marine 
Biotechnology; establishing and operating a 
European Marine Biotechnology Portal; facilitat-
ing access to essential infrastructure to ensure 
that European Marine Biotechnology research re-
mains competitive; training early stage scientists 
via a European Marine Biotechnology graduate 
development programme; operating a Marine 
Biotechnology resources centre and strengthen-
ing the awareness of Marine Biotechnology across 
European industry. In doing so, the European 
Marine Biotechnology Institute or Centre would 
capitalise the knowledge and experience gained in 
the different member states for further optimization 
of nationally based projects, cooperative initia-
tives, biobanks and funding. Such a Centre would 
also contribute to securing adequate supplies of 
biological material and provide a basis for much 
stronger industry-academic collaborations and 
partnerships. The establishment of the European 
Marine Biotechnology Institute or Centre could play 
a catalysing role in strengthening European Marine 
Biotechnology research capability and would 
enable critical recommendations put forward 
throughout this Position Paper to be addressed.
4.3 Education, outreach, integration 
and interdisciplinarity
Education: training the next generation of 
marine biotechnologists
To promote Marine Biotechnological innovation, training 
of the next generation of scientists is critical. They must 
have more interdisciplinary expertise and use tools from 
various disciplines to address questions related to marine 
organisms and to solve problems posed by the marine 
environment. This statement is not specific to Marine 
Biotechnology; in fact the future of life sciences in the 
21st century will depend upon the ability of scientists to 
develop interdisciplinary projects embracing skills and 
concepts from, for example, phylogeny, mathematics, 
chemistry, and the physical, engineering, computational 
and social sciences. The challenge for the development 
of the Marine Biotechnology sector is to ensure that 
undergraduate and graduate training programmes 
related to marine sciences include adequate training 
in biotechnology.
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Outreach: training the European citizen and 
other relevant stakeholders
The proficient dissemination of novel research discoveries 
will unquestionably provide new opportunities in marine 
biotechnologies for the industrial sector. Nevertheless, 
the great potential of marine biology for biotechnology 
innovation is still not realised. Marine Research centres in 
academic institutions are largely focused on fundamental 
research and there is insufficient interaction between 
scientists from these centres and potential end-users in 
the private sector or in governmental decision-making 
bodies. There are many obstacles which can block 
the effective transfer of knowledge from the science 
community to the business world such as insufficient 
support and motivation, legal issues and cultural 
disparity. Therefore, improving the dissemination 
channels that will facilitate this knowledge transfer is 
an important challenge for the successful development 
of Marine Biotechnology in Europe. The Biosciences 
Knowledge Transfer Network (BKTN) in the UK, which 
provides neutral information on the value and applications 
in various biotechnology fields, provides a good example 
that could serve as a model for such initiatives.
Summary Box 17. Recommendations to 
improve education, training and outreach 
activities related to Marine Biotechnology 
research
Training the next generation of marine  
biotechnologists
- Include biotechnology in all marine biology train-
ing programmes;
- Create a European School or Course on Marine 
Biotechnology, which could be virtual and dis-
tributed. A distributed virtual institute would also 
be useful as a central point of interaction with the 
commercial sector;
- Create European MSc and PhD programmes in 
Marine Biotechnology;
- Create schools information packs based on an 
inventory of existing information and adaptation/
extension of this information, in relevant langua-
ges;
Training the European citizen and other relevant 
stakeholders
- Create a series of journalist and media briefings 
on Marine Biotechnology;
- Identify the needs for modern biotechnology re-
sulting from the development of basic and applied 
research in life sciences;
- Understand and take into account the diversity of 
needs of different stakeholders, from specialised 
marine biology researchers to SMEs;
- Remove or minimise the barriers to cooperation 
between researchers and high-tech companies 
(notably companies from the healthcare sector);
- Develop improved transfer pathways for data and 
results between marine researchers based in aca-
demic institutions and the private sector.
The proposed European Marine Biotechnology 
Institute or Centre could play an important role in all 
of the above activities.
Figure 40. Marine science fairs provide excellent opportunities 
to present the opportunities and societal benefits offered by 
biotechnological applications based on marine organisms to 
children and the public at large. 
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5.1 A vision for the future 
development of Marine 
Biotechnology Research in Europe
Considering:
- the uniqueness of marine ecosystems and the physical 
and chemical variability in marine environments which 
support adapted life forms from intertidal mud-flats 
to deep sea hydro-thermal vents;
- the extreme originality and diversity of marine 
organisms, the fact that they represent a unique 
source of genetic information and biochemical 
complexity;
- that the marine environment is a critical source of 
products and services of societal value including 
food, bio-active compounds and biomaterials with 
both medical and industrial applications;
- that marine ecosystems, and in particular marine 
organisms (excluding fisheries products), are largely 
unexplored, understudied and underexploited 
in comparison with terrestrial ecosystems and 
organisms;
- that Europe possesses a wide variety of marine 
habitats and has a long-standing tradition of marine 
bio-science research, a strong biotechnology 
expertise and significant relevant research 
infrastructures; and
- that Europe now needs to be highly strategic in its 
approach at national and European level, to ensure 
development of a strong Marine Biotechnology 
sector which can contribute to meeting the significant 
environmental and societal challenges ahead;
This Position Paper presents a shared vision for 
European Marine Biotechnology whereby:
By 2020, an organised, integrated and globally 
competitive European Marine Biotechnology sec-
tor will apply, in a sustainable and ethical manner, 
advanced tools to provide a significant contribution 
towards addressing key societal challenges in the 
areas of food and energy security, development of 
novel drugs and treatments for human and animal 
health, industrial materials and processes and the 
sustainable use and management of the seas and 
oceans.
5.2 Strategic recommendations 
and actions 
The strategy for the future development of Marine 
Biotechnology in Europe presented in this paper aims 
to enable the sector to much better contribute to 
the resolution of some of the most important social, 
economic, environmental and health challenges which 
we will encounter in the coming decade. In the context 
of a weakened global economy, the strategy will focus 
on optimising the use of marine biological resources, 
better coordination of research programmes at EU 
and national levels, and maximising the benefits for 
European citizens from products and services derived 
from Marine Biotechnology. 
The Strategy is designed such that its full implementation 
should contribute to wealth and job creation in EU 
Member and Associated States. It also aims to 
position Europe as a globally competitive leader in 
Marine Biotechnology research, in the advancement 
of associated technologies and in the development 
of marine derived products and services through 
biotechnological applications. At the same time, the 
strategy must provide the means to assist countries with 
limited access to marine resources and/or the means to 
valorise them. An underlying tenet of the strategy is that 
its recommendations must be implemented according 
to the principles of sustainability, ensuring the protection 
and preservation of coastal and marine ecosystems 
and their resources for future generations. More than 
that, there is a need for Marine Biotechnology to better 
contribute to the appropriate protection, remediation 
and management of the marine environment. Given 
that knowledge of marine ecology is critical in the 
understanding of the impacts of human activities on the 
oceans and for the design of conservation measures, 
recognition and better support of marine ecology 
research will be crucial in this respect.
At the background of these strategic recommendations 
and actions, it must be recognised that most of the 
knowledge, tools and progress to date in Marine 
Biotechnology arose from advances in basic disciplines 
such as marine microbiology, biology, biochemistry, 
biophysics and bioengineering. Hence, the strengthening 
of the European research potential in marine biology 
sensu lato will be one of the major enabling factors in the 
future development of Marine Biotechnology. As such, 
the integration of marine biology research and related 
policies at the European level is an important condition 
for a successful implementation of this strategy. 
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Four recommendations for specific actions constitute 
the core of the strategy to achieve the vision for Marine 
Biotechnology in Europe. These are:
RECOMMENDATION 1: Create a strong iden-
tity and communication strategy to raise the 
profile and awareness of European Marine 
Biotechnology research.
The broad range of disciplines and activities which 
contribute to Marine Biotechnology mean that it 
often suffers from a lack of identity and profile as a 
research field in its own right. This lack of a coherent 
identity in Europe is also a result of inadequate efforts 
to coherently communicate the needs, benefits and 
opportunities to the wider scientific community, to policy 
makers and to the public in general. There is an urgent 
need to communicate how marine biotechnological 
knowledge and applications can provide advances 
in, for example, industrial biotechnology, health and 
agriculture. In particular, there is insufficient awareness 
within the pharmaceutical industry of the potential for 
novel drug discovery based on bioactive molecules and 
compounds derived from marine organisms.
At the same time there is an urgent need to improve 
information exchange among those who are actively 
involved in European Marine Biotechnology. Mechanisms 
need to be developed to mobilise and facilitate the 
efficient pooling of knowledge, data and research 
capacities distributed throughout Europe. Mobility of 
researchers should be encouraged at all levels. The 
effective dissemination of novel Marine Biotechnology 
research discoveries can improve greatly Europe’s 
capacity to generate new commercial opportunities. 
Creating a common identity and information exchange 
platform will also reduce the apparent gap which currently 
exists between researchers and high-tech companies 
(notably companies from the healthcare sector).
Recommended Actions:
1a) Create a central European information portal (e.g. 
www.marinebiotechnology.eu), based on a Euro-
pean Marine Biotechnology open network, which 
provides an one-stop-shop for reports on novel 
discoveries and success stories, challenges and 
opportunities. 
 This portal should also provide access to 
documentation on marine resources, marine bio-
technological research, bioactive molecules, cultures 
of marine microorganisms and non-registered strains 
in international collections. In providing a central 
portal with access to all biobanks, compound and 
extract libraries and bioscreening facilities, it should 
be easier to avoid duplication of scientific effort or 
rediscovery of molecules. Ideally, this should be under 
the responsibility of a European Marine Biotechnology 
Institute or Centre (see recommendation 2a).
1b) Conduct, as soon as possible, an audit of Marine 
Biotechnology effort in Europe, providing accurate 
and up-to-date information on active research 
centres and laboratories, training programmes and 
outputs, companies, discoveries, patents and market 
information. This will allow an economic evaluation 
of the benefits of Marine Biotechnology in Europe 
and facilitate the development of strong support 
policies.
1c) Initiate a series of Marine Biotechnology demons-
tration projects that target the utilisation of marine 
materials in defined sectors – e.g. food, biomaterial 
and environmental remediation.
1d) Develop promotional and education support materials, 
based on, amongst others, the recommended audit 
and demonstration projects (see recommendation 1b 
and 1c), that highlight the potential and the successes 
of European Marine Biotechnology research.
RECOMMENDATION 2: Stimulate the develop-
ment of research strategies and programmes 
for Marine Biotechnology research and align 
these at the national, regional and pan-Europe-
an level.
The EU currently lacks a coherent Marine Biotechnology 
RTD policy and needs to prepare one without delay. 
Instead, individual European countries support, to 
varying degrees, national Marine Biotechnology 
initiatives, programmes, and RTD policies and/
or strategies. As a result, the European Marine 
Biotechnology effort is fragmented and based on 
national rather than EU needs and priorities. There is a 
need, therefore, to better co-ordinate and plan existing 
Marine Biotechnology activities and to identify and 
coordinate future R&D needs at multiple geographical 
scales, taking into account the variable levels of access 
to marine resources. A coordinated effort is also 
needed at pan-European level to mobilise and optimise 
human resources and available infrastructures. Such 
efforts should address both fundamental research and 
advanced application-oriented research and take an 
industry-academia collaborative approach.
Recommended Actions:
2a) Create a European Marine Biotechnology Institute 
or Centre at the European level or as an inter-
governmental research organisation (at least virtual, 
through e.g. a permanent Secretariat, coordinated 
network and key nodes) charged with developing 
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level of Marine Biotechnology research and 
corresponding infrastructures, among others 
through a future Framework Programme support 
action or a dedicated ERA-NET.
2c) Strengthen common European platforms in the field 
of omics research which include corresponding 
bioinformatics and e-infrastructures and the 
development of centres for systems biology and 
synthetic genomics, recognising that Marine 
Biotechnology draws from a wide range of multi-
disciplinary research outputs and tools;
2d) Develop high level European Marine Biotechnology 
research programmes taking an industry-academia 
collaborative and multidisciplinary scientific 
approach in the following thematic areas:
- Food: Development of food products and 
ingredients of marine origin (algae, invertebrates, 
fish) with optimal nutritional and functional 
properties for human health. 
- Energy: Development and demonstration 
of viable renewable energy products and 
processes, notably through the use of marine 
algae for biodiesel, biogas and by-products for 
biorefineries.
- Health: Development of novel drugs and 
healthcare products involving all levels of 
industry and research in an integrated manner 
Europe’s Marine Biotechnology research capabilities 
through a range of collaborative actions including:
- the provision of research leadership in Marine 
Biotechnology;
- establishing and operating the European Marine 
Biotechnology Portal (see recommendation 1a);
- providing essential infrastructure to ensure 
European Marine Biotechnology research 
remains competitive (see also recommendation 
2c below);
- training early stage scientists via a European 
Marine Biotechnology graduate development 
programme (see recommendation 4d below);
- operating a Marine Biotechnology resources 
centre and strengthening the awareness of Marine 
Biotechnology across European industry. 
 In doing so, the European Marine Biotechnology 
Institute or Centre would capitalise the knowledge 
and experience gained in the different Member 
States for further optimisation of nationally based 
projects, cooperative initiatives, biobanks and 
funding. Such a Centre would also contribute to 
securing adequate supplies of biological material 
and provide a basis for much stronger industry-
academic collaborations and partnerships.
2b) Develop a coherent European Marine Biotechnology 
RTD policy to strengthen the integration at EU 
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Recommended Actions:
3a) Better adapt future EU Framework Programme finan-
cial rules and Grant Agreements to ensure that SMEs 
are attracted to participate in a way that maximises 
the reward and minimises economic risks.
3b) Establish completely new mechanisms and policies 
to circumvent the high risk of investments in critical 
novel drugs developed from marine bioresources, 
in particular for the development of new antibiotics 
of marine origin.
3c) Harmonise the property rights and procedures for 
the protection of intellectual property for marine-
derived products at European level but with a global 
relevance. Develop new European protocols to 
facilitate the publication of academic research results 
whilst protecting, through innovative procedures, the 
intellectual property on new discoveries, thereby 
addressing the divergent goals of the academic and 
industrial spheres and enabling them to cooperate 
more effectively.
3d) Develop a common European position on the 
simplification and harmonisation of regulations on 
access and fair and equitable benefit sharing from 
the exploitation of marine genetic resources to 
strengthen Europe’s voice at the International level. 
In its analysis, Europe must take into account three 
‘territories’: (i) inside Europe; (ii) outside Europe; and 
(iii) international waters. 
3e) Conduct a survey of industry stakeholders to guide 
research towards applications and processes to 
address current industry needs. Such a survey 
should consist of a wide consultation on the kind 
of marine products that industry would like to 
see developed, followed by specific requests for 
concrete applications. 
RECOMMENDATION 4: Improve training and 
education to support Marine Biotechnology in 
Europe.
While the strengthening of fundamental science is 
essential, specific education and training pathways are 
required to provide both research and industry with skilled 
graduates. The future of life sciences in the 21st century 
is closely linked to the ability of scientists to develop and 
participate in interdisciplinary projects embracing skills 
and concepts from other disciplines. Hence, training the 
next generation of marine biotechnologists must focus 
on the use of interdisciplinary and holistic approaches 
to solve technological problems specific to dealing with 
marine organisms and the marine environment. 
with targeted outcomes (e.g. five new antibiotics 
of marine origin by 2020). 
- Environment: Development of biotechnological 
approaches, mechanisms and applications 
to address key environmental issues such as 
biofouling, harmful algal blooms, oil spills and 
bioremediation in the marine environment.
- Industrial Products and Processes:   
Development of marine derived biomaterials and 
molecules including enzymes and biopolymers 
that have applications in human and animal health, 
in industrial and environmental areas. 
RECOMMENDATION 3: Significantly improve 
technology transfer pathways, strengthen the 
basis for proactive, mutually beneficial inter-
action and collaboration between academic 
research and industry and secure access to, 
and fair and equitable benefit sharing of, marine 
genetic resources.
With a few notable exceptions, most industrial 
contributions to Marine Biotechnology in Europe are 
generated through specialised SMEs. These small 
companies assume most of the risks inherent in RTD 
in a highly unstable economic environment and are 
characterised by a rapid turn-over. There is a danger 
that the current global financial crisis, coupled with 
reductions in available venture capital and public 
research funding, may reduce the capacity of Marine 
Biotechnology SMEs to continue to play a key role in 
developing new technologies, products and processes. 
Nevertheless, efforts to involve larger, established 
industries should also be intensified as the technology 
transfer is often incomplete if they are not involved. 
The participation of SMEs in EU research projects can 
place significant pressure on their cash flow which is a 
disincentive for them to get involved. It is crucial that 
future research and technology development funding 
mechanisms open to industry are designed to minimise 
the risks for participating SMEs and to maximise their 
potential to gain commercial advantage. Research 
contracts could allow, for example, for up to 100% of 
the additional costs to be reimbursed to participating 
SMEs, with a partial reimbursement clause to be defined 
in case of takeover by a large company. 
Another reason why academic scientists do not always 
cooperate effectively with industry is related to different 
objectives and interests in terms of publications and 
intellectual property protection and this also needs to 
be addressed. 
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Recommended Actions:
4a) Assure that appropriate biotechnology modules 
are included in all bio-science undergraduate 
educational programmes.
4b) Initiate actions that will ensure the participation 
of researchers from non-marine backgrounds in 
Marine Biotechnology, thus ensuring a growing 
pool of exceptional research talent is available to 
the Marine Biotechnology sector. 
4c) Organise regular trainings or summer schools on 
Marine Biotechnology subjects supported, for 
example, by the EU Framework Programme.
4d) Create a European School or Course on Marine 
Biotechnology (virtual and distributed) and a 
European PhD programme on Marine Biotechnology 
both of which include business and entrepreneurship 
training.
5.3 Strategic research priorities
Throughout this Position Paper, strategic areas for 
further development of Marine Biotechnology in Europe 
have been discussed, highlighting past achievements, 
current gaps and challenges and future research 
priorities. The implementation of the presented strategy 
should enable these research priorities to be addressed 
through advanced, collaborative and interdisciplinary 
research projects and programmes. For this reason, a 
summary overview of the research priorities is given in 
Summary Box 18. 
 
Figure 42. Flow-chart of recommended priority actions for immediate implementation and their expected impact
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Summary Box 18. Overview of strategic areas for Marine Biotechnology development in Europe  
and associated research priorities 
Target research area 
for development 
Research priorities and objectives
A. Marine Biotechnology contribution to key societal challenges
Food: 
Development of food  
products and ingre-
dients of marine origin 
(algae, invertebrates, 
fish) with optimal 
nutritional properties 
for human health
- Develop innovative methods based on -omics and systems biology for selective 
breeding of aquaculture species;
- Develop biotechnological applications and methods to increase sustainability of 
aquaculture production, including alternative preventive and therapeutic measures 
to enhance environmental welfare, sustainable production technologies for feed 
supply, and zero-waste recirculation systems;
- Integration of new, low environmental impact feed ingredients to improve quality of 
products and human health benefits.
Energy: 
Development and  
demonstration of 
viable renewable 
energy products and 
processes, notably 
through the use of 
marine algae 
- Produce an inventory of microalgae resources for biofuel production to support 
optimisation of the most appropriate strains;
- Improve knowledge of basic biological functions, tools for steering the metabolism, 
and cultivation methods of marine microalgae to improve the photosynthetic 
efficiency, enhance lipid productivity and obtain microalgae with optimum 
characteristics for mass cultivation (mixed & mono cultures), biofuel production 
and biorefinery;
- Develop efficient harvest, separation and purification processes for micro- and 
macroalgae.
Health: 
Development of novel 
drugs, treatments and 
health and personal 
care products
- Increase the focus on the basic research (taxonomy, systematics, physiology, 
molecular genetics and (chemical) ecology) on marine species and organisms from 
unusual and extreme environments to increase the potential for success in finding 
novel bioactives;
- Improve the technical aspects of the biodiscovery pipeline, including the 
separation of bioactives, bio-assays that can accommodate diverse material from 
marine sources, dereplication strategies and structure determination methods and 
software;
- Overcome the supply problem to provide a sustainable source of novel 
pharmaceutical and healthcare products through scientific advances in the fields 
of aquaculture, microbial and tissue culture, chemical synthesis and biosynthetic 
engineering.
Environment: 
Development of 
biotechnological 
approaches, 
mechanisms and 
applications to  
address key 
environmental issues
- Develop automated high-resolution biosensing technologies allowing in situ marine 
environmental monitoring to address coastal water quality, including prediction 
and detection of HABs and human health hazards;
- Develop cost-effective and non-toxic antifouling technologies combining novel 
antifouling compounds and surface engineering;
- Consolidate knowledge on DNA-based technologies for organism and population 
identification and support the development of commercial tools and platforms for 
routine analysis.
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Industrial Products 
and Processes: 
Development of 
marine derived 
molecules exploitable 
by industry including 
enzymes, biopolymers 
and biomaterials
- Develop enabling technologies for high throughput enzyme screening and for the 
expression of marine proteins and enzymes through dedicated hosts;
- Produce marine biopolymers as novel competitive commercial products in food, 
cosmetics and health.
B. Marine Biotechnology toolkit research priorities
Genomics and  
meta-genomics, 
molecular biology  
in life sciences
- Implement genomic analyses of marine organisms, including the systematic 
sampling of different microorganisms (viruses, bacteria, archaea, pico- and micro-
plankton), algae and invertebrate taxa;
- Implement metagenomic studies of aquatic microbiomes and macrobiomes.
Cultivation of marine 
organisms
- Develop enabling technologies for culture and isolation of uncultivated 
microorganisms;
- Develop innovative culture methods adapted to vertebrate or invertebrate cell lines 
for production of active compounds.
Bio-engineering 
of marine micro- 
organisms
- Optimise microalgal cultivation systems with respect to energy supply, productivity 
and cost;
- Develop innovative photobioreactors adapted to different species of interest and 
production sites;
- Promote research on the biorefinery approach based on microalgae production to 
develop a long-term alternative to petrochemistry.
Marine Model  
Organisms
- Identify and prioritise new marine model organisms that are still not investigated in 
the tree of life and which are needed to fill critical knowledge gaps;
- Investigate identified marine model organism cultivation and perform genomic and 
chemical analyses.
 
Biotechnology CWG-MB, the EU-US Task Force on 
Biotechnology 11) have highlighted the potential of the 
sector and provided clear recommendations to support 
the development of Marine Biotechnology in Europe. 
Unfortunately, the recommendations arising from 
previous strategic initiatives have only been partially 
implemented and, as a result, the final objectives have 
never been fully met. Meanwhile the scientific and policy 
landscape has changed significantly and awareness has 
grown to a point where decisive support through an up-
to-date and coordinated strategy can provide a renewed 
impetus for European Marine Biotechnology research. 
The strategy proposed in this Position Paper, therefore, 
builds on previous initiatives whilst bringing new insights 
and highlighting current needs and opportunities. At the 
same time, implementation of the strategy will require 
openness, flexibility and integration within a wider policy 
and strategic framework.
11. http://ec.europa.eu/research/biotechnology/ec-us/tf_en.html 
5.4 Implementing the strategy
The strategy presented in this Position Paper contains 
a set of concrete and achievable recommendations and 
actions designed to support and develop European 
Marine Biotechnology research, enhance the European 
biotechnology and bioscience industries, and provide 
a considerable contribution to the Knowledge Based 
Bio-Economy (KBBE). 
It is not the first time that Marine Biotechnology has 
been championed as a sector where progress will be 
considerable if properly supported. Previous position 
papers (e.g. Marine Board Position Paper 4 9), science-
policy meetings (e.g. Bremen Meeting 10) and working 
groups (e.g. EC Collaborative Working Group on Marine 
9. Marine Board Position Paper 4 on Marine Biotechnology was 
published in 2001 and is available for download on www.esf.org/
marineboard/publications 
10. http://ec.europa.eu/research/press/2007/maritime-briefing/pdf/37-
bremen-marine-biotechnology-research_en.pdf 
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Successful implementation of the strategy will require 
a joint effort with active support and involvement from 
a range of stakeholders. Europe needs to mobilise 
the necessary support in terms of funding, human 
resources and research infrastructures, and to secure 
the engagement of all of the relevant actors. These 
actors include the science community, the private 
sector (e.g. individual companies, associations and 
technology platforms), policy makers and advisors 
at national and European level, national strategy and 
programme developers and managers. As each actor 
has an important responsibility to bring forward key 
elements of the strategy, mobilising, in a coordinated 
way, this diverse range of actors will be critical.
The 2020 vision presented at the beginning of the 
strategy will only be achieved through the coordinated 
implementation of all the recommendations and actions 
presented. However, some of the recommended actions 
provide a structural basis for realisation of the strategy 
and should be prioritised for early implementation. 
These include: (i) the preparation of a European 
Marine Biotechnology RTD Policy; (ii) the creation of 
a European Marine Biotechnology Institute or Centre 
and Information Portal (recommended actions 1a 
and 2a); (iii) an audit of Marine Biotechnology effort 
in Europe (including an economic evaluation of the 
benefits of Marine Biotechnology) (recommended 
action 1b); and (iv) development of a dedicated support 
action or ERA-NET to coordinate the programming 
and investments of national research funding 
organisations (recommendation 2a). Once up and 
running, these activities will act as a catalyst to drive 
implementation of the other recommended actions that 
make up the strategy. For example, a European Marine 
Biotechnology Institute or Centre could develop a 
roadmap for implementation of the strategy, coordinate 
its implementation and mobilise the relevant actors. A 
Framework Programme support action or ERA-NET, 
bringing together national funding organisations which 
support Marine Biotechnology research, can also play 
a key role in aligning existing programmes, coordinating 
investments and informing the development of new 
research programmes and initiatives.
Summary Box 19. Priority actions for immediate 
implementation
Key recommended actions which provide a struc-
tural basis for realisation of the strategy should be 
prioritised for early implementation. These include: 
• Preparation of a European Marine Biotechnology 
RTD Policy; 
• Creation of a European Marine Biotechnology 
Institute or Centre and Information Portal; 
• An audit of Marine Biotechnology effort in Europe 
(including an economic evaluation of the benefits 
of Marine Biotechnology); and 
• Development of a dedicated support action or 
ERA-NET to coordinate the programming and 
investments of national research funding organi-
sations. 
There is now a strong momentum to drive progress in 
European Marine Biotechnology in the coming decade. 
If Europe does not act now through a concerted effort 
by all the identified actors and stakeholders and 
through increasing its support with targeted funding 
and coordinated research, it will begin to lose ground 
on other global leaders in this field such as the USA, 
Japan and China. The successful implementation of 
the integrated strategy presented in this Position Paper 
has the potential, not only to significantly advance 
European research in Marine Biotechnology, but, in turn, 
to contribute significantly towards the development of 
knowledge-based jobs and economic growth and to 
meet critical societal challenges in the areas of food, 
environment, energy and health in the coming decade 
and beyond.
5. A European Strategy for Marine Biotechnology 
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AF: Antifouling
AMBIO: Advanced Nanostructured 
Surfaces for the Control of 
Biofouling (sixth Framework 
Programme project)
ARA: Arachidonic acid  
(a polyunsaturated omega-6 fatty 
acid)
BAC: Bacterial Artificial Chromosome
BRC: Biological Resource Centre 
 
COGs: Clusters of Ortholog Groups
COLIPA: The European Cosmetics 
Association
COMB: Center of Marine 
Biotechnology of the University of 
Maryland Biotechnology Institute
DHA: Docosahexaenoic acid (an 
omega-3 fatty acid)
DIN: Dissolved Inorganic Nutrients
DNA: Deoxyribonucleic acid
dsDNA: doubled-stranded 
Deoxyribonucleic acid
EC: European Commission
EC CWG-MB: European Commission 
Collaborative Working Group on 
Marine Biotechnology 
ECDP: European Centre for Disease 
Prevention
EEZ: Exclusive Economic Zone
EMBL: European Molecular Biology 
Laboratory
EMBRC: European Marine Biological 
Resource Centre
EMSO: European Multidisciplinary 
Seafloor Observatory 
EPA: Eicosapentaenoic acid (an 
omega-3 fatty acid)
EPS: Exopolysaccharides
ERA: European Research Area
ERA-NET: European Research Area 
Network
ERVO: European Research Vessel 
Operators
ESF: European Science Foundation
ESFRI: European Strategy Forum on 
Research Infrastructures
EU: European Union
EU-OPENSCREEN: European 
Infrastructure of Open Screening 
Platforms for Chemical Biology
EURO-ARGO: European component 
of a world wide in situ global 
ocean observing system, based on 
autonomous profiling floats (Argo 
floats)
EUR-OCEANS: Ocean Ecosystems 
Analysis (EU Network of 
Excellence)
F&PF: Faeces and Pseudo-Faeces
FAO: Food and Agriculture 
Organization of the United Nations
FDA: United States Food and Drug 
Administration 
FP: European Commission 
Framework Programme
GFP: Green Fluorescent Protein
GMO: Genetically Modified 
Organisms
GOED: Global Organization for EPA 
and DHA Omega-3s
Gyr: Gigayear, i.e. 1 billion years
HAB: Harmful Algal Bloom
IDSA: Infectious Diseases Society  
of America
IMTA: Integrated Multi-Trophic 
Aquaculture
IP: Intellectual Property
KBBE: Knowledge Based Bio-
Economy
KBBE-NET: Experts Group  
of officials from Member States 
on the Knowledge Based Bio-
Economy
Kbp: Kilo base pair
LDL: Low-density lipoprotein
LIFE WATCH: Science and 
Technology infrastructure 
for Biodiversity data and 
observatories 
MAP: Mussel Adhesive Proteins
MAR: Mid-Atlantic Ridge
MarBEF: Marine Biodiversity and 
Ecosystem Functioning (EU 
Network of Excellence)
MARS: European network of Marine 
Research Institutes and Stations
MEOR: Microbial Enhanced Oil 
Recovery
MGE: Marine Genomics Europe (EU 
Network of Excellence)
MGR: Marine Genetic Resource 
MS: Mass spectrometry
NIOO-KNAW: Netherlands Institute 
of Ecology
NMR: Nuclear Magnetic Resonance 
NoE: Networks of Excellence
OECD: Organisation for Economic 
Co-operation and Development
OFEG: Ocean Facilities Exchange 
Group
PCR: Polymerase Chain Reaction
PHA: Polyhydroxyalkanoate
POM: Particulate Organic Matter
PUFA: Polyunsaturated fatty acid
R&D: Research and Development
RAS: Recirculating Aquaculture 
Systems
RNA: Ribonucleic acid
ROV: Remotely Operated Vehicle
RTD: Research and Technical 
Development
SAMS: Scottish Association for 
Marine Sciences
SAP: Shrimp Alkaline Phosphatase
SMEs: Small to Medium sized 
Enterprises
SMM: Small molecule microarray
SPR: Surface Plasmon Resonance
TBT: Tributyltin 
UK: United Kingdom
UNCLOS: United Nations Convention 
on the Law on the Sea
UCSD: The University of California, 
San Diego, USA
VLIZ: Flanders Marine Institute
WG BIOTECH: Marine Board 
Working Group on Marine 
Biotechnology
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Annex 2. Overview of major achievements of the marine 
Networks of Excellence Marbef, MGE and EUR-OCEANS
A. The Network of Excellence MGE ‘Marine 
Genomics Europe’
Bringing together about 450 scientists from 45 institu-
tions in 16 countries, MGE has considerably improved 
integration and strongly promoted interaction and col-
laboration in the field of marine genomic research. Some 
examples of MGE outputs and achievements include:
- MGE promoted, developed and spread a better 
understanding of the functioning of marine 
ecosystems and the biology of marine organisms 
throughout the European Union; 
- Contributed significantly to the acquisition of 
important genomics data on marine model organisms 
and to the development of new genomics tools;
- Established agreement to focus on a few model 
organisms on which genomics and post-genomics 
resources could be collectively developed in order 
to structure the community around specific research 
priorities and to gain access to large scale sequencing 
centres. Results included a significant contribution 
to the sea urchin genome project that was headed 
by BaylorCollege (Houston, Texas) Human Genome 
Centre; 
- Contributed to education and outreach with 16 
short training courses (mainly in Bioinformatics, 
Transcriptomics and Proteomics) and 10 summer 
courses (Marine Evolutionary & Ecological Genomics, 
Marine diversity, Life History Strategies, and plankton 
bloom dynamics); 
- MGE members have presented their data or the 
activities of the consortium in about 350 conferences; 
more than 230 articles acknowledging MGE were 
published in International peer reviewed journals with 
an average impact factor of 4.557.
http://www.marine-genomics-europe.org 
B. The Network of Excellence MarBEF 
‘Marine Biodiversity and Ecosystem 
Functioning’
Bringing together over 700 scientists from around Eu-
rope to integrate their research, Marbef addressed the 
scientific challenges of the most topical marine biodiver-
sity questions and provided new insights and answers at 
a scale of research never before attempted in this field 
in Europe. With 95 member institutes, MarBEF devel-
oped the critical mass to promote, unite and represent 
European marine biodiversity research at a global scale. 
Examples of major outputs and achievements include:
- MarBEF has established a baseline from which trends 
in marine biodiversity change can be detected at the 
relevant spatial and temporal scales; 
- Recent advances in molecular technologies allowed 
MarBEF scientists to identify the key microbes that 
participate in biogeochemical cycling in different 
areas in Europe;
- Marine biological valuations in the form of maps 
developed by MarBEF could be used as baselines for 
future spatial planning in the marine environment; 
- MarBEF scientists applied the most advanced 
genetic technologies to study marine biodiversity 
and phylogeographic structures which is of use to 
help improve the way fisheries are managed;
- MarBEF scientists gave us a better understanding of 
the role of secondary metabolites in maintaining marine 
biodiversity and driving ecosystem functioning;
- MarBEF scientists have shown that alterations of key 
species abundances affect ecosystem functioning 
more than changes in species diversity;
- Capture of 5.2 million distribution records of 17,000 
species and a total of 137 species new to science 
have been added to the European Register of Marine 
Species (ERMS) by MarBEF. Publication of 415 
scientific articles, 82% of which are ‘open access’.
http://www marbef.org/ 
C. Network of Excellence EUR-OCEANS 
‘EURopean network of excellence for OCean 
Ecosystems Analysis
From 2005 to 2008, the EUR-OCEANS Network of 
Excellence brought together more than 160 Principal 
Investigators and 350 Associated Scientists, from 61 
member research institutes and universities in 25 coun-
tries in Europe and beyond. As such, EUR-OCEANS 
has significantly contributed to the integration European 
research organisations working on global change and 
pelagic marine ecosystems. Selected achievements: 
- Fostered integration through education and training with 
funded PhD projects for 19 students, a postdoctoral 
programme with eleven scientists, organisation or co-
organisation of 40 summer schools and workshops 
and creation of mobility opportunities;
- Design and implementation of a database for sharing 
more than 110 major facilities (mesocosms, mass 
spectrometers, equipment at sea, etc.); 
- Development of models for assessing and forecasting 
the impacts of climate and anthropogenic forcing on 
food-web dynamics (structure, functioning, diversity and 
stability) of pelagic ecosystems in the open ocean. 
http://www.eur-oceans.eu/
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Annex 3. Selected examples of enzymes discovered  
from marine biotic sources
Activity Source Habitat
Esterase
Feruloyl esterase
Metagenome Deep-sea sediment
Metagenome Deep-sea basin
Metagenome Surface seawater
Metagenome Arctic sediment
Vibrio sp. Sea Hare Eggs
Pseudoalteromonas haloplanktis
Pseudoaltermonas haloplanktis
Antarctic Seawater
Antarctic Seawater
Lipase Metagenome Tidal Flat
Metagenome Deep-sea sediment
Metagenome Baltic Sea sediment
Pseudoalteromonas haloplanktis TAC125 Antarctic Seawater
Aureobasidium pullulans HN2.3 Sea saltern
Cellulase Pseudoalteromonas sp. DY3 Deep-sea sediment
Pseudoalteromonas haloplanktis Antarctic Seawater
Teredinibacter turnerae T7902T Shipworm
Marinobacter sp. MSI032. Marine sponge
Chitinase Metagenome Estuary
Arthrobacter sp. TAD20 Antarctic ice
Rhodothermus marinus Marine hot spring
Amidase Metagenome Marine sediments / sludges
Amylase Aureobasidium pullulans N13d Deep-sea sediment
Metagenome
Nocardiopsis sp.
Deep-sea hydrothermal vent
Deep-sea sediment
Phytase Kodomaea ohmeri BG3 Fish gut
Protease Pseudomonas strain DYA, Deep-sea sediment
Aerpyrum pernix K1 
Pseudoalteromonas, Shewanella, Colwellia, 
Planococcus species
Antarctic Seawater
Sub-Antarctic sediment 
Coastal solfataric vent
Alkane hydroxylase Metagenome Hydrocarbon seep
Metagenome Deep-sea sediment
Xylanase Pseudoalteromonas haloplanktis Antarctic Seawater
Alanine ehydrogenase Psychrophilic bacterium strain PA-43 Sea Urchin
Chitinase Arthrobacter sp. TAD20
Rhodothermus marinus
Antarctic ice
Marine hot springs
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Activity Source Habitat
β-Galactosidase Arthrobacter sp. SB
Guehomyces pullulans
Antarctic seawater
Alcohol ehydrogenase Flavobacterium frigidimaris KUC-1 Antarctic seawater
Malate dehydrogenase Flavobacterium frigidimaris KUC-1 Antarctic seawater
Isocitrate ehydrogenase Colwellia psychrerythraea Arctic marine sediment
Isocitrate lyase Colwellia psychrerythraea Arctic marine sediment
Catalase Vibrio salmonicida Fish Microbiota
Uracil Dna Glycosylase Marine bacterium strain BMTU3346 Marine sample
Epoxide hydrolases Erythrobacter litoralis HTCC2594 Seawater
Aminopeptidase Colwellia psychrorythraea strain 34H Marine sediment
Subtilisin Bacillus TA41 Antarctic seawater
Trehalase Rhodothermus marinus Marine Hotsprings
Pectate lyase Pseudoalteromonas haloplanktis strain 
ANT/505
Antarctic sea ice
β-D-glucosidase Shewanella sp. G5 Munida subrrugosa 
Homoserine ranssuccinylase Thermotoga maritima Marine sediment
Quinol oxidase Shewanella sp. strain DB-172F Deep-sea sediment
Agarase Pseudoalteromonas gracilis B9
Microbulbifer sp.
Microscilla sp.
Pseudoalteromonas carrageenovora
Zobellia galactinovorans
Pseudomonas atlantica T6C
Alteromonas agarylytica
Agarivorans sp. JAMB-A11
Vibrio sp. JT0107
Marine macroalgae
Deep-sea sediment
Marine sediment
Marine macroalgae
Marine macroalgae
Marine macroalgae
Marine macroalgae
Marine macroalgae
Seawater
Carrageenase Pseudoalteromonas carrageenovora
Zobellia galactinovorans
Alteromonas fortis
Marine macroalgae
Marine macroalgae
Marine macroalgae
Porphyranase Zobellia galactinovorans Marine macroalgae
Fucanase Marineflexile fucanivorans Alginate plants waste waters
Fucoidan-degrading enzyme Fucophilus fucoidanolyticus Marine echinoderme
Sulfatase Zobellia galactinovorans
Rhodopirellula baltica
Marine macroalgae
Water column Batic sea
Mannuronan C5-epimerase Laminaria digitata Sea shore
Galactose sulfurylase Chondrus crispus Sea shore
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Activity Source Habitat
Alginate-lyase Haliotis discus discus
Pseudoalteromonas atlantica AR06
Pseudoalteromonas sp. IAM14594
Pseudoalteromonas sp. CY24
Vibrio sp. A9m
Cobetia marina
Agarivorans sp. JAM-A1m
Porphyra yezoensis
Streptomyces sp. 
Pseudomonas alginovora XO 17
Sea shore
Coastal water
Marine macroalgae
Seawater
Deep-sea sediment
Marine environment
Marine macroalgae
Sea shore
Marine macroalgae
Marine macroalgae
Halo-peroxidase Laminaria digitata Sea shore
Annex 3. Selected examples of enzymes discovered  
from marine biotic sources
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Taxonomy  
(phylum  
or class)
Applications Species Genomic  
resources
Other resources 
(enabling 
technologies, 
post-genomics)
Eukaryotes
Animals
Cnidaria Evo-Devo
Phylogenomics
Clytia 
hemisphaerica
Jellyfish
Genome sequencing 
in progress 
ESTs
Ctenaires Evo-Devo 
Ecology
Phylogenomics
Regeneration
Pleurobrachia pileus
comb jellies
Genome sequencing 
in progress
ESTs
Acoela Evo-Devo 
Ecology
Phylogenomics
Regeneration
Photosymbiosis
Symsagittifera 
roscoffensis
ESTs, BACs In situ 
hybridization 
Immuno-
localization
Echinodermata Evo-Devo
Ecology
Ecotoxicology
Immunologie
Human disease 
(cancer)
Strongylocentrotus 
purpuratus
Sea urchin
Genome sequence  
available 
ESTs, BACs
Knock down using 
morpholinos 
Transient  
transformation 
Echinodermata Evo-Devo 
Human disease 
(cancer)
Paracentrotus 
lividus 
Sea urchin
ESTs In situ  
Hybridization 
Echinodermata Evo-Devo 
Regeneration
Echinodermata Evo-Devo 
Ecology
Immunology
Regeneration
Asterias rubens
starfish
Genome sequencing 
on going
Ascidiacea Genetics
Evo-Devo 
System biology
Study of the  
nervous system
Ciona intestinalis
Ciona savignyi
tunicate
Genome sequence 
available
ESTs, BACs 
Electroporation 
injection technics,
Knocking 
out using 
morpholinos and 
transformation
Annex 4. Overview of marine model organisms
Below table presents an overview of marine organisms 
currently used as model organisms for various purpos-
es. To improve contributions of marine model organism 
studies for biotechnological purposes, there is a need for 
an in-depth evaluation to identify, prioritise and select a 
limited number of appropriate marine model organisms 
which could provide critical knowledge to stimulate the 
development of biotechnological applications.
* Evo-Devo = Evolutionnary and Developmental Biology
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Taxonomy  
(phylum  
or class)
Applications Species Genomic  
resources
Other resources 
(enabling 
technologies, 
post-genomics)
Cephalochordata Evo-devo
Phylogenomics
Branchiostoma 
lanceolatum
Branchiostoma 
floridae
Amphioxus, Lancelet
Genome sequence 
available for  
B. floridae
Knock down using 
morpholinos 
Transient  
transformation
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture
Salmo salar 
Atlantic Salmon
ESTs, BACs
Genome sequence 
available
Physical 
and genetic 
maps, QTL 
Transcriptomics
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture
Sparus Auratus
Seabream
ESTs, BACs, BAC 
end sequences
Molecular 
markers, Genetic 
map, Radiation 
hybrid map,
Transcriptomics
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture
Dicentrarchus labrax
Seabass
ESTs, BACs, Draft 
genome sequence 
Molecular markers
Genetic map, 
Radiation hybrid 
map
Transcriptomics
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture
Gadus mohrua
Cod
ESTs Molecular markers
Chordata,
Actinopterygii
Evo-Devo Tetraodon nigroviridis
Green spotted Puffer 
fish
ESTs,  
Genome sequence
Genetic map
Chordata,
Actinopterygii
Evo-Devo Takifugu rubripes
Japanese puffer fish
ESTs, cDNA,  
Genome sequence
Chordata,
Actinopterygii
Evolution
Ecotoxicology
Fundulus heteroclitus 
mummichog
linkage map;
transcriptomics
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture
Gadus morhua 
cod
Genome fully
sequenced
linkage map, SSR/
SNP, SNP-array,
Chordata,
Actinopterygii
evolution/ 
ecology
Gasterosteus 
aculeatus 
threespined 
stickleback
Genome fully
sequenced and well 
assembled  
EST, BAC 
linkage map, oligo 
expression array, 
SNP chip
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture 
Paralichthys olivaceus 
bastard halibut
ESTs
BAC
linkage map, 
SSR markers 
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture 
Scophthalmus 
maximus
turbot
ESTs linkage map;
SSR and SNP 
markers
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture 
Solea senegalensis 
Senegal sole
transcriptomics,
SSR markers
Chordata,
Actinopterygii
Fisheries/ 
Aquaculture 
Solea sole 
sole
transcriptomics, 
SNP-chip
Annex 4. Overview of marine model organisms
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Taxonomy  
(phylum  
or class)
Applications Species Genomic  
resources
Other resources 
(enabling 
technologies, 
post-genomics)
Chondrichthyes Ecotoxicology 
Evo-Devo 
Scyliorhinus canicula
dogfish
ESTs In situ 
Hybridization 
Cephalaspido-
morphs
Ecotoxicology 
Evo-Devo
Petromyzon marinus
Sea lamprey
Genome sequencing 
on going 
In situ 
Hybridization 
Knocking out 
using morpholinos
Transient 
transformation
Polychaeta Evo-Devo Platynereis dumerilii
Marine annelid worm
ESTs
BACs
In situ 
hybridization
Knock down using 
morpholinos
Transient 
transformation
Platyhelminthes Evo-Devo 
Stem cells biology 
Apoptose 
regeneration
Schmidtea  
mediterranea
flatworm
Genome sequencing 
done
ESTs
In situ 
hybridization
RNAi gene knock 
out
transcriptomics
Bivalvia Aquaculture Crassostrea gigas
Oyster
ESTs, BACs,
Genome sequencing 
in progress
RNAi gene knock 
out
In situ 
hybridization
Transcriptomics
Bivalvia Aquaculture Mytilus galloprovincalis
Mussel
ESTs Molecular markers
Genetic map
Transcriptomics
Gastropoda Neurobiology
Human disease 
(cancer)
Green plants
Monocotyledons
Alistmatidae
Ecology Zostera Marina ESTs
Genome sequencing 
in progress
Green algae
Prasinophytes
(unicellular)
Cellular Biology 
Ecology 
Cellular cycle 
Photosynthesis
Circadian rythms
Ostreococcus taurii Genome sequence 
available, BACs, EST
Transformation
Transcriptomics
Ecotypes 
collection
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Taxonomy  
(phylum  
or class)
Applications Species Genomic  
resources
Other resources 
(enabling 
technologies, 
post-genomics)
Heterokonta
Phaeophyta Evo-Devo 
Ecophysiology, 
Ecology, stress
Cell-wall
Photosynthesis
Ectocarpus siliculosus Genome sequence 
available
EST
Transcriptomics, 
Mutants, 
proteomics,
Tiling, genetic 
map
Protoplasts, 
ecotypes 
collection, 
molecular markers
Phaeophyta Ecology, 
Polysaccharides
Aquaculture
Laminaria digitata EST protoplasts
Diatoms Ecology
Development
Cell division
Environmental 
genomics
Photosynthesis
Phaeodactylum  
tricornutum
Genome sequence 
available
EST
Genetic 
transformation
Transcriptomics
Diatoms Ecology
Development
Cell division
Environmental 
genomics
Photosynthesis
Thalassiosira  
Pseudonana
Genome sequence 
available
EST
Genetic 
transformation
Transcripomics
Rhodophyta (red algae)
Rhodophyceae Biology, ecology, 
ecophysiology, 
polysaccharides
Photosynthesis
aquaculture
Chondrus crispus
Irish moss
Genome sequencing 
in progress,
ESTs
Transcriptomics, 
protoplasts
Bangiophyceae Biology, ecology, 
ecophysiology, 
Photosynthesis
aquaculture
Porphyra umbilicalis
nori
Genome sequencing 
in progress
ESTs
Protoplast fusion
Molecular markers
Mutants
Haptophytes
Prymnesio-
phyceae
Environmental 
genomics,
Ecology,
Paleoclimatology
Emiliania huxleyi
Coccolithophores
Genome sequencing 
in progress,
ESTs
Transcriptomics
Annex 4. Overview of marine model organisms
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Taxonomy  
(phylum  
or class)
Applications Species Genomic  
resources
Other resources 
(enabling 
technologies, 
post-genomics)
Prokaryotes
Archaea
Euryarchaeota Environmental
Biotechnology
Biology
Pyrococcus sp Genome sequence 
available
Transcriptomics
Eubacteria
Cyanobacteria Environmental  
genomics
Prochlorococcus 
marinus Strain 
PCC9511
Genome sequence 
available
Transcriptomics
Cyanobacteria Environmental  
genomics
Synechococcus 
WH7803, WH8102, 
RS9916
Genome sequence 
available
Transcriptomics
Mutants
Bacteroidetes Environmental 
genomics, metabo-
lism, carbohydrate 
modifying enzymes
Zobellia 
galactinovorans
Genome sequence 
available
Transcriptomics
Genetic 
transformation
Mutants
Gamma  
proteobacteria, 
Vibrionales
Environmental  
genomics,
aquaculture
Vibrio tapetis CECT Genome fully 
sequenced
Genetic 
transformation
GFP
Gamma  
proteobacteria, 
Vibrionales
Environmental 
genomics, 
aquaculture
Vibrio tapetis LP2 Genome fully 
sequenced
GFP
Gamma  
proteobacteria, 
Vibrionales
Environmental 
genomics
Vibrio harveyi, ORM4 Genome fully 
sequenced
Genetic 
transformation, 
GFP
Gamma  
proteobacteria, 
Vibrionales
Environmental 
genomics
Vibrio harveyi, 7890 Genome fully 
sequenced
Genetic 
transformation, 
GFP
Gamma  
proteobacteria, 
Vibrionales
Environmental 
genomics
Vibrio nigripulchritudo Genome fully 
sequenced
Genetic 
transformation, 
GFP
Gamma  
proteobacteria, 
Vibrionales
Environmental 
genomics
Vibrio aesturianus Genome fully 
sequenced
Proteomics, 
Genetic 
transformation, 
GFP
Gamma  
proteobacteria, 
Vibrionales
Environmental 
genomics
Vibrio splendidus Genome fully 
sequenced
Proteomics, 
Genetic 
transformation, 
GFP
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Marine Board-ESF
The Marine Board provides a pan-European platform 
for its member organisations to develop common pri-
orities, to advance marine research, and to bridge the 
gap between science and policy in order to meet future 
marine science challenges and opportunities.
The Marine Board was established in 1995 to facilitate 
enhanced cooperation between European marine sci-
ence organisations (both research institutes and research 
funding agencies) towards the development of a common 
vision on the research priorities and strategies for marine 
science in Europe. In 2010, the Marine Board represents 
30 Member Organisations from 19 countries.
The Marine Board provides the essential components for 
transferring knowledge for leadership in marine research 
in Europe. Adopting a strategic role, the Marine Board 
serves its Member Organisations by providing a forum 
within which marine research policy advice to national 
agencies and to the European Commission is developed, 
with the objective of promoting the establishment of the 
European Marine Research Area.
http://www.esf.org/marineboard
European Science Foundation
The European Science Foundation (ESF) is an inde-
pendent, non-governmental organisation, the members 
of which are 79 national funding agencies, research 
performing agencies, academies and learned societies 
from 30 countries.
The strength of ESF lies in the influential membership 
and in its ability to bring together the different domains 
of European science in order to meet the challenges of 
the future.
Since its establishment in 1974, ESF, which has its 
headquarters in Strasbourg with offices in Brussels 
and Ostend, has assembled a host of organisations 
that span all disciplines of science, to create a common 
platform for cross-border cooperation in Europe.
ESF is dedicated to promoting collaboration in scientific 
research, funding of research and science policy across 
Europe. Through its activities and instruments ESF has 
made major contributions to science in a global con-
text. The ESF covers the following scientific domains:
•  Humanities
•  Life, Earth and Environmental Sciences
•  Medical Sciences
•  Physical and Engineering Sciences
•  Social Sciences
•  Marine Sciences 
•  Materials Science and Engineering
•  Nuclear Physics
•  Polar Sciences
•  Radio Astronomy
•  Space Sciences
www.esf.org
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